Quarterlytics / Personal Products & Services / McPherson's Limited

McPherson's Limited

mcp · ASX
Claim this profile
Ticker mcp
Exchange ASX
Sector
Industry Personal Products & Services
Employees 201-500
← All annual reports
FY2024 Annual Report · McPherson's Limited
Sign in to download
Loading PDF…
Health. Wellness. Beauty.
ANNUAL REPORT 2024

CONTENTS
02.	 Financial overview 
04.	 Key Achievements 
06.	 Message from the Company Chair 
08.	 Message from the CEO 
10.	 Understanding Our Legacy 
12.	 Our People
13.	 ESG 
14.	 Serving Our Community
15.	 Review of Operations 
20.	 Category and Brand Overview
26.	 Information on Directors
28.	 Directors’ Report 
54.	 Financial Report 
100.	Shareholder Information
102.	Corporate Governance Statement 
103.	Corporate Directory and Financial Calendar
McPherson’s Limited

ABOUT MCPHERSON’S LIMITED
McPherson’s Limited is a leading supplier of 
some of Australia’s most well-known essential 
health, wellness and beauty products. The 
company’s portfolio is anchored by five core 
household brands: Manicare, Lady Jayne, 
Dr. LeWinn’s, Swisspers, and Fusion Health. 
McPherson’s strategic focus is on investing 
in and growing these brands through key 
channels including pharmacy, grocery, 
and e-commerce.
In addition to these flagship brands, 
McPherson’s also supplies a diverse range of 
popular products across attractive segments 
such as haircare, vitamins and supplements, 
fragrance, and nutrition. Headquartered 
in Sydney, McPherson’s operates offices 
in Melbourne, Auckland, Hong Kong, and 
Shanghai, and is publicly listed on the 
Australian Securities Exchange.
Annual Report 2024  |  01

Financial 
Overview
In FY24, McPherson’s reported sales from continuing 
operations of $144.6 million, a 6.8% decline from FY23’s 
$155.2 million. Of this, $122.4 million came from our core 
brands. Underlying EBITDA 1 from continuing operations was 
$7.7 million, reflecting a 36.8% decrease from $12.1 million 
in FY23. The statutory net loss after tax from continuing 
operations was $11.4 million, compared to a $1.3 million loss 
in the previous year.
Total group results, which include both continuing and 
discontinued operations, show sales of $197.6 million, 
down 6.0% from $210.3 million in FY23. Group underlying 
EBITDA remained relatively stable at $15.2 million, up 1.1% 
from $15.0 million in FY23. The statutory net loss after tax 
for the total group was $16.0 million, compared to a loss of 
$5.1 million in the previous year.
The decline in sales from continuing operations largely 
reflects McPherson’s strategic decision to exit non-core 
brands. Notwithstanding a more challenging trading 
environment, core brand sales remained broadly in line with 
FY23, outperforming portfolio and other Group brands. 
Underlying EBITDA from continuing operations was also 
negatively impacted by unfavourable currency movements 
(weaker AUD/USD) and the exit of non-core brands from 
the business. 
The total Group’s underlying EBITDA remained steady, 
supported by an improved result from the Multix business, 
which benefited from more favourable commodity and 
freight prices during the year. Improved operating cash 
flows, along with proceeds from the divestment of the 
Multix brand and inventory assets 2, resulted in an overall 
improvement in the Group’s net cash position to $14.1 million 
compared to a net debt position of $6.5 million in FY23.
1.	 Earnings before interest, tax, depreciation and amortisation (EBITDA) is a 
non-GAAP measure and does not have a standardised meaning prescribed 
by GAAP. However, the Company believes that, in combination with 
GAAP measures, it assists in providing investors with a comprehensive 
understanding of the underlying operational performance of the business. 
A reconciliation of EBITDA to net profit after tax is shown on page 74 of 
this report.
2.	On 28 June 2024, McPherson’s announced the completion of the sale of its 
Multix brand and inventory assets.
PRECISION 
TWEEZERS
02  |  McPherson’s Limited

RANGE
1.	 On 28 June 2024, McPherson’s announced the sale of its Multix brand and inventory assets (Multix), which is reported as a discontinued operation. Results from 
continuing operations excludes the results from Multix.
2.	Total Group results are inclusive of continuing and discontinued operations.
3.	Earnings before interest, tax, depreciation and amortisation (EBITDA) is a non-GAAP measure and does not have a standardised meaning prescribed by GAAP. 
However, the Company believes that, in combination with GAAP measures, it assists in providing investors with a comprehensive understanding of the underlying 
operational performance of the business. A reconciliation of EBITDA to net profit after tax is shown on page 74 of this report.
SALES
$144.6m
 6.8%  |  On FY23: $155.2m
SALES
$197.6m
 6.0%  |  On FY23: $210.3m
UNDERLYING EBITDA  3
$7.7m
 36.8%  |  On FY23: $12.1m
UNDERLYING EBITDA  3
$15.2m
 1.1%  |  On FY23: $15.0m
STATUTORY NET LOSS 
AFTER TAX
$(11.4)m
On FY23: $(1.3)m
STATUTORY NET LOSS 
AFTER TAX
$(16.0)m
On FY23: $(5.1)m
TOTAL GROUP RESULTS 2
RESULTS FROM CONTINUING OPERATIONS  1
Annual Report 2024  |  03

Key Achievements
DURING THE YEAR, MCPHERSON’S MADE 
SIGNIFICANT PROGRESS ON ITS TRANSFORMATION 
PLAN TO RE-SHAPE THE BUSINESS AND TO 
GENERATE VALUE FOR SHAREHOLDERS. FY24 
REPRESENTED THE FIRST YEAR IN OUR MULTI-YEAR 
JOURNEY, WITH SEVERAL KEY ACHIEVEMENTS 
CONTRIBUTING TO A YEAR OF STRONG PROGRESS.
Key achievements across FY24:
	
– We set a new strategic direction for the Company to drive productivity 
and growth.
	
– Foundational steps were undertaken across brands and cost structures.
	
– We made investment in sales software and technology to support 
business growth. 
	
– We have a new and experienced leadership team in place to deliver on 
productivity, growth and execution of our transformation.
	
– We divested the Multix brand and inventory assets.
	
– We experienced stable core brand performance during a challenging 
macroeconomic environment.
	
– We are now a pure-play health, wellness and beauty company 
(after divesting the Multix brand and inventory assets).
A two-phased approach was taken to drive transformation and 
unlock value.
Phase 1, initiated in the first half of FY24, was focused on resetting the 
Company’s strategy. This involved establishing a clear plan to transform 
the business and to take logical steps toward value generation. During this 
phase, McPherson’s streamlined its brand portfolio by focussing on its five 
core brands, ceasing private label operations, and exiting non-strategic and 
agency brands. Additionally, a headcount reduction was implemented to 
more efficiently manage costs.
As part of Phase 2, McPherson’s continued to support its core brand 
performance with ongoing investment in consumer advertising and 
promotion (A&P). The Company identified long-tail stock keeping units 
(SKUs) for reduction to enhance efficiency, following the divestment of 
Multix brand and inventory assets in June 2024. 
Productivity and efficiency improvements remains a priority, with 
our focus on enhancing inventory management, and overhauling our 
systems and processes. McPherson’s also implemented Salesforce 
CRM for improved retail execution. The supply of domestic logistics 
services and the manufacture of formulated products were successfully 
competitively tendered.
New and experienced 
leadership team 
IN PLACE TO DELIVER ON 
PRODUCTIVITY, GROWTH 
AND EXECUTION OF OUR 
TRANSFORMATION
Investment in 
sales software 
and technology 
TO SUPPORT 
BUSINESS GROWTH
04  |  McPherson’s Limited

MAPLE WOOD 
PADDLE BRUSH 
Annual Report 2024  |  05

FY24 HAS BEEN A SIGNIFICANT YEAR FOR YOUR 
COMPANY. GIVEN THE CURRENT CONSUMER LANDSCAPE 
AND COMPETITIVE ENVIRONMENT, DECISIVE ACTION AND 
A STRATEGIC RESET WAS REQUIRED AT MCPHERSON’S.
The strategy that has been set out, and the steps that have been taken mark the 
beginning of a new chapter for your company, one that we believe will deliver 
sustainable long-term growth for all stakeholders.
To initiate the required changes, the Board appointed a new CEO, Brett Charlton, 
who commenced in August 2023. Following a comprehensive review of operations, 
a clear set of priorities were identified to unlock value. Management has since 
taken significant steps to simplify the business, focus on core strengths, and lay the 
groundwork for a stronger future.
As part of the reset, a new leadership team has been recruited, including individuals 
who have extensive experience in driving operational turnarounds and their focus 
on enhancing business performance is vital as we navigate the Company through 
this period of transformation. 
The management team’s efforts in FY24 were centred on right-sizing the 
organisation, optimising our cost base, and implementing initiatives that will deliver 
long-term benefits. While this groundwork involves significant one-off costs and 
restructuring efforts, these steps have been foundational, and the business is 
now better placed to implement its transformation. The divestment of the Multix 
brand and inventory assets was a key milestone in this journey. By streamlining 
the portfolio and exiting non-strategic categories, McPherson’s is now a pure-play 
health, wellness and beauty company in highly attractive and resilient segments of 
the market.
Through the year, the macroeconomic environment continued to prove 
challenging, and trading performance reflects this. Nevertheless, our core brands 
showed resilience, with revenue remaining broadly in line with the previous year 
and the gross margin reflecting the start of a shift to higher margin products. 
Notwithstanding our statutory loss, these early results provide confidence that our 
strategy is yielding the intended outcomes, even as we navigate the current tough 
trading environment.
Due to the retained earnings balance and current year loss, McPherson’s was 
not in a position to pay a final dividend for FY24. The total dividend for FY24 was 
therefore 2 cents per share paid on 22 March 2024. As part of the next stage 
of its transformation, the Company will conduct a review of its capital allocation 
framework and dividend policy to better align with McPherson’s refreshed strategy.
With your new management team in place, a refreshed strategic focus, and a 
portfolio of market leading brands, McPherson’s is well-positioned for the future.
On behalf of the Board, I would like to thank Brett and his management team, 
and all of McPherson’s employees for their dedicated commitment to improving 
the Company. I would also like to thank my fellow directors for their support and 
valuable input throughout the year. And finally, I would like to thank you, our 
shareholders for your enduring support in our vision.
ARI MERVIS
Chair
Message from the 
Company Chair
HELEN 
THORNTON
BRETT 
CHARLTON
06  |  McPherson’s Limited

ARI 
MERVIS
JANE 
McKELLAR
ALISON 
COOK
With our new management team in place, a refreshed 
strategic focus, and a portfolio of market leading brands, 
McPherson’s is well‑positioned for the future.
Annual Report 2024  |  07

When I stepped into the role as CEO 
of McPherson’s in August last year, 
I made it clear that our priority was to 
simplify, focus, and reset the Company. In 
November 2023, we set out a refreshed 
strategy and a clear plan to unlock 
growth. It has been a year of significant 
change for the business, with more 
transformation to come, but I am pleased 
to report that we have made steady and 
meaningful progress and delivered what 
we set out in November. In doing so, we 
have created a stronger business for the 
next stage of transformation.
FINANCIAL RESULTS
Our financial results for FY24 reflect the 
scale of the transformation underway in 
the business. Following the divestment of 
the Multix brand and inventory assets, we 
reported our financials as McPherson’s 
Continuing Operations. We also provided 
Total Group financials, including Multix, 
to allow investors to compare FY23 
and FY24 more easily, as well as some 
further financial information on Multix 
to help understand the implications of 
the divestment.
A number of material items impacted 
the result for the year, arising from the 
re-set of the business in FY24. The pre-
tax value of these material items totalled 
$12.7 million, resulting in an EBITDA 
loss from Continuing Operations (after 
material items) of $5.0 million, down from 
a gain of $8.5m in FY23. Our statutory 
net loss from Continuing Operations 
was $11.4 million compared to a loss of 
$1.3 million in FY23. These are not the 
results we want to see but they do reflect 
some of the decisions we have made to 
re-set and transform the business during 
the year.
REFRESHED STRATEGY
Under our refreshed strategy, our first 
major step was to focus on our five core 
brands in health, wellness and beauty. 
These brands are Manicare, Lady Jayne, 
Dr LeWinn’s, Swisspers and Fusion 
Health and they are McPherson’s most 
recognisable and most successful brands 
in high margin categories. Consistent with 
our refreshed strategy, McPherson’s will 
continue to invest in these core brands to 
achieve sustainable growth and seek to 
increase our market share.
Message from the CEO:
DRIVING TRANSFORMATION AND DELIVERING ON OUR STRATEGY
Revenue from Continuing Operations 
was $144.6 million, down 6.8% compared 
to $155.2 million in FY23. This decline 
reflects the decision to exit non-strategic 
brands from the portfolio, reflecting 
deliberate steps to simplify and focus 
the business. Sales of the company’s 
core brands outperformed other group 
brands, resulting in a shift towards a 
more favourable, higher margin product 
mix. Notwithstanding a more challenging 
trading environment, core brand revenue 
of $122.4 million was broadly in line 
with the prior year (down 0.7% from 
$123.3 million). 
Underlying EBITDA 1 from Continuing 
Operations was $7.7 million, down from 
$12.1 million in FY23, chiefly reflecting 
the impact of a weaker AUD / USD and 
the performance of non-core brands, 
including the exit of non-strategic and 
agency brands from the Group.
NIKKI 
BURKE
NATHAN 
ALEXANDER
STUART 
MACAULAY
HANLI 
PRETORIUS
1.	 Earnings before interest, tax, depreciation and amortisation (EBITDA) is a non-GAAP measure and does not have a standardised meaning prescribed by GAAP. 
However, the Company believes that, in combination with GAAP measures, it assists in providing investors with a comprehensive understanding of the underlying 
operational performance of the business. A reconciliation of EBITDA to net profit after tax is shown on page 74 of this report.
08  |  McPherson’s Limited

Our next step was the decision to review, 
and then divest, the Multix brand and 
inventory assets, a legacy part of our 
business that no longer aligned with 
our strategic direction. This was not just 
about removing a non-core brand with 
fundamentally different drivers to our 
core business, but also about freeing up 
resources to reinvest in our core brands, 
which are the foundation of our business. 
The completion of this divestment in 
June 2024 resulted in the receipt of 
19 million in proceeds (prior to completion 
adjustments). This is important for two 
reasons. Firstly, it allows us to focus on 
what we do best: building market-leading 
brands in the health, wellness, and beauty 
categories. Secondly, our strengthened 
balance sheet and net cash position 
allows us to de-risk and accelerate our 
investment in growth and transformation.
We also took significant steps this year 
to strengthen the business operationally. 
From exiting non-strategic brands and 
reducing our cost base to restructuring 
our team, each decision has been 
purpose-driven, aimed at ensuring we 
have the agility and focus needed to 
compete effectively. These initiatives, 
while necessary, have naturally come 
with material costs that impacted our 
statutory result. However, the underlying 
performance, particularly in our core 
brands, gives us confidence that we are 
on the right path.
LOOKING AHEAD
Looking ahead, FY25 will be about 
building on the foundations we have 
laid in FY24. Our immediate priorities 
will be to further develop our plans for a 
potential new route to market strategy 
to assist in right-sizing the cost-base and 
to support business growth. We are also 
actively pursuing efficiencies across our 
supply chain and infrastructure. We will 
also look to deepen our investment in our 
core brands, ensuring they are supported 
by the right innovation, marketing, and 
channel strategies to drive growth and 
increased market share.
Transforming an organisation is rarely 
straightforward, but the progress we 
have made this year has positioned 
us to accelerate our plans with 
greater confidence. 
In closing, I’d like to thank the Board 
for their faith in myself and the 
executive team to execute this plan. 
The experience around the table, as 
we deal with complex issues, is an 
inspiration to me and the team. We have 
an experienced team in place executing 
on our strategy and I continue to be 
inspired by the potential that they see in 
McPherson’s every day.
I also want to extend my thanks to the 
entire McPherson’s teams for their efforts 
over the year. One of the things that 
drew me to McPherson’s originally was its 
people and their clear passion for what 
we do. I’ve seen this in action throughout 
the year as the whole team has pulled 
together and worked hard to deliver on 
our strategy and to support each other 
through a time of change.
Finally, I’d like to thank you, our 
shareholders, for your support through 
our journey. We are committed to 
delivering sustainable results and creating 
lasting value as we enter this next phase 
of our transformation.
BRETT CHARLTON
Chief Executive Officer & 
Managing Director
CRAIG 
DURHAM
JANE 
BERKERY
BRETT 
CHARLTON
JADE 
PEAK
MARK 
SHERWIN
MELISSA 
SHERRY
Annual Report 2024  |  09

UNDERSTANDING OUR LEGACY:
A Foundation for Future Growth 
From Bolts to Beauty
McPherson’s has a rich 
history dating back over
1860 Thomas 
McPherson 
established an iron 
business, Thomas 
McPherson & Son, 
in Melbourne.
1883 Hunter 
McPherson, one 
of Thomas’ three 
sons, sent to open a 
branch in Sydney.
1889 Thomas 
McPherson passed, 
leaving to sons 
William and Edward 
the Melbourne 
business.
1896 Edward 
McPherson passed, 
William became sole 
proprietor of Thomas 
McPherson & Son, 
Melbourne, with 
eight employees.
1900 Manufacture of Bolts 
and Nuts commenced at 
West Melbourne.
1911 William opened a 
branch in Wentworth 
Street, Sydney.
1913 Name changed to 
McPherson’s Pty. Ltd.
1914 A new Sydney 
branch was opened on 
Bathurst Street.
1915 McPherson’s Pty. Ltd. 
contract with a Melbourne 
firm to make lathes under 
McPherson’s supervision
1918 McPherson’s Pty. Ltd. 
establish their own Machine 
Tool Works at Kensington, 
Victoria to produce the 
Macson Lathe.
1944 Name changed 
to McPherson’s Ltd. 
when firm became 
a public company 
with William E. 
McPherson as 
Chairman.
1921 Adelaide 
branch opened.
1924 Bolt Works 
transferred to 
Richmond, Victoria
1929 Sir William 
McPherson resigned 
as Governing 
Director and was 
succeeded by his 
son William.
1930 Perth branch opened.
1934 Bolt Works established at 
Alexandria, NSW.
1936 McPherson’s Melbourne 
House moved to new building 
546-566 Collins Street.
1938 Machine Tool Works 
enlarged and modernised. 
McPherson’s acquired Tool 
Equipment Co. Pty. Ltd. and 
Australian Abrasive Pty. Ltd. 
commenced manufacturing.
1939 Ajax Pump Works 
established at Tottenham, 
Victoria. Ajax Bolt and Rivet Co. 
Ltd. commenced manufacturing 
in New Zealand with 
McPherson’s holding controlling 
interest. Machine Tool Foundry 
transferred to Tottenham.
years
GOLD RUSH BOOM INTO WW1
INTERWAR
1860 1880 1900
1920 1930
1940
10  |  McPherson’s Limited

The Company has risen from a humble 
metal and hardware merchant into a 
strong and diversified business in the 
health, wellness and beauty sector. Our 
rich history demonstrates a tangible value 
that strengthens our brand, enhances 
our culture, and supports our ongoing 
transformation and future growth.
UNEARTHING OUR PAST
The McPherson’s story began in the mid-
19th century when Thomas McPherson, 
a Scottish immigrant, established the 
Company as an iron merchant to meet 
the needs of a growing Melbourne 
during a gold rush. From these humble 
beginnings, McPherson’s expanded into 
bolt manufacturing, machinery, and later 
diversified into areas such as printing, 
ultimately evolving into the consumer 
goods company we are today.
Over the decades, McPherson’s has 
continuously adapted to meet market 
demands, from pioneering engineering 
tools to today’s focus on health, wellness, 
and beauty. Our ability to anticipate 
industry trends and adapt has been key 
to our sustained growth.
ENHANCING COMPANY CULTURE
Throughout our history, we have placed 
great importance on fostering long-term 
relationships with our customers, our 
people, and the communities in which 
we operate. From launching one of 
Australia’s first profit-sharing programs in 
1896 to establishing employee shares and 
superannuation schemes, McPherson’s 
has consistently put its people at the 
heart of the business. This legacy 
continues to shape our culture today, 
where employee support and community 
engagement remain core to our values.
DRIVING FUTURE GROWTH: 
BUILDING ON OUR 
TRANSFORMATION
FY24 marked a pivotal year in 
McPherson’s transformation. Our 
rich heritage has reinforced the 
values that shape our business as we 
progressed through the first year of our 
transformation roadmap. This has allowed 
us to align our past achievements with 
our current strategic initiatives, ensuring 
that our development and change is built 
on the same principles that have driven 
our success for over 160 years.
With a strong foundation rooted in 
innovation, employee well-being, and 
community engagement, McPherson’s is 
well-positioned for future growth. 
1957 Brisbane 
branch opened. 
Guest, Keen & 
Nettlefold’s Ltd., 
a New Zealand 
company, purchased 
interest in Ajax 
Bolt & Rivet Co. 
Ltd., the New 
Zealand subsidiary. 
Name of Company 
changed to Ajax 
G.K.N. Ltd. with 
McPherson’s Ltd. 
and Guest, Keen & 
Nettlefold’s Ltd. as 
equal shareholders. 
1960 Acquired 
substantial interest 
in LS Barker Pty 
Ltd a woodworking 
company. William 
David McPherson, 
son of W. E. 
McPherson, became 
Deputy Chairman 
to make the fourth 
generation to lead 
the organisation. The 
Sydney business of 
Thomas McPherson 
& Son, which had 
continued its 
operations under 
separate ownership 
since 1888, merged 
with McPherson’s. 
The turbulent years.
The beginnings of a 
period of decline. 
1970s Head office 
moved to 500 Collins 
Street Melbourne.
From Bolts to 
Beauty. 
A difficult transition. 
Extended interests 
in the printing 
and housewares 
businesses. 
Purchased 
balance of: 
1980 Wiltshire;
1981 The Dominion 
Press, and;
1983 the William 
Brooks & Co. 
Directory Printing 
Operation.
Major transformation. Core commitment to Health, 
Wellness & Beauty. ‘De-risking’ the business.
2003 McPherson’s acquired Cork International’s Asia 
Pacific Business (Manicare & Lady Jayne brands).
2004 Further acquisitions with the purchase of Accantia 
Health & Beauty (July) Multix (October).
2011 company vision to be a world class consumer 
products company.
2012 McPherson’s printing business was demerged from 
the group. The focus now purely on consumer products.
2014 Divestments including Crown glassware business. 
Move into home appliances (Euromaid).
2015 McPherson’s Limited designs, sources and markets 
products under four broad categories: Health & Beauty, 
Home Appliances, Household Consumables and 
Impulse Merchandising.
2016 Housewares business fully divested. Chinese market 
seen as key opportunity for beauty products.
2024 Divested Multix brand and inventory
WW2 & POST-WAR RECONSTRUCTION
A NEW ‘MODERN’ ERA
1950
1960
1970
1980 2000–2024
Annual Report 2024  |  11

Our People
OUR PEOPLE HAVE ALWAYS BEEN THE CORNERSTONE OF 
MCPHERSON’S SUCCESS. WE ARE COMMITTED TO UNLOCKING 
THEIR FULL POTENTIAL BY PROVIDING OPPORTUNITIES FOR 
CAREER-DEFINING ACHIEVEMENTS AND TRANSFORMING 
PRODUCTIVITY THROUGH INNOVATIVE TECHNOLOGY. 
FOSTER A CULTURE OF SAFETY AND WELLBEING
At McPherson’s, the safety and well-being of employees is paramount. This year, we 
introduced enhanced and automated safety incident reporting through Employment 
Hero, streamlining how incidents are reported and managed across the company. 
This system empowers our employees to quickly and easily report safety concerns in 
real‑time, ensuring better visibility of incidents. 
BUILDING A HIGH-PERFORMANCE CULTURE
Building a high-performance culture is a key focus of our transformation. To drive 
accountability and alignment, we implemented OKRs (Objectives and Key Results) 
and introduced a 90-day performance cycle, ensuring regular progress tracking and 
agile goal setting. Each quarter, our teams participate in “pitstops” where we review 
progress, celebrate successes, and recalibrate for the next cycle. 
RECOGNISING AND CELEBRATING OUR PEOPLE
Recognising and celebrating the exceptional efforts of our people is a core part of our 
culture. Each month, we present Values Awards to acknowledge those who go above 
and beyond in their roles and make meaningful impact. These awards highlight our 
dedication to recognising teamwork and high performance. 
PRODUCTIVITY ENHANCEMENTS THROUGH TECHNOLOGY
The implementation of the Salesforce Retail Execution module (REX) is enhancing 
our field sales team’s capabilities, providing real-time data access to optimise 
decision‑making and improve in-store execution. Complementing this, the introduction 
of Employment Hero as our people management system has streamlined HR processes, 
from recruitment to performance management. Both systems are designed to be fit 
for purpose, giving us the tools to increase efficiency and align our operations with 
business objectives. 
HIGHLIGHTS AS OF 
JUNE 2024:
EMPLOYEES 
264
FEMALE 
REPRESENTATION 
66%
NEW HIRES 
58
12  |  McPherson’s Limited

FY24 HAS SEEN A SUBSTANTIAL INCREASE IN ESG FOCUS 
BOTH AT OPERATIONAL AND REGULATORY LEVELS.
Governments, industry, global organisations and educational and research institutions 
around the world are currently grappling with the challenges of climate change, 
sustainability, aging infrastructure and the increasing costs of energy production.
In Australia, we’ve seen the introduction of mandatory climate related financial 
disclosure as well as the pending introduction of Extended Producer Responsibility for 
product packaging. At present, McPherson’s will be required to commence climate 
related financial disclosure reporting for the financial year commencing 1 July 2027.
Given the evolving regulatory landscape, changing market and stakeholder 
expectations and the transformative changes within our business, during FY24 
McPherson’s carried out an independent ESG materiality assessment. This 
assessment involved an analysis of aspects of ESG that are highly relevant to our 
business as well as important insights received from a variety of our stakeholders 
including shareholders, customers, suppliers and our people. This materiality 
assessment has directed our ESG focus to lay solid foundations to address the 
Company’s identified ESG priorities.
During FY24, we:
	
– Completed our baseline Scope 1,2 and 3 Green House Gas emissions footprint.
	
– Completed our ESG materiality assessment.
	
– Continued the work to transition our brands to meet the goals of the National 
Packaging Targets.
	
– Incorporated climate risks into our Enterprise Risk Register.
	
– Improved visibility into our supply chain through our SEDEX membership (which is 
the world’s largest data platform for ESG related supply chain assessment. With 
over 85,000 members globally, the platform enables McPherson’s to analyse 
sustainability practices across our supply chain).
Our focus for FY25 will be to continue our work to embed our identified ESG priorities 
in our business for long-term value creation for our shareholders and stakeholders 
and lay the foundation to ensure compliance for current and future regulations. These 
priorities are centred around delivering on our product packaging (i.e. seeking to meet 
relevant and applicable sustainability requirements for the packaging of our products), 
delivering a sustainable supply chain (i.e. seeking to ensure our supply chain meets 
relevant and applicable sustainability standards and relevant laws and regulations) and 
preparing for our upcoming mandatory climate related financial disclosures.
Our ESG risks are identified, assessed, mitigated and reported by management 
and are overseen by the Company’s Risk & Compliance Committee and the Board. 
Regular reports on the Company’s risks, including identifying and managing our 
ESG risks, are provided to the Risk & Compliance Committee. Along with these risk 
reports, progress reports on the implementation of the Company’s ESG priorities 
are provided to the Board.
Environmental, Social and 
Governance (ESG)
RESTORATIVE 
BRUSH — MASSAGE 
& CLEANSE
Annual Report 2024  |  13

FROM LITTLE THINGS BIG THINGS GROW
Women’s Safety Services (South Australia) Ltd — Inner North | July 2024
In July 2024, McPherson’s, provided $33,593 (RRP) worth of Dr. LeWinn’s 
skincare and A’kin hair care products to Women’s Safety Services in South 
Australia. This organisation supports women and children who escape 
domestic and family violence, offering emergency accommodation and 
vital resources.
For the 50 lives impacted by this donation, access to basic hygiene 
products like skin cleansers and hair conditioners is more than just a 
necessity it restores pride during an incredibly challenging time. The brand 
new, sealed products provided a touch of luxury that these individuals 
might not have experienced before, offering them comfort and a sense 
of normalcy amid the upheaval of their lives.
Serving Our Community 
AT MCPHERSON’S, OUR COMMITMENT TO COMMUNITY SERVICE 
IS AMPLIFIED THROUGH OUR PARTNERSHIP WITH GOOD360, AN 
ORGANISATION DEDICATED TO CONNECTING BUSINESSES WITH 
NONPROFITS TO PROVIDE ESSENTIAL GOODS TO THOSE IN NEED. 
Good360 works tirelessly to ensure that surplus products find their way to communities where 
they can make the most impact, turning everyday essentials into instruments of hope and change.
In early 2024, our collaboration with Good360 enabled us to support impactful initiatives that 
brought essential products and to vulnerable communities across Australia.
BEAUTY BEYOND BASICS
Salisbury Primary School | June 2024
In June 2024, Salisbury Primary School in South 
Australia received a generous donation of Dr. LeWinn’s 
beauty and skincare products, valued at $57,905 
(RRP). Facilitated by Good360, this contribution provided essential skin 
cleansers, toners, repairers, and hair conditioners to 200 individuals within 
the school’s community.
For many families in Salisbury, financial challenges mean that non-essential 
items like beauty and skincare products become unaffordable luxuries. This 
donation not only alleviated that burden but also brought a sense of dignity 
and joy to those who received it. The positive reactions from the mothers, 
who were particularly appreciative of these donations, underscore the 
significant impact that such contributions can have on communities.
MAKING A LASTING IMPACT
These impact stories underscore the meaningful difference that McPherson’s donations have made 
in communities facing challenges. We are proud to support those who need it most, ensuring they 
have access to essential resources and a renewed sense of wellbeing. Together with Good360, 
we are committed to building stronger, more resilient communities.
14  |  McPherson’s Limited

RESULTS FOR THE YEAR
FY24 has been a year of progress for McPherson’s. Following the appointment of a new CEO 
in August 2023, McPherson’s announced a refreshed strategy and clear plan to unlock value 
for shareholders. During the year, McPherson’s has taken deliberate steps to simplify and 
focus the business, including divesting the Multix brand and inventory assets. The FY24 result 
reflects the scale of the transformation underway, including one-off costs incurred. 
Review of Operations 
Total Group Sales ($m)
Total Group underlying profit before tax ($m)1
Net (Debt) / Cash (excl lease liabilities) ($m)
Total Group underlying earnings (EPS) and 
dividends per share (cps)1
2024
2023
55.1
53.0
155.2
144.6
2022
214.0
210.3
197.6
2021
200.5
2020
222.2
2024
2023
7.5
(0.1)
2022
10.7
2021
9.6
2020
24.0
2024
2023
14.1
(6.5)
2022
(1.7)
2021
(8.4)
2020
(9.2)
2024
2023
2022
2021
11.0
2020
15.3
5.0
5.1
5.0
5.3
3.0
2.0
3.4
Earnings per share
Dividends per share
Continuing operations
Discontinued operations
Continuing operations
Discontinued operations
2.9
7.4
7.3
4.4
3.0
1.	 Underlying performance excludes material items on page 72 of this report.
Annual Report 2024  |  15

CONTINUING OPERATIONS
Continuing Operations results
FY24
($m)
FY23
($m)
Change
($m)
Change
(%)
Revenue
144.6
155.2
(10.5)
(6.8%)
Underlying EBITDA
7.7
12.1
(4.5)
(36.8%)
Material items (before tax)
(12.7)
(3.7)
(9.0)
(246.2%)
EBITDA including material items
(5.0)
8.5
(13.5)
(158.9%)
Revenue from Continuing Operations was $144.6 million, down 6.8% compared to 
$155.2 million in FY23. Sales of the Company’s core brands have outperformed portfolio 
and other group brands, and the results reflect a shift towards a more favourable, 
higher margin product mix. Across the Group, and notwithstanding a more challenging 
trading environment, core brand revenue of $122.4 million was broadly in line with 
the prior year of $123.3 million in FY23. This performance reflects a relatively stronger 
second half with revenue growth up 1.8% vs. the prior comparable period, compared to 
a decline in 1H24 of 2.9% vs. the prior comparable period.
Sales of the Company’s portfolio brands declined $2.7 million during the year, mostly 
driven by supply challenges, which management has been focused on resolving through 
the appointment of new manufacturers and resolving product dating issues, and a 
transition of focus from our Oriental Botanical’s brand to the Fusion Health brand. In 
line with the strategic reset announced in November 2023, the Company began exiting 
private label and non-strategic brands. Sales from these products declined $6.9 million 
during the year.
Underlying EBITDA from Continuing Operations was $7.7 million, down from $12.1 million 
in FY23. This result primarily reflects the unfavourable impact of a weaker AUD/USD, 
a decline in the contribution after A&P (CAAP) from portfolio brands and the need for 
stock provisioning on certain SKUs due to shelf-life constraints. The Group’s exit from 
non-strategic and agency brands also contributed to a CAAP decline. This was partially 
offset by the shift to higher margin core brands. Reduced operating costs primarily 
reflect an overall reduction in employee costs of $1.1 million related to restructuring 
activities in 1H24 and an increase in other expenses including new sales software licence 
fees and increased market research. 
EBITDA from Continuing Operations after material items was ($5.0) million, down from 
$8.5 million in FY23. Material items from Continuing Operations were $12.7 million pre‑tax 
and are discussed in more detail below.
TOTAL GROUP
Total Group results 
FY24
($m)
FY23
($m)
Change
($m)
Change
(%)
Revenue
197.6
210.3
(12.6)
(6.0%)
Underlying EBITDA
15.2
15.0
0.2
1.1%
Material items (before tax)
(26.7)
(12.0)
(14.7)
(123.2%)
EBITDA including material items
(11.5)
3.1
(14.6)
(473.6%)
Total Group revenue was down 6.0% on the previous year, with revenue from 
continuing operations down 6.8%, largely reflecting the decision to exit non-strategic 
agency brand relationships; and revenue from discontinued operations (Multix) down 
3.8%, reflecting the continued shift of consumers to private label products in the bags, 
wraps and foils category. 
Total Group underlying EBITDA for the year was steady at $15.2 million, with EBITDA 
margin increasing +0.5 ppts to 7.7%. This uplift primarily reflects an improved underlying 
EBITDA result from the Multix business, which benefited from more favourable 
commodity and freight prices during the year.
REVIEW OF OPERATIONS CONTINUED
TOTAL GROUP SALES
$197.6m
TOTAL GROUP 
UNDERLYING EBITDA
$15.2m
16  |  McPherson’s Limited

DIVESTMENT OF MULTIX
On 28 June 2024, McPherson’s announced it had completed the sale of the Multix 
brand and inventory assets for $19 million (prior to completion adjustments). The sale 
followed a strategic review of the Multix brand, which concluded that the revenue 
drivers, opportunities and challenges for Multix were different to those for McPherson’s 
core brands, and that there was not sufficient strategic alignment with McPherson’s 
core business to retain Multix. In particular, the review considered:
	
– Structural changes in the bags, wraps and foils category due to changing consumer 
preferences and government and regulatory focus on packaging materials;
	
– The strong representation of private label products within the competitor universe 
and the challenges of establishing a point of difference; and
	
– The volatility of McPherson’s earnings from Multix as a result of cyclical currency, 
commodity and freight cost exposures.
McPherson’s impaired the Multix brand by $8.3 million in FY23 because of these factors. 
With an improvement in commodity and freight costs in FY24, the Board determined it 
was an opportune time for the divestment of the brand and inventory assets. Due to its 
relative size and nature, the Multix business is reported as a discontinued operation.
Results
FY24
($m)
FY23
($m)
Change
($m)
Change
(%)
Revenue
53.0
55.1
(2.1)
(3.8%)
Underlying EBITDA
7.5
2.9
4.6
160.7%
Material items (before tax)
(14.0)
(8.3)
(5.7)
(68.9%)
EBITDA including material items
(6.5)
(5.4)
(1.1)
(19.9%)
Loss on sale after tax
(9.4)
—
(9.4)
100%
Loss from discontinued operations
(4.6)
(3.8)
(0.8)
(21.6%)
Revenue from discontinued operations was $53.0 million, down 3.8% compared to 
$55.1 million in FY23. In addition to the shift of consumers to private label products, the 
decline in sales revenue during FY24 reflects the full year impact of range reductions by 
a key grocery customer during FY23.
Underlying EBITDA of $7.5 million, represents a significant increase on the prior year, 
and reflects the combined impact of favourable commodity and freight prices (net of 
unfavourable FX), and reduced operating costs – primarily reduced A&P investment and 
employee costs.
OPERATIONAL TRANSFORMATION UPDATE
Following the divestment of Multix, notwithstanding the exit of direct variable costs, the 
continuing operations retain a large portion of the shared fixed cost base that supports 
its remaining brands, including warehouse capacity and associated distribution and 
operating costs. 
Addressing this residual cost base, and ensuring the business has the right cost 
structure to drive efficiency and growth in its core and portfolio brands, is now a key 
priority for the business. The existing cost infrastructure supporting the Group’s brands 
is significant, underutilised and will increase over time as a result of rent reviews, and 
outdated and unsupported warehouse systems that will require replacement and 
modernisation at significant cost.
As a result of these factors, management identified a potential new route to market 
strategy to assist in right-sizing the cost-base and to support business growth. 
With the sale of Multix now completed, McPherson’s is a pure-play health, wellness and 
beauty company focused on investing in, and growing, its five core brands: Manicare, 
Lady Jayne, Dr LeWinn’s, Swisspers and Fusion Health. These core brands operate in 
attractive categories such as beauty accessories, hair accessories, skincare, cotton and 
vitamins, minerals and supplements, that show strong and consistent growth and the 
potential for higher margins.
REVIEW OF OPERATIONS CONTINUED
MULTIX BRAND AND 
INVENTORY ASSET SALE
$19.0m
Annual Report 2024  |  17

BUSINESS UNIT PERFORMANCE
Australia and New Zealand (ANZ)
Results
FY24
($m)
FY23
($m)
Change
($m)
Change
(%)
CONTINUING OPERATIONS
Revenue
139.1
146.6
(7.5)
(5.1%)
Underlying EBITDA
12.8
17.6
(4.8)
(27.3)
TOTAL ANZ
Revenue
192.1
201.6
(9.5)
(4.7%)
Underlying EBITDA
20.3
20.5
(0.2)
(1.0%)
The ANZ Business Unit reported revenue of $192.1 million, down 4.7% on FY23, and 
underlying EBITDA of $20.3 million, broadly in line with FY23. 
When adjusted for discontinued operations, revenue declined 5.1% to $139.1 million and 
underlying EBITDA was down $4.8 million to $12.8 million. This decline in EBITDA reflects 
similar drivers to those discussed in relation to the continuing operations of the Group — 
namely, the impact of a weaker AUD/USD, the performance of the portfolio brands and 
non-strategic and agency brands, and stock provisioning; partially offset by employee 
cost savings from restructuring activities during the year.
Revenue from McPherson’s five core brands was $117.9 million in FY24, marginally 
behind FY23 ($118.4) million. Dr LeWinn’s, Swisspers and Lady Jayne grew moderately 
compared with the previous year, while Manicare was impacted by increased 
competitor activity and Fusion was hampered by supply challenges.
The ANZ business is typically weighted to 1H, reflecting the timing of seasonal 
promotional events and the lead-in to Christmas. As a result, core brand sales in 2H24 
were below 1H24. However, the relative performance of core brands improved in 2H24, 
with growth of 2.4% on the prior comparable period, compared to a decline of 2.9% 
in 1H24. 
Revenue from supporting portfolio brands decreased $2.3 million or 12.2%, with weaker 
performances by certain brands particularly impacted by supply challenges and the 
transition of focus from our Oriental Botanical’s brand to the Fusion Health brand.
Revenue from the EDA brands for the full year was below expectations. McPherson’s is 
reviewing its strategy with respect to EDA brand performance, including opportunities 
to expand deeper into the pharmacy channel, and different supply chain solutions 
to expand shelf-life. However, in light of current performance, accounting standards 
require the inventory prepayment be fully written down during the current period. This 
recognises that the recoverability of the asset, at this stage, is sufficiently uncertain to 
warrant amortisation over the remaining 3 years of the initial 5-year term. 
In November 2023, McPherson’s announced it would cease private label and exit 
non‑strategic agency brands. In FY24, these brands accounted for $4.7 million in 
revenue, down from $8.8 million in FY23.
REVIEW OF OPERATIONS CONTINUED
ANZ TOTAL SALES
$192.1m
ANZ TOTAL 
UNDERLYING EBITDA
$20.3m
1
1.	 Earnings before interest, tax, depreciation and amortisation (EBITDA) is a non-GAAP measure and does not have a standardised meaning prescribed by GAAP. 
However, the Company believes that, in combination with GAAP measures, it assists in providing investors with a comprehensive understanding of the underlying 
operational performance of the business. A reconciliation of EBITDA to net profit after tax is shown on page 74 of this report.
18  |  McPherson’s Limited

International
Results
FY24
($m)
FY23
($m)
Change
($m)
Change
(%)
CONTINUING OPERATIONS
Revenue
5.6
9.3
(3.8)
(40.5%)
Underlying EBITDA
(0.6)
(1.3)
0.7
55.9%
The international business achieved revenue of $5.6 million, down 40.5% from 
$9.3 million in FY23. This decline primarily reflects the decision to exit non-strategic 
agency and distributor partners in Singapore. Notwithstanding some supply constraints, 
the performance of Dr LeWinn’s in China was marginally ahead of the prior year (+0.5%), 
and sales of Manicare, although modest, increased off a low base. 
Underlying EBITDA of ($0.6) million represents an improvement of 55.9% on FY23. 
Notwithstanding the decline in sales, this improvement reflects favourable product 
mix from a higher weighting of core brand sales, coupled with employee and other 
cost savings.
Material Items
McPherson’s has recognised $26.7 million in pre-tax material items, resulting primarily 
from the re-set of the business in FY24, but also reflecting the impact of the trading 
performance of certain non-core brands. 
Pre-tax material items from continuing operations were $12.7 million and comprise:
	
– $3.7 million impairment and $1.2 million amortisation of the EDA inventory prepayment.
	
– $2.8 million impairment of other non-core portfolio brands, including Maseur, Oriental 
Botanicals and Revitanail. These impairments reflect the trading performance of these 
brands, and the impact of the Multix brand residual cost base on the profitability of 
other brands in the portfolio.
	
– $2.3 million inventory write-down associated with product rationalisation and exit of 
non-core agency brands.
	
– $1.7 million in restructuring costs associated with right-sizing the organisation’s 
employee base.
	
– $1.0 million in other material items including transition costs associated with the 
leadership refresh and professional fees in relation to the ASIC matter.
Pre-tax material items from discontinued operations were $14.0 million and comprise:
	
– $13.4 million loss on divestment of the Multix brand and inventory assets, including 
$11.9 million non-cash write-down of brand and allocated goodwill; and $1.5 million of 
related transaction and other costs.
	
– $0.6 million in restructuring costs associated with the Multix divestment.
REVIEW OF OPERATIONS CONTINUED
INTERNATIONAL SALES
$5.6m
INTERNATIONAL 
UNDERLYING EBITDA
$(0.6)m
1
1.	 Earnings before interest, tax, depreciation and amortisation (EBITDA) is a non-GAAP measure and does not have a standardised meaning prescribed by GAAP. 
However, the Company believes that, in combination with GAAP measures, it assists in providing investors with a comprehensive understanding of the underlying 
operational performance of the business. A reconciliation of EBITDA to net profit after tax is shown on page 74 of this report.
Annual Report 2024  |  19

CATEGORY & BRAND OVERVIEW: 
We continued to invest in 
our 5 core brands
MANICARE
Manicare continues to be the #1 beauty tools and 
accessories brand in Australia holding ~29% market 
value share 1. During the year, the trading environment 
in the beauty tools and accessories category has been 
challenging, as consumers pull back on discretionary 
spending and seek value alternatives in the Private 
Label space.
Competition within the category continued to escalate 
in FY24 with the expansion of Private Label offerings 
within grocery and pharmacy. The result has been 
downward pressure on price within the category, 
which has disproportionately impacted Manicare as the 
premium brand.
In FY24, Manicare continued to prioritise innovation, 
particularly within the pharmacy channel, to strengthen 
brand presence. This year, we successfully expanded 
our salon beauty device range with the Manicare Salon 
Firming Face & Body Sculptor which is our first multi-
purpose face and body device. Combining LED Red 
Light, EMS, and Lipo Vacuum Suction technologies, 
the Sculptor has been clinically proven to reduce 
forehead wrinkles by 22%, with 80% of users reporting 
smoother, firmer, and more toned skin. Independent 
beauty trial teams for Beauty Crew have awarded 
the Manicare Salon Firming Face & Body Sculptor 
a 4-star rating, underscoring the strength of our 
product development.
Manicare also made strides in the on-trend makeup 
tools segment, delivering premium value to beauty 
enthusiasts. Products such as the Wet & Dry Puff, 
Brow & Lash Spoolie Set, Precision Brow Grooming Kit, 
and Air Cushion Sponge Duo have been well-received 
in the pharmacy channel. Additionally, the Precision 
Brow Grooming Kit will be ranged in grocery starting 
early FY25, marking a notable expansion in distribution.
The reinvention of our core range remains a key pillar 
of the Manicare strategy. In May 2024, we relaunched 
the Manicare nail treatment system, introducing three 
new line extensions. Among them, the Overnight Nail 
Treatment and All-in-One Oil have received a 4.5-star 
rating from Beauty Heaven’s independent trial teams, 
further solidifying our brand’s credentials in nail care.
Our commitment to media investment saw an increase 
in the second half of FY24, with the introduction of 
four new digital assets showcasing beauty routines. 
These campaigns, designed to elevate beauty routines 
by featuring both our new products and trusted 
staples, generated over 34.5 million impressions. The 
latest consumer brand equity tracking from May 2024 
sees Manicare strengthen brand awareness to 67%.2
1.	 Circana scan data (Grocery & Pharmacy) MAT to end June 2024
2.	Brand Health Tracking (Paradigm Shift) April 2024
AIR CUSHION 
SPONGE
20  |  McPherson’s Limited

GLAM BY MANICARE
Glam continues to be the #1 Eyelash and Eyebrow brand in Australia.1
The eyelash and eyebrow category faced challenges in FY24, with a 6.5% decline in 
category sales as consumers reduced discretionary spending.1 A shift away from ‘party’ 
occasions contributed to fewer purchases, impacting both Glam and competitors. 
Despite this, Glam remains top of mind for category shoppers, with Consumer Brand 
Equity research indicating a record high awareness level of 19%, a significant 10 
percentage point increase from the previous year.2
Innovation has been a key driver of success for Glam in FY24, contributing 11% of retail 
scan sales through New Product Development.1 The launch of Glam’s Glue-On and 
Pre‑Glued nail range, featuring 8 SKUs, propelled Glam to the #2 position in the artificial 
nail market in Australia.1
A standout innovation in the first half of FY24 was the introduction of the Glam Flexi 
lash range, a breakthrough in lash wear designed to enhance comfort with a stretchy, 
invisible band that adapts to eye movements. This innovation directly addresses a key 
consumer pain point of discomfort, further strengthening our position in the market.
During the year, we also expanded our distribution by securing national placement of 
five lash SKUs in a major supermarket. This strategic move significantly enhances Glam’s 
market presence and is expected to drive increased category penetration, positioning 
the brand for growth in the coming fiscal year.
1.	 Circana scan data (Grocery & Pharmacy) MAT to end June 2024
2. Brand Health Tracking (Paradigm Shift) April 2024
CATEGORY & BRAND OVERVIEW CONTINUED
INNOVATION 
CONTRIBUTING TO
11%
1
of retail scan sales 
through new product 
development
Annual Report 2024  |  21

LADY JAYNE
Lady Jayne continues to be a #1 hair 
tools and accessories brand in Australia, 
maintaining market value share of 27%.1 The 
brand has experienced mixed performances 
across segments, with strong retail scan sales 
growth in brushes (up 8.9%) and challenges in 
accessories (down 10.5%).1
A key focus for Lady Jayne has been the 
continued elevation of its ‘rechargeables’ 
range, which has become a significant growth 
driver. In FY24, this range generated $2.2 
million in retail scan sales, further boosted 
by the launch of the Lady Jayne 2-in-1 
Rechargeable Hair Styler.1 This innovative 
product addresses the increasing demand 
for convenience and versatility in personal 
grooming. The Salon Pro Rechargeable 2-in-1 
Hair Styler is designed to deliver salon-quality 
straight or curly styles on the go, offering 45 
minutes of cordless styling with heat control 
and ceramic technology for a smooth finish.
Distribution expansion was also a key 
objective for Lady Jayne in FY24. Our 
efforts to extend the reach of the brand 
were successful, particularly in grocery. 
Based on FY24 scan data, Lady Jayne was 
#1 in the hairbrush segment in one of the 
national supermarkets.1
Lady Jayne continues to innovate and grow, 
solidifying its position as a leading brand 
in hair tools & accessories category across 
Australia. The brand remains focused on 
meeting the evolving needs of consumers 
while expanding its footprint in the market. 
CATEGORY & BRAND OVERVIEW CONTINUED
1.	 Circana scan data (Grocery & 
Pharmacy) MAT to end June 2024
 ARIA 
STRAIGHTENER
22  |  McPherson’s Limited

DR. LEWINN’S
Dr. LeWinn’s remains a key player in the anti-aging skincare sector. The brand has 
seen a varied performance across its product lines during the year. Notably, the Ultra 
R4 range achieved robust growth, up 17.5%, driven by its innovative formulations 
and strong market positioning. The Inner Beauty range also expanded by 8.3%, 
demonstrating consumer interest in holistic skincare solutions.1
In FY24, Dr. LeWinn’s strengthened its position in the skincare market through a series 
of innovative product launches and strategic communication efforts. Key innovations 
included the expansion of the Ultra R4 range, which saw growth, and the introduction 
of new products in the Cleanser Series and Ceramide range. These launches, such 
as the Daily Cleansing Balm and Barrier Protect Ceramide Balm, reflect the brand’s 
commitment to delivering luxurious, effective skincare solutions tailored to diverse 
consumer needs.
Dr. LeWinn’s supported these innovations with robust marketing campaigns, 
leveraging partnerships with leading media partners. These campaigns targeted 
beauty enthusiasts through digital and influencer channels, ensuring broad reach and 
engagement. Additionally, personalised events and collaborations with influencers 
further amplified brand visibility, driving consumer interest and strengthening Dr. 
LeWinn’s presence in the competitive skincare market.
Through these efforts, Dr. LeWinn’s continues to be a leader in anti-aging delivering 
cutting-edge skincare solutions that cater to diverse skin needs.
CATEGORY & BRAND OVERVIEW CONTINUED
1.	 Circana scan data (Grocery & Pharmacy) MAT to end June 2024
ULTRA R4 RANGE 
ACHIEVED GROWTH BY
17.5%
1
INNER BEAUTY RANGE 
EXPANDED BY
8.3%
1
Annual Report 2024  |  23

SWISSPERS
Swisspers continues to be the #1 cotton brand in Australia, holding a significant 65% 
market value share.1 This success was bolstered by strong growth in the Pharmacy 
channel, where the brand continues to thrive. However, the brand has experienced 
a difficult trading environment in grocery as consumers pull back on discretionary 
spending and seek alternatives in the Private Label space. 
Competitive pricing dynamic has been a focal point of the category throughout 
FY24 as Private Label offerings have adjusted their pricing strategies to draw 
foot traffic from other retailers. The brand has responded with improved range 
recommendations for both major supermarkets to better align with shopper needs 
and provide greater value in consumer baskets. 
In FY24, Swisspers strategically segmented its marketing efforts to maximise 
impact. The first quarter featured a social media campaign promoting the 3-in-1 
Cleanser Infused Pads, focusing on educating consumers and encouraging a shift 
from traditional facial wipes.
In the second quarter, the focus shifted to the baby range, using respected 
parenting platforms like Tell Me Baby, Bounty Parents, and Mouths of Mums to 
drive awareness and reviews. Samples were also distributed through Bounty Bags, 
directly reaching new parents.
The brand’s marketing efforts in the last two quarters included a relaunch of the 
3-in-1 social campaign, complemented by collaborations with paid influencers to 
further boost visibility and engagement. 
Swisspers remains committed to adapting to market conditions and evolving 
consumer needs, with a focus on maintaining its leadership in the cotton category 
and continuing to innovate across its product offerings.
1.	 Circana scan data (Grocery & Pharmacy) MAT to end June 2024
CATEGORY & BRAND OVERVIEW CONTINUED
MARKET VALUE 
SHARE
65%
1
#1
COTTON BRAND IN 
AUSTRALIA 1
24  |  McPherson’s Limited

FUSION HEALTH
Fusion Health which blends modern and ancient 
medicine, continues to grow awareness and 
distribution and delivered scan sales growth in the 
Pharmacy channel of 38.9%,1 through expanded 
availability but was challenged by some supply chain 
issues (now resolved) and declines in the Health 
Food Store channel. We have focussed the brand on 
its core strengths in key growth segments, including 
Immune Health, Mind & Body Support, and Physical 
Activity Support, where it continues to hold a strong 
competitive position.
A major strategic objective for Fusion Health was 
distribution expansion, and a significant milestone 
was achieved in November 2023, when Fusion 
Health secured ranging in a large pharmacy group. 
This new range includes top-selling Fusion Health 
SKUs and exclusive 30-pack SKUs designed to 
differentiate the brand for retailers and cater 
specifically to pharmacy consumers.
In FY24, Fusion Health grew brand awareness 
through increased investments in television, outdoor, 
and radio advertising. This heightened visibility 
contributed to the brand’s growth in the Pharmacy 
channel and bolstered overall brand health
Innovation remained a focal point for Fusion Health, 
particularly in enhancing its market-leading formulas. 
The launch of Curcumin Advanced exemplified this 
commitment. The new formulation, which features 
75% more Curcumin and the addition of clinically 
tested Boswellia extract Après Flex, is designed to 
relieve symptoms of mild osteoarthritis, such as joint 
pain and stiffness.
Fusion Health remains dedicated to growth through 
innovation, distribution expansion, and education, 
ensuring it continues to meet the evolving needs of 
both consumers and healthcare professionals.
1.	 Circana scan data (Pharmacy) MAT to end June 2024)
CATEGORY & BRAND OVERVIEW CONTINUED
SALES GROWTH IN THE 
PHARMACY CHANNEL
38.9%
1
Annual Report 2024  |  25

Information on Directors
Mr. Mervis was appointed an Independent 
Non-Executive Director of McPherson’s Limited 
on 16 February 2021, Deputy Chair on 27 April 
2021 and Chair of the Board from 21 July 2021. 
Mr. Mervis is a professional company director 
with global experience spanning a range 
of industries in branded goods, consumer 
staples, agriculture, food and beverages. Mr. 
Mervis has vast experience having lived and 
operated businesses in complex geographies 
and having led and been involved in both listed 
and unlisted companies, as well as joint venture 
structures and not for profit organisations. His 
experience is further enhanced through having 
actively participated in significant mergers and 
acquisitions, and divestments, including post-
acquisition integration and synergy delivery. 
Mr. Mervis is the current Non-Executive Chair 
of Endeavour Group Limited. His previous roles 
include Executive Chair for Accolade Wines 
and CEO and Managing Director for Murray 
Goulburn. Prior to that, he had a successful 
career at SABMiller, culminating as CEO for 
CUB and MD for the Asia Pacific region. He 
was also Chair of China Resources Snow Beer, 
SABMiller India and SABMiller Vietnam. 
Mr. Mervis holds a Bachelor of Commerce from 
the University of Witwatersrand, South Africa, 
with majors in Economics, Commercial Law 
and Marketing.
Special Responsibilities
	
– Executive Chair 
(from 1 June 2023 until 31 July 2023)
	
– Member of the Audit Committee 
(appointed 22 February 2022)
	
– Member of the People & Culture Committee 
(appointed 22 February 2022)
Other current listed Directorships
	
– Endeavour Group Limited 
(Non-Executive Chair)
Former listed Directorships (last three years)
	
– Myer Holdings Limited 
(from September 2021 to March 2024)
Interests in shares and options
	
– 150,000 ordinary shares in 
McPherson’s Limited
	
– No performance rights held
Ms. McKellar was appointed an Independent 
Non-Executive Director of McPherson’s Limited 
on 23 February 2015. 
Ms. McKellar is an experienced international 
senior executive with extensive customer-
focused, brand, marketing and digital 
experience across a number of high-profile, 
global brands. Ms. McKellar commenced 
her career at Unilever in London and her 
subsequent roles have included global CEO 
of Stila Corporation, Managing Director of 
Elizabeth Arden Australia, Founding CEO of 
Excite.com Asia Pacific, Director of Sales and 
Marketing for Microsoft (MSN), and Founding 
Director of Ninemsn. Ms. McKellar is also on the 
Board of The NRMA. 
Ms. McKellar holds a Master of Arts (Hons) from 
the University of Aberdeen and is a Graduate 
of the Australian Institute of Company Directors 
and Cambridge Institute of Sustainability 
Leadership.
Special Responsibilities
	
– Chair of the People & Culture Committee 
(appointed 27 April 2015)
	
– Member of the Risk & Compliance Committee 
(appointed 22 February 2022)
Other current listed Directorships
	
– Non-Executive Director of Noumi Limited
Former listed Directorships (last three years)
	
– Non-Executive Director of GWA Group 
Limited (from October 2016 to October 2023)
Interests in shares and options
	
– 11,533 ordinary shares in McPherson’s Limited
	
– No performance rights held
Mr. Charlton was appointed CEO and 
Managing Director of McPherson’s Limited on 
1 August 2023. 
Mr. Charlton is a growth-focused CEO, 
Non‑Executive Director, and commercial leader 
who has developed an international career in 
the consumer goods industry across the Asia 
Pacific region. Mr. Charlton has worked with 
a gold standard set of companies, including 
Diageo, PepsiCo, Fonterra, Sanofi, and Private 
Equity, for over 25 years before channelling 
his experience into advisory and consulting 
services. Mr. Charlton is a strategic thinker 
who connects the dots between divisions for 
organisations, with a speciality in governance 
and operations of organisations large and small. 
He is a respected confidant to leaders in the 
ASX c-suite and a trusted advisor to Boards, 
CEOs, and functional General Managers. 
Mr. Charlton is a Graduate and Fellow of the 
Australian Institute of Company Directors and 
the Graduate School of Management from 
IMD in Lusanne, Switzerland, and holds a 
Bachelor of Commerce (Marketing and Human 
Resources) from Griffith University.
Other current listed Directorships
	
– None
Former listed Directorships (last three years)
	
– None
Interests in shares and options
	
– 1,336,000 High Level Performance 
(HLP) Rights
	
– 668,000 Exceptional Level Performance 
(ELP) Rights
ARI MERVIS
Independent Chair of the Board
JANE McKELLAR
Independent Non-Executive Director
BRETT CHARLTON
Chief Executive Officer and Managing Director
26  |  McPherson’s Limited

Ms. Cook was appointed an Independent Non-
Executive Director of McPherson’s Limited on 
24 July 2018. 
Ms. Cook has more than 30 years of leadership 
and executive management experience in 
Australasia across a diverse range of functions 
within the biopharmaceutical and health 
services sectors. Her experience includes 
product manufacturing, quality systems, 
logistics, sales and marketing, as well as 
research and development. Ms. Cook is also 
familiar with the regulatory environment that 
governs the healthcare market. In addition 
to these technical and operational activities, 
Ms. Cook has been involved in corporate 
acquisitions and divestments as well as 
the strategic planning process. Ms. Cook 
has held the positions of Chief Operating 
Officer and then Chief Executive Officer of 
Genetic Technologies Limited, an ASX and 
NASDAQ listed leading edge genetic testing 
services business.
Ms. Cook holds a Bachelor of Science and 
a Master of Science (Microbiology), has 
undertaken the Executive Development 
Programme at Melbourne Business School 
and is a Graduate of the Australian Institute of 
Company Directors.
Special Responsibilities
	
– Interim Chief Operating Officer 
(from 1 June 2023 until 8 August 2023)
	
– Chair of the Risk & Compliance Committee 
(appointed 22 February 2022)
	
– Member of the Audit Committee 
(appointed 22 February 2022)
	
– Member of the People & Culture Committee 
(appointed 22 February 2022)
Other current listed Directorships
	
– None
Former listed Directorships (last three years)
	
– None
Interests in shares and options
	
– 15,500 ordinary shares in 
McPherson’s Limited
	
– No performance rights held
Ms. Thornton was appointed as Non-Executive 
Director on 20 December 2021. 
Ms. Thornton is a professional company 
director and has extensive financial, risk 
management, audit and governance expertise, 
aligned with strong strategic and leadership 
capabilities. Ms. Thornton is a Chartered 
Accountant with a diverse background in 
financial services, manufacturing, utilities, 
mining and property in both public and private 
corporations, and also with government 
statutory authorities. Ms. Thornton’s executive 
roles have included Vice President - Risk 
Management of BlueScope Steel Ltd and senior 
roles at BHP, Deloitte and KPMG. Current non-
executive directorships include ISPT Pty Ltd, 
Arena REIT Limited, Treasury Corporation of 
Victoria and Ansvar Insurance Ltd.
Ms. Thornton holds a Bachelor of Economics 
from Monash University and is a member of 
Chartered Accountants Australia and New 
Zealand and a graduate member of the 
Australian Institute of Company Directors. 
Special Responsibilities
	
– Chair of the Audit Committee 
(appointed 22 February 2022)
	
– Member of the Risk & Compliance Committee 
(appointed 22 February 2022)
Other current listed Directorships
	
– Non-Executive Director of Arena REIT Limited
Former listed Directorships (last three years)
	
– None
Interests in shares and options
	
– 20,000 ordinary shares in 
McPherson’s Limited
	
– No performance rights held
ALISON COOK
Independent Non-Executive Director
HELEN THORNTON
Independent Non-Executive Director
Annual Report 2024  |  27

A)	 DIRECTORS
The following persons were Directors of McPherson’s Limited 
from the beginning of the financial year to the date audit of 
this report except as indicated:
A. Mervis
	
– Chair of the Board
	
– Member of the Audit Committee and 
the People and Culture Committee
	
– Appointed as Executive Chair on 
1 June 2023 until 31 July 2023
B. Charlton
	
– Appointed as Chief Executive Officer and 
Managing Director on 1 August 2023
J.M. McKellar
	
– Chair of the People and Culture Committee
	
– Member of the Risk and Compliance 
Committee 
A.J. Cook
	
– Chair of the Risk and Compliance Committee 
	
– Member of the Audit Committee and the 
People and Culture Committee
	
– Appointed as Interim Chief Operating 
Officer on 1 June 2023 until 8 August 2023
H. Thornton
	
– Chair of the Audit Committee 
	
– Member of the Risk and Compliance 
Committee
B)	 PRINCIPAL ACTIVITIES
McPherson’s, established in 1860, is a leading supplier of 
Health, Wellness and Beauty products with operations in 
Australia, New Zealand and Asia. McPherson’s markets 
and distributes beauty care, hair care, skin care, vitamins, 
supplements and personal care items such as facial wipes, 
cotton pads and foot comfort products. 
McPherson’s revenue is primarily derived from its diversified 
portfolio of owned market-leading brands, including Dr. 
LeWinn’s, A’kin, Manicare, Lady Jayne, Swisspers, Fusion 
Health, Oriental Botanicals and Maseur. McPherson’s also 
manages a small number of brands for agency partners.
Manufacturing is outsourced to various suppliers, 
predominantly in Asia and Australia. McPherson’s maintains 
a presence in Hong Kong and has representation in mainland 
China, focused on product sourcing and quality assurance.
On 28 June 2024, the Group completed the sale of its 
Multix brand and inventory to International Consolidated 
Business Group for $19.2 million (inclusive of post-completion 
adjustments). There have been no other significant changes 
in the activities of the Group during the year. 
THE BOARD OF DIRECTORS PRESENTS THE FOLLOWING REPORT ON THE CONSOLIDATED 
ENTITY CONSISTING OF MCPHERSON’S LIMITED (THE COMPANY OR MCPHERSON’S) AND 
THE ENTITIES IT CONTROLLED (COLLECTIVELY REFERRED TO HEREAFTER AS THE GROUP) 
AT THE END OF, OR DURING, THE YEAR ENDED 30 JUNE 2024.
Directors’ Report
C)	 DIVIDENDS
Details of dividends paid or declared in respect of the current 
financial year are as follows:
$’000
2024 Interim ordinary dividend of 2.0 cents per 
fully paid ordinary share paid on 22 March 2024 
(fully franked)
2,879
2024 Final ordinary dividend
—
Total dividends in respect of the financial year
2,879
The 2023 final ordinary dividend of $1,439,000 (1.0 cents per 
fully paid ordinary share) was paid on 22 September 2023. A full 
year dividend of $4,318,000 (3.0 cents per fully paid ordinary 
share) was paid in respect of the 2023 financial year.
D)	 REVIEW OF OPERATIONS
An extract of the review of operations of the Group is set out 
on pages 15 to 19 of the Annual Report and forms part of the 
Directors’ Report.
Risk management and compliance
Risk and risk management is an integral part of the Company’s 
decision-making process and all risks and opportunities are 
adequately and appropriately assessed to ensure that material 
risk exposures are minimised and managed appropriately. 
The Company’s risk management and compliance framework 
is designed to ensure that material risks and compliance 
obligations are identified, assessed, managed and reported, 
that the Company’s risk management and compliance systems 
and processes are adequate and effective and that appropriate 
insurances are in place to mitigate the financial impact of any 
covered occurrences.
The Company’s Board, through the Risk & Compliance 
Committee, has the primary responsibility for the oversight of 
risk management and compliance, as well as responsibility for 
matters pertaining to compliance and governance. The Managing 
Director is accountable to the Board for the development and 
management of the Company’s risk and compliance framework 
and is supported by the Group General Counsel & Company 
Secretary in terms of adopting appropriate risk management and 
compliance policies, systems and processes, including regular 
reporting to the Risk & Compliance Committee of the Board. 
The Executive Leadership Team of the Company is also actively 
involved in the identification, assessment, management and 
reporting of material risks and each Executive Leadership Team 
member and senior manager below them is also responsible for 
the identification, assessment, management and reporting of 
relevant compliance obligations.
28  |  McPherson’s Limited

Directors’ Report
D)	 REVIEW OF OPERATIONS CONTINUED
Risk management and compliance continued
The material risks that have potential to affect the Company’s 
financial prospects, and how the Company seeks to mitigate 
these risks, include:
	
– Workplace health and safety
Given the physical nature of the Company’s operations, 
workplace health and safety is of paramount importance. 
A tone of ‘safety first’ is set at the top of the organisation 
and is reinforced through policies, procedures, employee 
engagement, training and mandatory safety incident 
(including ‘near miss’) reporting.
	
– Transformation execution
The Company is currently embarking on a transformation 
journey centred on its customers, its core and portfolio 
brands and its people to achieve increasing profitability 
and improving returns for shareholders. The Company’s 
transformation activities aim to drive productivity and 
growth in higher margin and higher growth categories 
where the Company has a competitive advantage and 
allows for disciplined re-investment into core brands and 
portfolio expansion opportunities. There are execution 
risks in any corporate transformation. However, these risks 
are mitigated by the Company having a well-defined and 
resourced transformation plan (including contingencies) and 
deliberate project management structures in place (such as 
the appointment of a dedicated project management officer) 
for the Executive Leadership Team to carefully consider 
all aspects of transformation activities including risks and 
mitigation strategies. 
	
– Inflationary pressures
In recent years, the global economy has experienced 
significant inflationary pressure. The Company has been 
impacted by material cost increases in many input costs, most 
materially in sea freight. The Company seeks to mitigate the 
impact of cost increases by improving operational efficiencies, 
using local manufacturers and suppliers, where appropriate 
and increasing selling prices, where required.
	
– Foreign currency fluctuation
The Company sources a large proportion of its inventory in 
currencies other than Australian dollars, with the US dollar 
the predominant sourcing currency. Consequently, significant 
fluctuations in the AUD / USD exchange rate can materially 
impact the Company’s result. The Board has established, and 
regularly reviews the Company’s foreign currency hedging 
policy with the objective of mitigating short to medium 
term foreign currency risk. Consistent with the policy, the 
Company continues to operate a comprehensive foreign 
exchange hedging program, which mitigates the impact 
of AUD and USD movements over the short to medium 
term. The Company’s foreign exchange hedging and the 
instruments used for foreign exchange hedging remain 
unchanged, being options and foreign exchange contracts 
on a forward rolling basis. 
	
– Raw material price fluctuation
Prior to the divestment of Multix on 28 June 2024, the 
Company’s inventory costs were influenced by movements in 
the price of commodities such as resin and aluminium. Such 
commodity prices were usually denominated in US dollars and 
historically had some correlation with movements in the AUD / 
USD exchange rate. This correlation usually provided a degree 
of natural hedge against the profit impact of AUD / USD 
currency movements. Post the sale of Multix, this is no longer 
considered to be a key business risk.
	
– Reduction in consumer demand or decline in a singular 
product category
Given the Company’s reliance on consumer sentiment and 
spending, adverse changes to the general economic landscape 
in Australasia or consumer demand for the Company’s 
products could impact its financial results. This risk is mitigated 
through monitoring and analysis of consumer data, consumer 
purchasing trends, such as the increase in on-line shopping, 
economic research, participation in international trade 
shows, innovative product development and brand building. 
The Company also mitigates against the risk of singular 
category decline, by maintaining broad category and sales 
and distribution channel participation, in Beauty Essentials, 
Skincare, Haircare and Vitamins, Mineral and Supplements.
	
– Loss of a major customer or deranging of a major 
product range
A significant proportion of the Company’s sales from 
continuing operations are to two significant Australian 
pharmacy customers and a large customer in the grocery 
channel. The deletion of a core product or reduction in a core 
product range by these customers could materially reduce 
the Company’s profitability. To mitigate this risk, the Company 
strives to provide quality products, delivered on time and in full, 
superior customer service (including analytics and information 
that is data driven), product and packaging innovation and 
competitive pricing (including trade promotions). The Alliance 
with Chemist Warehouse, established in March 2022, has 
formalised a much closer relationship with this key customer 
and is part of the Company’s risk mitigation. 
	
– Loss of key suppliers
The Company places significant reliance on key manufacturers 
and suppliers of its products. Many such suppliers are based 
in China, with key skincare and health product suppliers 
predominantly based in Australia. Alternate suppliers have 
been identified for all key suppliers. The Company also 
regularly reviews its manufacturers and suppliers and actively 
manages their performance, particularly around product quality 
and meeting customer delivery metrics. Manufacturers and 
suppliers who do not meet the Company’s expectations in this 
regard will be performance managed and may be replaced.
Annual Report 2024  |  29

D)	 REVIEW OF OPERATIONS CONTINUED
Risk management and compliance continued
	
– Investment of capital
In seeking to grow the business and, in turn, shareholder value, 
the deployment of capital to investments that do not ultimately 
result in those outcomes may present a risk. The following 
measures are taken to mitigate this risk:
	. restriction of the number of opportunities under review 
to ensure appropriate focus and resourcing;
	. careful assessment of risk and return metrics associated 
with opportunities; and
	. engagement of external assistance, such as due diligence 
expertise were deemed necessary for smaller investments 
and mandatory for investments more than $10 million.
	
– Deficiency in product quality
As a supplier of branded consumer products to retailers, 
the Company has an exposure to product faults which could 
lead to liability claims and product withdrawals or recalls. 
To mitigate this risk, the Company conducts, or has conducted, 
due diligence on existing manufacturers and suppliers. The 
Company also conducts, where appropriate, competitive 
tenders for manufacturing and supply arrangements with 
experienced counterparties who can demonstrate the required 
capability. The Company also adopts appropriate quality 
control, supplier review and verification procedures and 
conducts regular reviews of customer complaints and other 
external communications to the Company about its products. 
Changes in processes may result after these reviews. The 
Company also maintains adequate product and public liability 
and product recall cover.
	
– Compliance with debt facility undertakings
A portion of the Company’s capital requirement is in the form 
of debt facilities supplied by Financial Institutions that require 
the Company to comply with various undertakings, including 
specific financial ratios or covenants, for the Company to 
continue to access facilities. This risk is mitigated by the 
Company seeking to adopt a debt structure that in both 
quantum and terms has sufficient capacity to withstand a 
short-term decline in earnings or assets that may impact 
its ability to meet its various debt facility undertakings. The 
Company also regularly reports to the debt facility manager 
on compliance with financial ratios and covenants and 
the manager also receives regular formal updates on the 
Company’s operations and financial position.
	
– Cyber security
The Company places significant reliance on its Information 
Technology (IT) systems to transact with customers and 
connect with consumers. The inability to utilise or access our 
IT systems through a successful denial of service, ransomware 
or other form of attack could materially impact the Company’s 
ability to transact and hence affect its earnings. The Company 
uses firewall monitoring software and anti-virus software to 
block potential cyber threats. Additionally, it has a network 
monitoring and alert tool that is designed to detect and 
signal unusual network behaviour. Ongoing internal staff 
training, external review and input are implemented to ensure 
the effectiveness of ‘cyber’ controls to meet ever evolving 
threats of this nature.
Directors’ Report
	
– Talent management
The loss, and potential underutilisation, of key management 
talent represents a risk to the business. This risk is mitigated by 
the Company establishing and maintaining talent development 
plans, good practice recruitment to contribution profiles, 
market benchmarked remuneration and incentive programs 
and adequate succession plans, where appropriate.
	
– ESG / Sustainability
The rapid evolution of regulatory requirements and social 
expectations in Environmental, Social and Corporate 
Governance is manifest in legislation and the expectations 
of key stakeholders such as customers, consumers and 
employees to adopt more sustainable products and practices. 
The Company recognises the need to have a well-articulated 
ESG strategy in relation to the packaging of its products, a 
sustainable supply chain and in climate related disclosures. This 
risk is mitigated by the Company having a well-defined ESG 
strategy based on a rigorous and independently conducted 
materiality assessment as well as the Company having 
experienced internal resources to manage the implementation 
and execution of the Company’s ESG strategy. These steps 
seek to ensure that the ESG strategy is embedded, where 
appropriate, in the Company’s operations. Progress in the 
implementation and execution of the Company’s ESG strategy 
is overseen by the Company’s Risk & Compliance Committee.
	
– Regulatory compliance
The general risk of compliance with changes in Australian 
Consumer Law and product standards, with related 
implications for supplier and inventory management, as 
well as penalties for non-conformance, is managed by the 
employment of appropriately experienced employees having 
the benefit of industry updates, internal resources and external 
advice on changes in law and standards. Additionally, staff 
training has been conducted by the Company’s external 
advisors in Australian Consumer Law. 
	
– Intangible asset valuation
As an owner of brands and other intangible assets, the size of 
this asset class on the Company’s balance sheet is relatively 
high. Given the sensitivity of key assumptions (such as discount 
rates) used to determine the valuation of intangible assets, it 
is an area of high inherent risk. This risk is managed through 
regular assessment of individual brand and cash generating 
unit cashflow projections and the engagement of external 
valuation experts in the review of key assumptions and 
valuation methodologies.
E)	 SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS
On 28 June 2024, the Group completed the sale of its Multix 
brand and inventory to International Consolidated Business 
Group. Multix is disclosed as a discontinued operation as at 
30 June 2024. There were no other significant changes in the 
state of affairs of the Group during the financial year.
30  |  McPherson’s Limited

Directors’ Report
F)	 EVENTS SUBSEQUENT TO BALANCE DATE
On 19 August 2024, an amendment to the terms of the 
$45 million working capital facility was approved. In respect 
of the calculation period ending on 30 June 2024, the 
Divestment of Multix was removed from the calculation of 
the Interest Cover Ratio.
In August 2024, the Group announced its intention to streamline 
Hong-Kong operations, with supply and procurement functions 
to operate from a centrally managed hub in Australia. As a 
result, several roles in Hong Kong will be impacted. The Group 
expects the restructuring associated with the reduction in 
positions to cost between $0.7 million and $1.0 million in 2025. 
There are no other items, transactions or events of a material 
or unusual nature that have arisen in the period between 
30 June 2024 and the date of this report that, in the opinion 
of the directors, have significantly affected or may significantly 
affect the operations of the Group, the results of those 
operations, or the state of affairs of the Group in future 
financial years. 
G)	 LIKELY DEVELOPMENTS AND EXPECTED 
RESULTS OF OPERATIONS 
McPherson’s is a pure-play health, wellness and beauty 
company focused on investing in, and growing, its five core 
brands: ‘Manicare’, ‘Lady Jayne’, ‘Dr LeWinns’, ‘Swisspers’ 
and ‘Fusion.’ These core brands operate in highly attractive 
categories, where McPherson’s considers it has a competitive 
advantage. In addition, the Company supplies a supporting 
portfolio of other popular brands in attractive segments of the 
market including haircare, vitamins and supplements, fragrance, 
and nutrition.
A key part of McPherson’s strategy is becoming a more 
simplified, streamlined organisation with a focus on driving 
productivity and efficiency. As part of this, McPherson’s may 
implement a new route to market for its brands, at such time 
as its current Kingsgrove warehouse and office property can 
be re-let. In addition the Company will conduct a review of its 
capital allocation framework and dividend policy to better align 
with McPherson’s refreshed strategy. The review will include 
exploring the most efficient way to distribute the Company’s 
franking credits to shareholders. 
The Company’s strategy is part of a clear plan to unlock value. 
The Board’s view is that, by using the company’s balance 
sheet to fund continued investment, the Company can de-risk 
and accelerate the substantial transformation of the business 
that is underway. 
In the opinion of the Directors, it would prejudice the interests 
of the Group to include additional information, except as noted 
above, and as reported elsewhere in the Directors’ Report and 
the financial statements, which relates to likely developments 
and the expected results of operations in financial periods 
subsequent to 30 June 2024.
H)	 INFORMATION ON DIRECTORS
Particulars of the qualifications, experience and special 
responsibilities of each Director as at the date of this report are 
set out on pages 26 to 27 of the Annual Report and form part of 
the Directors’ Report.
I)	
COMPANY SECRETARIES
Craig Durham
General Counsel and Company Secretary 
Mr Durham was appointed General Counsel & Company 
Secretary of McPherson’s Limited on 15 January 2024. With a 
career spanning over 30 years, he brings extensive executive 
leadership, legal and corporate governance experience from 
both listed and unlisted environments and in highly regulated 
industries including beverages, intelligent traffic systems, gaming 
technology and financial services.
Mr Durham holds a Bachelor of Laws (Honours) from QUT, a 
Master of Laws from the University of Melbourne, a Graduate 
Diploma in Legal Practice from QUT and a Graduate Diploma in 
Applied Corporate Governance from the Governance Institute 
of Australia (GIA). He is a Member of the Australian Institute 
of Company Directors, a Fellow of the GIA, a Member of the 
Institute of Chartered Secretaries and Administrators, a Member 
of the New York Bar, the New York State Bar Association, and 
the American Bar Association. He is also admitted in Queensland, 
Victoria and New York in the United States and holds a current 
practising certificate in New South Wales.
Paul Witheridge (until 30 April 2024)
Mr Witheridge was appointed Chief Financial Officer and Joint 
Company Secretary of McPherson’s Limited on 1 December 2011 
and resigned on 30 April 2024. Mr Witheridge has significant 
financial experience, having held senior financial and company 
secretarial positions with a number of listed companies in the 
retail sector including as Chief Financial Officer of Angus and 
Coote Limited and OPSM Limited. Prior to that, Mr. Witheridge 
spent six years within KPMG’s Audit and Assurance Practice. Mr. 
Witheridge holds a Bachelor of Commerce and is a Fellow of the 
Institute of Chartered Accountants in Australia and New Zealand.
Linda Gough (until 30 November 2023)
Ms. Gough was appointed Company Secretary of McPherson’s 
Limited on 16 January 2023 and resigned on 30 November 
2023. Ms. Gough has over twenty years legal and governance 
experience, advising listed and non-listed entities in ANZ, Asia 
and North America, including WPP AUNZ Limited, Fairfax Media 
Limited, SAP Australia and George Weston Foods. She holds 
a Bachelor of Law from the University of Toronto, Canada, a 
Master of Laws from the University of New South Wales, a 
graduate diploma in governance from the Governance Institute 
of Australia and is a graduate member of the Australian Institute 
of Company Directors.
Annual Report 2024  |  31

J)	 REMUNERATION REPORT
Letter from the Chair of the People and Culture Committee 
Dear Shareholders,
On behalf of the Board, I am pleased to present the Company’s remuneration report for FY24.
This past year has been a period of significant transformation for McPherson’s. Amid the Company’s strategic reset 
(see ASX announcement dated 15 November 2023) and the sale of the ‘Multix’ brand assets during the year, the Board has 
remained committed to ensuring that remuneration structures are strongly aligned with shareholder interests and value creation 
while also attracting and retaining experienced executive leadership, reflecting current industry benchmarking and being 
underpinned by sound risk management practices.
Our People
From a people and culture perspective, the actions we have taken this year support the Company’s transformation journey. 
Eight new executive appointments were made during the financial year in areas including marketing, customer insights, supply 
chain, information and data, and people and culture. As part of these executive appointments, two new critical KMP appointments 
were made during the financial year: 
	
– Brett Charlton was appointed CEO and Managing Director of McPherson’s Limited on 1 August 2023. Brett brings significant 
experience from over two decades in leadership roles in the consumer goods industry across the Asia Pacific region, where he 
has led significant turnaround and growth initiatives.
	
– Mark Sherwin was appointed CFO of McPherson’s on 6 May 2024. Mark has over 18 years’ experience across a range of 
industries, including consumer goods, construction and engineering, with his expertise extending beyond core financial disciplines 
to encompass investor relations and risk management.
The appointment of this new experienced leadership team brings fresh perspectives and will support the delivery of the 
Company’s transformation. 
FY24 Performance and Remuneration 
The FY24 remuneration outcomes are reflective of the overall Group financial performance in this year of transformation. 
The executives did not qualify for an STI award in FY24 as minimum thresholds were not achieved. Executive LTIs, in the form 
of performance rights issued during FY21, which have been assessed on FY24 outcomes, did not vest in the current year as the 
Earnings Per Share (EPS) and Total Shareholder Return (TRS) measures were below the minimum thresholds set by the Board. 
Total Fixed Remuneration (TFR) for KMP and non-executive directors was also not adjusted in FY24. 
Detail about McPherson’s financial performance is available in the Review of Operations section on pages 15 to 19 of this report.
Changes to remuneration structures 
The Board regularly reviews executive remuneration to ensure it continues to drive shareholder value. A 50% deferral component 
was introduced this year in respect to any payment of the CEO and Managing Director’s STI award. There were no changes in the 
STI performance measures or to their respective weightings. Further, no changes were made to the LTI performance measures 
during the year. Additional detail is provided in section 3. 
The Board remains confident that the Company’s remuneration structure continues to support the Group’s strategic goals and 
financial objectives. The Board also remains committed to transparency on remuneration structure and, to this end we have sought 
to improve the remuneration report to provide clear and concise and readily understood information. We are confident in the 
current actions being taken by the Company and management to streamline core operations and drive value creation, laying a 
foundation for future success. 
On behalf of the Board, I encourage you to read the full remuneration report and we thank you for your continued support of 
the Company. 
Yours sincerely
JANE McKELLAR
Chair of the People and Culture Committee
Directors’ Report
32  |  McPherson’s Limited

J)	 REMUNERATION REPORT CONTINUED
Content
The McPherson’s Limited FY24 remuneration report sets out key aspects of the Company’s remuneration policy and framework, and 
details of the remuneration awarded this year. 
The remuneration report contains the following sections:
1.	 Key Management Personnel (KMP)
2.	 Remuneration Framework and Governance
3.	 Elements of remuneration
4.	 Performance and executive remuneration outcomes in FY24
5.	 Statutory remuneration
6.	 Contractual arrangements for executive KMP
7.	 Non-Executive Director arrangements
8.	 Share-based compensation
9.	 Additional statutory information
The information provided in this remuneration report has been audited as required by section 308(3C) of the Corporations Act 2001.
1.	 Key Management Personnel 
KMP are those persons having authority and responsibility for planning, directing and controlling the activities of an entity, directly or 
indirectly, including any director (whether executive or otherwise) of that entity including: 
	
– Executive directors and certain senior executives (collectively the Executives)
	
– Non-executive directors
Name
Role
Term as KMP in FY24
EXECUTIVES
B. Charlton
Chief Executive Officer and Managing Director 
Appointed on 1 August 2023
A.J. Cook
Interim Chief Operating Officer
Appointed on 1 June 2023 until 8 August 2023
A. Mervis
Executive Chair
Appointed on 1 June 2023 until 31 July 2023
M. Sherwin
Chief Financial Officer
Appointed on 6 May 2024
P. Witheridge
Chief Financial Officer and Joint Company Secretary
Resigned on 30 April 2024
NON-EXECUTIVE DIRECTORS
A. Mervis
Chair of the Board
Full year
J.M. McKellar
Non-executive Director
Full year
A.J. Cook
Non-executive Director 
Full year 
H.L. Thornton
Non-executive Director
Full year
Changes since the end of the reporting period
There have been no other changes in KMP since the end of the reporting period.
Directors’ Report
Annual Report 2024  |  33

J)	 REMUNERATION REPORT CONTINUED
2.	 Remuneration Framework and Governance
How we determine executive remuneration policies and structures 
The Company’s remuneration policies and structures are focused on the alignment between performance, sound risk management 
and reward outcomes. In particular, the board aims to ensure that remuneration practices are:
	
– Market-competitive, enabling the attraction and retention of high performing talent required to deliver superior and sustained results 
to shareholders.
	
– Performance-based, promoting mutually beneficial outcomes by aligning employee, customer and shareholder interests and 
underpinned by a sound risk management framework.
	
– Equitable, providing a fair level of reward to all employees.
Our remuneration policies and structure 
We reward executives with a level and mix of remuneration appropriate to their position, responsibilities and performance, in a way 
that aligns with the business strategy. The table below provides a summary of the structure of executive remuneration in FY24:
Element1
Purpose
Performance Measures
Potential Value
Fixed 
Remuneration 
including 
superannuation 
and benefits
Provide competitive 
market salary which may 
be delivered as cash, 
prescribed non-cash financial 
benefits including motor 
vehicles and superannuation 
contributions. 
Nil
Market rate
Reviewed annually to reflect 
increases in responsibility and 
to ensure it remains market 
competitive. Increases are not 
guaranteed in the executives’ 
contracts.
Short-term 
performance 
incentives (STI)
Reward for current year 
performance available when 
value has been created for 
shareholders and when profit 
and other outcomes are 
consistent with or exceed 
financial targets for the 
business plan. 
Growth in underlying profit before 
tax (PBT) and growth in sales 
revenue, together with 
pre-determined significant role 
specific objectives.
Managing Director
Up to 75% of fixed remuneration
Chief Financial Officer
Up to 50% of fixed remuneration
Former Chief Financial Officer
Up to 50% of fixed remuneration
Long-term 
incentives (LTI)
Alignment to long-term 
shareholder returns via the 
Performance Rights plan. 
Participants benefit from 
the vesting of Performance 
Rights if performance 
objectives are met.
Managing Director
i.	 High Level Performance Rights 
(HLP) – 100% of vesting is 
determined with reference to 
EPS CAGR, over three years.
ii.	 Exceptional Level Performance 
Rights (ELP) – 100% vesting is 
determined with reference to 
the TSR CAGR outcome, over 
three years.
Managing Director
i.	 High Level Performance 
Rights (HLP) – 100% of fixed 
remuneration. 
ii.	 Exceptional Level Performance 
Rights (ELP) – 50% of fixed 
remuneration.
Chief Financial Officer
67% of vesting is determined 
with reference to EPS CAGR and 
33% with reference to TSR CAGR, 
each over three years.
Chief Financial Officer
Up to 50% of fixed remuneration
Former Chief Financial Officer
67% of vesting is determined 
with reference to EPS CAGR and 
33% with reference to TSR CAGR, 
each over three years
Former Chief Financial Officer
Up to 40% of fixed remuneration
1.	 Fixed Remuneration is a contractual entitlement. Participation in the STI and LTI schemes are at the discretion of the board.
Alison Cook received fixed monthly remuneration of $33,000 inclusive of superannuation for her services as Chief Operating Officer in 
addition to the remuneration she received for her non-executive director responsibilities. No additional remuneration was received by 
Ari Mervis for his services as Executive Chair.
Directors’ Report
34  |  McPherson’s Limited

Directors’ Report
J)	 REMUNERATION REPORT CONTINUED
2.	 Remuneration Framework and Governance continued
Governance framework
The illustration below summarises the Company’s remuneration governance framework:
BOARD
Overall responsibility for the remuneration strategy and outcomes for Executives and Non-Executive Directors 
Reviews and, if appropriate, approves recommendations from the People and Culture Committee
PEOPLE AND CULTURE COMMITTEE
Reviews, evaluates and makes recommendations to the Board in relation to the following remuneration matters: 
Executive remuneration and incentive policies and plans
Remuneration for Non-Executive Directors
Managing Director and other Executives’ remuneration packages and performance objectives
Managing Director’s performance and development plans
MANAGEMENT
Management is responsible for making 
recommendations to the 
People and Culture Committee.
Management provides the Board with the 
relevant information and analysis required 
to support decision making.
EXTERNAL CONSULTANTS
The People and Culture Committee and the Board may 
seek advice from independent remuneration consultants in 
determining appropriate senior executive remuneration.
Remuneration consultants support the Board in making 
remuneration decisions that are in the best interest of 
McPherson’s and its shareholders.
Remuneration Mix – at Target
The graph below shows the structure of the FY24 remuneration opportunity mix for KMP. It reflects the STI opportunity for the current 
year that will be available if the performance conditions are satisfied at target, and the value of the LTI performance rights granted 
during the year, as determined at the grant date.
Chief Financial Officer
50.0%
25.0%
25.0%
Managing Director
30.8%
11.5%
11.5%
46.2%
Former Chief Financial Officer
52.6%
26.3%
21.1%
Fixed Rem
STI Cash
STI Deferred
LTI
Annual Report 2024  |  35

J)	 REMUNERATION REPORT CONTINUED
3.	 Elements of remuneration
Fixed annual remuneration 
Fixed remuneration consists of base salary, superannuation and other non-monetary benefits and is designed to reward for:
	
– The scope of the executive’s role
	
– The executive’s skills, experience and qualifications
	
– Individual performance
Remuneration reviews may occur annually to ensure it remains market competitive. Executive Fixed Annual Remuneration will 
not automatically be increased as a result of any review. In FY24, there was no increase in annual fixed remuneration given to 
executive KMPs. 
Short-term incentives (STI)
Each year the People and Culture Committee considers the appropriate targets and key performance indicators for the Executive 
Leadership Team, together with the appropriate STI payable should targets be met or exceeded. 
How is it paid?
The Managing Director, CFO & former CFO receive their awards in cash. The Managing director receives 
his reward as 50% paid in cash after the assessment of annual performance and 50% deferred for a 
further one year period. The CFO and former CFO receive their award as 100% paid in cash after the 
assessment of annual performance.
How much can 
executives earn?
The maximum STI opportunities of executives are summarised below: 
	
– Managing Director: 75% of fixed remuneration
	
– CFO: 50% of fixed remuneration
	
– Former CFO: 50% of fixed remuneration
How is performance 
measured?
STI performance measures were chosen as they reflect the core drivers of short-term performance and 
also provide a framework for delivering sustainable value to the Group, its shareholders and customers. 
Metric
FY24 Target
Weighting
Profit before Tax
Vesting commences at $11.0 million, then pro rata 0% 
from $11.0 million to 100% at $15.8 million being 18% above 
the budgeted FY24 underlying PBT
50%
Sales Revenue
Vesting commencing at $10.0 million below budgeted FY24 
sales revenue, then pro rata to 100% vesting at $10.0 million 
above budgeted FY24 sales revenue
20%
Individual performance
Specific to individuals
30%
From time to time additional short-term cash bonuses are paid to executives in relation to the 
achievement of specific outcomes associated with certain significant events. Examples of such events 
may include, among others, completing a significant acquisition or investment, achieving a required 
divestment outcome, completing a significant restructure project or completing a refinancing of the 
business. The Board is responsible for approving such bonus payments. In FY24, no such additional 
short-term cash bonuses were paid to executives.
When is it assessed 
and paid?
The STI award is determined after the end of the financial year following a review of performance 
against measures by the People & Culture Committee and the Board. Payments are normally made 
following the release of statutory audited results. 
Directors’ Report
36  |  McPherson’s Limited

J)	 REMUNERATION REPORT CONTINUED
3.	 Elements of remuneration continued
Long-term incentives (LTI)
The FY24 LTI program for KMP was structured as follows:
How is it paid?
Certain Executives are eligible to receive performance rights, being a right to an ordinary share 
in McPherson’s Limited with zero exercise price, subject to meeting vesting conditions over the 
performance period.
How much can 
executives earn?
The maximum LTI opportunities of executives are summarised below: 
Executive
LTI Opportunity
Managing 
Director
HLP: 100% of fixed remuneration
ELP: 50% of fixed remuneration
CFO
50% of fixed remuneration
Former CFO
40% of fixed remuneration
The number of performance rights granted is determined using the 20 day volume weighted average 
price share price prior to the time of grant. 
How is performance 
measured?
LTI performance measures are chosen to align executives with the objective of improving long-term 
shareholder returns. The Board considers EPS to be the most effective measure for determining the 
underlying profitability of the business. The Absolute TSR hurdle was selected as it focuses executives 
on shareholder value creation.
Performance measures are summarised below:
Executive
LTI Opportunity
Managing 
Director
HLP: 100% of vesting is determined with reference to EPS CAGR, over three years.
ELP: 100% of vesting is determined with reference to the TSR CAGR outcome over 
three years.
CFO
67% of vesting is determined with reference to EPS CAGR and 33% with reference 
to TSR CAGR, each over three years.
Former CFO
67% of vesting is determined with reference to EPS CAGR and 33% with reference 
to TSR CAGR, each over three years.
How are payouts 
determined? 
Awards are subject to two measures:
Earnings per share compound annual growth rate (EPS CAGR):
The EPS CAGR will be determined by calculating the compound annual growth rate for EPS over the 
vesting period from an EPS base determined by the Board prior to the offer, to the actual underlying EPS 
at 30 June 2026. The proportion of performance rights that may vest based on EPS performance is 
determined based on the following vesting schedule:
EPS CAGR Achieved
Percentage vesting
Below the 40th percentile
0%
At the 40th percentile 
30%
Between the 40th and 60th percentile 
Straight-line vesting between 30-100%
At or above the 60th percentile
100%
The actual underlying EPS will be normalised by the Board as considered necessary (at the Board’s 
discretion) so that it reflects underlying profit.
Directors’ Report
Annual Report 2024  |  37

Directors’ Report
J)	 REMUNERATION REPORT CONTINUED
3.	 Elements of remuneration continued
Long-term incentives (LTI) continued
How are payouts 
determined?
continued
Absolute total shareholder return compound annual growth rate (TSR CAGR):
The TSR CAGR will be determined by calculating the amount by which the 20-trading day volume-weighted 
average price of the Company’s ordinary Shares in the period ending at close of trade on 30 June 2026 
exceeds a base share price determined by the Board prior to the offer, plus dividends paid by the 
Company during the three-year period. The proportion of performance rights that may vest based on 
TSR performance is determined based on the following vesting schedule:
TSR CAGR achieved
Percentage vesting
Below the 50th percentile
0%
At the 50th percentile 
30%
Between the 50th and 75th percentile 
Straight-line vesting between 30-100%
At or above the 70th percentile
100%
When is 
performance 
measured?
The performance measures are tested at the end of the three year performance period to determine the 
number of performance rights that vest. There is no opportunity for re-testing. Performance rights will 
lapse if the performance measures are not met at the end of the performance period.
Sign on Payments
No sign on payments were made to new executives on commencement of employment in FY24.
Voting and comments made at the Company’s 2023 Annual General Meeting (AGM)
Of the total votes cast in relation to the adoption of the 2023 remuneration report by shareholders participating in the AGM and by 
proxy, 95.89% voted in favour of the resolution. Several general questions relating to remuneration and the 2023 remuneration report 
were asked by shareholders at the 2023 AGM, which were appropriately responded to by the Chair of the Board and other Non-
Executive Directors at the meeting.
38  |  McPherson’s Limited

Directors’ Report
J)	 REMUNERATION REPORT CONTINUED
4.	 Link between remuneration and performance
FY24 performance and impact on remuneration
The FY24 financial result reflects the scale of transformation underway within the business, including one-off costs incurred. As a result, 
the Profit before Tax and Revenue results fell below targets set. The remuneration outcomes reflect the Group’s financial performance 
in this year of transformation. For more information on 2024 results and strategic priorities, refer to the Review of Operations section 
on pages 15 to 19 of this report.
Performance against STI measures
Neither Profit Before Tax or Sales Revenue targets for FY24 were met, resulting in no STI payments being made to Executives.
Performance against LTI measures
Metric
Vesting hurdle
Outcome
Vesting during FY24 
FY21 Grant to P. Witheridge
3 year EPS
First 50% of Rights: Zero Rights vesting at +3.0% of underlying EPS CAGR 
then pro-rata to 100% of Rights vesting at +8.0% of underlying EPS CAGR
Below target, 0% vesting
3 year TSR
Remaining 50% of rights: 25% of Rights vesting at +8% of underlying TSR CAGR 
then pro-rata to 100% of Rights vesting at +13.0% of underlying EPS CAGR
Below target, 0% vesting
Vesting post FY24
Refer to Section 8. Share based compensation for further details on Performance Rights vesting post FY24.
Statutory performance indicators
The overall level of executive reward considers the performance of the Company over several years, with greater emphasis given to 
the current year. The following table summarises the performance of the Company over the last five years: 
FY24
FY23
FY22
FY21
FY20
(Loss) / profit for the year after tax from continuing operations ($’000)
(11,386)
(1,273)
333
(5,371)
6,062
(Loss) / profit for the year after tax from continuing operations excluding 
material items ($’000)
(362)
2,285
6,963
6,184
16,336
Basic EPS (cents) from continuing operations
(7.9)
(0.9)
0.3
(4.4)
5.7
Basic EPS (cents) from continuing operations excluding material items
(0.3)
1.6
5.3
5.1
15.3
Total dividends (cents per share)
2.0
3.0
5.0
5.0
11.0
Share price at year end ($)
0.41
0.40
0.66
1.10
2.77
Annual Report 2024  |  39

J)	 REMUNERATION REPORT CONTINUED
5.	 Details of remuneration
Amounts of remuneration
Details of the remuneration expense recognised for the Group’s key management personnel for the current and previous financial 
year are set out below.
Directors’ Report
Short-term benefits
Post-
employ-
ment 
benefits
Long-
term
 benefits
Share-based 
payments
Termi-
nation 
pay-
ments
$
Total
remun-
eration
$
Perfor-
mance
related
%
Salary 
& Fees
$
Cash
 bonus
 (STI)
$
Non- 
monetary
	
benefits	1
$
Superan-
nuation
$
Leave 
entitle-
ments
$
Cash-
settled
$
Equity-
settled
$
B. Charlton 
(Managing Director)2
2024
552,292
—
—
25,208
23,815
—
182,540
—
783,855
23%
2023
—
—
—
—
—
—
—
—
—
0%
G.W. Peck (former 
Managing Director) 3
2024
—
—
—
—
—
—
—
—
—
0%
2023
593,542
—
—
27,500
(23,811) 	 (230,180)	4 	 68,250	5
323,750
759,051
-21%
M. Sherwin 
(Chief Financial Officer) 6
2024
69,901
—
—
4,566
3,870
—
1,273
—
79,610
2%
2023
—
—
—
—
—
—
—
—
—
0%
P. Witheridge (former 
Chief Financial Officer) 7
2024
325,168
—
—
13,400
1,158
—
	 105,356	8
224,410
669,492
16%
2023
378,943
—
—
26,400
(540)
—
6,651
—
411,454
2%
A.J. Cook
2024 	
130,568	9
—
—
14,362
—
—
—
—
144,930
0%
2023 	
124,267	9
—
—
13,048
—
—
—
—
137,315
0%
A. Mervis 
(Board Chair) 
2024
152,340
—
—
16,757
—
—
—
—
169,097
0%
2023
153,029
—
—
16,068
—
—
—
—
169,097
0%
J.M. McKellar
2024
89,279
—
—
9,821
—
—
—
—
99,100
0%
2023
89,683
—
—
9,417
—
—
—
—
99,100
0%
G.R. Pearce 10
2024
—
—
—
—
—
—
—
—
—
0%
2023
31,411
—
—
3,298
—
—
—
—
34,709
0%
H.L. Thornton 
2024
89,279
—
—
9,821
—
—
—
—
99,100
0%
2023
89,683
—
—
9,417
—
—
—
—
99,100
0%
Total KMP
2024
1,408,827
—
—
93,935
28,843
—
289,169
224,410
2,045,184
2023
1,460,558
—
—
105,148
(24,351) (230,180)
74,901
323,750
1,709,826
1.	 Non-monetary benefits comprise salary sacrificed components of remuneration packages including motor vehicles and related fringe benefits tax and allowances.
2.	 Mr. Charlton was appointed as a Chief Executive Officer and Managing Director on 1 August 2023. 
3.	 Mr. Peck resigned effective 31 May 2023.
4.	 Includes $(183,134) from the fair value revaluation of unvested cash based performance rights (624,000 HLP rights and 312,000 ELP rights) retained upon resignation 
and $(47,046) forfeiture of 200,000 commencement rights upon resignation of the former Managing Director.
5.	 Includes expense accelerated in respect to share-based performance rights (909,000 HLP rights and 455,000 ELP rights) retained upon resignation of the former 
Managing Director.
6.	 Mr. Sherwin was appointed as a Chief Financial Officer on 6 May 2024.
7.	 Mr. Witheridge resigned as a Chief Financial Officer on 30 April 2024. Termination benefits are accrued obligations as at 30 June 2024. 
8.	 Includes expense accelerated in respect to share-based performance rights (705,000 performance rights) retained upon resignation of the former Chief Financial Officer.
9.	 Includes additional remuneration of $36,590 excl. superannuation (FY23: $29,864 excl. superannuation) for services as Chief Operating Officer in addition to the 
remuneration received for non-executive director responsibilities.
10.	Mr Pearce resigned effective 22 November 2022. 
40  |  McPherson’s Limited

J)	 REMUNERATION REPORT CONTINUED
6.	 Contractual arrangements for executive KMP
Use of remuneration consultants 
No advice was received from remuneration consultants in FY24. 
Executive employment agreements
Remuneration and other terms of employment for the Managing Director and the CFO are formalised in employment agreements. 
Each of these agreements set out details of the base package amount, inclusive of superannuation and other benefits, and provide for 
performance incentives. The agreements also provide for participation, when eligible, in the McPherson’s Limited Performance Rights Plan. 
The agreements do not normally reflect a fixed term of employment or nominate a specified amount to be paid on termination of 
employment. The agreements normally provide that the termination notice period may be paid out by the Group. 
The major provisions of the employment agreements relating to remuneration for the executives considered to be key management 
personnel are set out below.
Name
Term of 
agreement
Fixed 
remuneration 
including 
superan-
nuation 1
Termination 
notice
Termination of employment (without 
cause)
Termination 
of employment 
(with cause) 
B. Charlton
Managing 
Director
Appointed on 
1 August 2023
$630,000
Contract may 
be terminated 
on 6 months’ 
notice by either 
the Company 
or executive.
STI: Not awarded for that financial 
year, however any entitlement to 
STI payments deferred or delayed 
will still be payable after the 
deferral period.
LTI: An executive has 30 days to 
exercise any vested Rights from 
the date employment was ceased. 
Except in limited circumstances, all 
Rights which have not yet vested 
will expire on the date employment 
is ceased. The Board reserves the 
right to apply discretion in the case 
of a “good leaver” (leaving due 
to ill health, death, redundancy or 
other circumstances) so that any 
unvested Rights of the employee 
will not automatically lapse on the 
date employment is ceased and 
instead remain in place.
STI: Not awarded.
LTI: Both vested 
and unvested LTI 
will expire on the 
date employment 
is ceased.
In the event of 
serious misconduct, 
the Board may 
also claw back 
performance-based 
remuneration 
paid in previous 
financial years.
M. Sherwin
Chief Financial 
Officer 
Appointed on 
6 May 2024
$478,000
Contract may 
be terminated 
on 6 months’ 
notice by either 
the Company 
or executive.
1. The annual fixed remuneration amounts quoted are as at 30 June 2024.
Directors’ Report
Annual Report 2024  |  41

J)	 REMUNERATION REPORT CONTINUED
7.	 Non-Executive Directors arrangements
The Group’s non-executive director fee policy is designed to attract and retain high calibre directors who exemplify strong oversight, 
governance, independence and objectivity. Non-executive directors receive a board fee and fees for chairing of or participating in 
board committees. They do not participate in any performance-related incentive awards. 
The People & Culture Committee reviews non-executive director remuneration against comparable companies and market data and 
makes recommendations to the Board accordingly. There was no increase in annual fixed remuneration for non-executive directors 
in FY24, nor has there been an increase since 1 July 2017. The People & Culture Committee intends to review and may recommend 
an increase in the remuneration of each non-executive director within the limit of the fee pool during FY25. The current maximum 
annual aggregate directors’ fee pool limit is $650,000 and was last approved by shareholders at the 2018 Annual General Meeting on 
21 November 2018. 
There has been no increase in annual fixed remuneration for Non-Executive Directors since 1 July 2017.
The table below summarises Board and Committee fees payable to the non-executive directors for FY24 (inclusive of superannuation):
$
BASE FEES
Chair
$158,667
Other non-executive directors
$83,303
ADDITIONAL FEES
Audit Committee (Chair) 
$10,582
Audit Committee (Member)
$5,215
People and Culture Committee (Chair)
$10,582
People and Culture Committee (Member) 
$5,215
Risk and Compliance Committee (Chair) 
$10,582
Risk and Compliance Committee (Member) 
$5,215
The amounts shown above for 2024 are inclusive of company superannuation guarantee contributions at 11.0%, payable on behalf of 
Directors on the base fees and additional fees (2023: at 10.5%). 
Directors’ Report
42  |  McPherson’s Limited

J)	 REMUNERATION REPORT CONTINUED
8.	 Share-based compensation
Performance Rights awarded, vested and lapsed during the year 
The table below discloses the number of performance rights (PR) granted, vested or lapsed during the year. Performance rights can 
only be exercised once the vesting conditions have been met. Unvested performance rights carry no dividend or voting rights.
 Name
 
Grant date
Vesting date
Exercise
 Price
Number
 of rights
 granted
Fair 
value per
right at
grant date1
Rights vested 
during the year
Rights forfeited 
during the year
No.
%
No.
%
B. Charlton 2
HLP
28/11/2023
22/09/2026
Nil 	 1,336,000	3 	
	
$0.44
—
—
—
—
ELP
28/11/2023
22/09/2026
Nil 	
668,000	3 	
	
$0.07
—
—
—
—
M. Sherwin 4
PR
17/06/2024
22/09/2026
Nil 	
77,904	3 	
EPS:	 $0.38
—
—
—
—
	
TSR:	 $0.07 
P. Witheridge 5
PR
25/09/2020 25/09/2023
Nil 	
50,000	6 	
EPS:	 $1.27
—
—
50,000
100
	
TSR:	 $1.42
PR
24/09/2021
24/09/2024
Nil 	
146,000	7 	
EPS:	 $2.80
—
—
—
—
	
TSR:	 $1.08
PR
23/09/2022 22/09/2025
Nil 	
213,000	8 	
EPS:	 $0.59
—
—
—
—
	
TSR:	 $0.19
PR
12/10/2023
22/09/2026
Nil 	
346,000	3 	
EPS:	 $0.34
—
—
—
—
	
TSR:	 $0.03
1.	 Determined at the time of grant per AASB 2. For details on the valuation of the performance rights including models and assumptions used, please refer to Note 22 
in the Financial Statements.
2.	Mr. Charlton was appointed as a Chief Executive Officer and Managing Director on 1 August 2023.
3.	Refer to section 3. Elements of Remuneration - LTI above for detail on vesting conditions of FY24 Performance Rights.
4.	Mr. Sherwin was appointed as a Chief Financial Officer on 6 May 2024.
5.	Mr. Witheridge resigned as a Chief Financial Officer on 30 April 2024. It was resolved by the Board that Mr. Witheridge was a “good leaver”. As such, unvested rights 
will be able to be exercised by Mr Witheridge in accordance with the Plan. 
6.	Refer to section 4. Link between Remuneration and Performance - Performance against LTI measures above for detail on vesting conditions of FY21 Performance Rights.
7.	Vesting conditions for FY22 Performance Rights are as follows: 
	
– 50% of Rights are subject to the satisfaction of a vesting condition relating to EPS CAGR - 30% of Rights vesting at +15.0% of underlying EPS CAGR, then pro rata to 
100% of Rights vesting at +20.0% of underlying EPS CAGR. 
	
– 50% of Rights are subject to the satisfaction of a vesting condition relating to TSR CAGR – 30% of Rights vesting at +15.0% underlying TSR CAGR, then pro rata to 
100% of Rights vesting at +20.0% TSR CAGR.
8.	Vesting conditions for FY23 Performance Rights are as follows: 
	
– 66.7% of Rights are subject to the satisfaction of a vesting condition relating to EPS CAGR - 30% of Rights vesting at +20.0% of underlying EPS CAGR, then pro rata 
to 100% of Rights vesting at +35.0% of underlying EPS CAGR.
	
– 33.3% of Rights are subject to the satisfaction of a vesting condition relating to TSR CAGR - 30% of Rights vesting at +30.0% of underlying TSR CAGR, then pro rata 
to 100% of Rights vesting at +45.0% TSR CAGR.
Performance rights holdings of KMP 
Name
Balance
at start of
the year
Granted as
compensation
Vested and
exercised
rights
Forfeited
Balance at 
the end of
the year
Vested and
exercisable
Unvested
B. Charlton 1
HLP
—
1,336,000
—
—
1,336,000
—
1,336,000
ELP
—
668,000
—
—
668,000
—
668,000
M. Sherwin 2
PR
—
77,904
—
—
77,904
—
77,904
P. Witheridge 3
PR
409,000
346,000
—
(50,000)
705,000
—
705,000
1.	 Balances for Mr. Charlton at the start of the year reflect balances at the date he commenced being a KMP 1 August 2023.
2.	Balances for Mr. Sherwin at the start of the year reflect balances at the date he commenced being a KMP 6 May 2024.
3.	Balances at the end of the year for Mr. Witheridge reflect balances at the date he ceased being a KMP on 30 April 2024.
Directors’ Report
Annual Report 2024  |  43

J)	 REMUNERATION REPORT CONTINUED
8.	 Share-based compensation continued
Shares issued on exercise of performance rights
No shares were issued in exercise of performance rights during the year.
Shares held by key management personnel
Name
Balance at the 
start of the year
Received during 
the year on 
the exercise of 
performance rights
Other changes 
during the year
Balance at the 
end of the period
B. Charlton 1
—
—
—
—
M. Sherwin 2
—
—
—
—
P. Witheridge 3
60,000
—
—
60,000
A.J. Cook
15,500
—
—
15,500
A. Mervis 
150,000
—
—
150,000
J.M. McKellar
11,533
—
—
11,533
H.L. Thornton 
20,000
—
—
20,000
1.	 Mr. Charlton was appointed as a Chief Executive Officer and Managing Director on 1 August 2023.
2.	Mr. Sherwin was appointed as a Chief Financial Officer on 6 May 2024.
3.	Mr. Witheridge resigned as a Chief Financial Officer on 30 April 2024. His share balance at the end of the period refers to shares held on the date of resignation.
9.	 Additional statutory information
Loans to Directors and Executives
There were no loans made to the Directors of McPherson’s Limited or to any KMP of the Company, including their related entities 
during the year, nor were there any loans outstanding at the end of the current or prior financial year.
Other Transactions with Directors and Executives
During the year, the Company sold minor quantities of its products for domestic use to the KMP on terms and conditions no more 
favourable than those adopted when dealing with other employees at arm’s length in the same circumstances. 
There were no transactions between the Company and the Directors of McPherson’s Limited or with any KMP of the Company, 
including their related entities, during the current financial year other than those disclosed above.
Directors’ Report
44  |  McPherson’s Limited

Directors’ Report
K)	 SHARES UNDER OPTION
At the date of this report, there were no unissued ordinary 
shares of McPherson’s under vested performance rights. 
There were no shares issued from the exercise of vested 
performance rights or options during the year ended 
30 June 2024 and up to the date of this report.
L)	 INDEMNIFICATION AND INSURANCE 
OF OFFICERS
The Group has agreed to indemnify the current Directors and 
certain current executives of the Group against all liabilities 
to another person (other than the Group or a related body 
corporate) that may arise from their position as Directors or 
officers of the Group, to the extent permitted by law. The 
agreement stipulates that the Group will meet the full amount 
of any such liabilities, including costs and expenses.
During the financial year, McPherson’s Limited paid a premium 
to insure Directors and certain officers of the Group. The 
Directors and officers covered by the insurance policy include 
the current Directors and Secretaries of McPherson’s Limited, 
Directors or Secretaries of controlled entities who are not or 
were not also Directors or Secretaries of McPherson’s Limited, 
senior management of the Group and senior management 
of divisions and controlled entities of McPherson’s Limited. 
As the insurance policy operates on a claim made basis, 
former Directors and officers of the Group are also covered.
The liabilities insured include costs and expenses that may be 
incurred in defending civil or criminal proceedings that may be 
brought against the officers in their capacity as officers of the 
Company or controlled entities. The insurance policy outlined 
above does not contain details of premiums paid in respect of 
individual Directors and officers of the Company. The insurance 
policy prohibits disclosure of the premium paid.
M)	 ENVIRONMENTAL REGULATION
The Company is not subject to significant environmental 
regulation in respect of its operations. The Company is 
committed to achieving a high standard of environmental 
performance and the Company monitors its compliance with 
environmental regulations. The Board is not aware of any 
significant breaches of environmental regulation during the 
period covered by this report.
N)	 PROCEEDINGS ON BEHALF OF THE GROUP
No person has applied to the Court under section 237 of 
the Corporations Act 2001 for leave to bring proceedings 
on behalf of the Company, or to intervene in any proceedings 
to which the Company is a party, for the purpose of taking 
responsibility on behalf of the Company for all or part of 
those proceedings.
No proceedings have been brought or intervened in on 
behalf of the Company with leave of the Court under 
section 237 of the Corporations Act 2001.
O)	 AUDIT AND NON-AUDIT SERVICES
Details of the amounts paid or payable to the auditor 
(PricewaterhouseCoopers Australia) for audit and non-audit 
services during the year are disclosed in note 25 Remuneration 
of Auditors.
The Company may decide to employ the external auditor on 
assignments additional to their statutory audit duties, where the 
external auditor’s expertise and experience with the Company 
are relevant.
The Board of Directors has considered the position and, in 
accordance with the advice received from the Audit Committee, 
is satisfied that the provision of the non-audit services is 
compatible with the general standard of independence for 
auditors imposed by the Corporations Act 2001. The Directors 
are satisfied that the provision of non-audit services by the 
auditor, as set out below, did not compromise the auditor 
independence requirements of the Corporations Act 2001 for 
the following reasons:
	
– All non-audit services have been reviewed by the Audit 
Committee to ensure they do not impact the impartiality and 
objectivity of the auditor; and
	
– None of the services undermine the general principles relating 
to auditor independence as set out in APES 110 Code of Ethics 
for Professional Accountants.
A copy of the auditor’s independence as required under section 
307C of the Corporations Act 2001 is set out on page 46.
P)	 ROUNDING
The Group is of a kind referred to in ASIC Corporations 
(Rounding in Financial/Directors’ Reports) Instrument 
2016/191 and, in accordance with that instrument, all financial 
information in this Directors’ Report and the Financial Report 
have been rounded to the nearest thousand dollars unless 
otherwise stated. 
Signed in accordance with a resolution of the Directors:
ARI MERVIS
Chair
29 August 2024
BRETT CHARLTON
Managing Director
29 August 2024
Annual Report 2024  |  45

Auditor’s Independence Declaration
 
PricewaterhouseCoopers, ABN 52 780 433 757 
One International Towers Sydney, Watermans Quay, Barangaroo, GPO BOX 2650, SYDNEY  NSW  2001 
T: +61 2 8266 0000, F: +61 2 8266 9999, www.pwc.com.au 
Level 11, 1PSQ, 169 Macquarie Street, Parramatta NSW 2150, PO Box 1155 Parramatta NSW 2124 
T: +61 2 9659 2476, F: +61 2 8266 9999, www.pwc.com.au 
Liability limited by a scheme approved under Professional Standards Legislation. 
Auditor’s Independence Declaration 
As lead auditor for the audit of McPherson's Limited for the year ended 30 June 2024, I declare that to 
the best of my knowledge and belief, there have been:  
(a) no contraventions of the auditor independence requirements of the Corporations Act 2001 in 
relation to the audit; and 
(b) no contraventions of any applicable code of professional conduct in relation to the audit. 
This declaration is in respect of McPherson's Limited and the entities it controlled during the period. 
 
 
 
 
Paddy Carney 
Sydney 
Partner 
PricewaterhouseCoopers 
  
29 August 2024 
 
46  |  McPherson’s Limited

Directors’ Declaration
In the Directors’ opinion:
a)	 the financial statements and notes as set out on pages 54 to 99 and the remuneration report on pages 32 to 44 are in 
accordance with the Corporations Act 2001, including:
i)	 complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting 
requirements; and
ii)	 giving a true and fair view of the consolidated entity’s financial position as at 30 June 2024 and of its performance for the 
financial year ended on that date;
b)	 there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due 
and payable;
c)	 at the date of this declaration, there are reasonable grounds to believe that the parties to the Deed of Cross Guarantee 
identified in Note 29 will be able to meet any obligations or liabilities to which they are, or may become, subject by virtue of 
the Deed of Cross Guarantee described in Note 29; and
d)	 the consolidated entity disclosure statement required by section 295(3A) of the Corporations Act is true and correct.
Note 1(a) confirms that the financial statements also comply with the International Financial Reporting Standards as issued by the 
International Accounting Standards Board.
The Directors have been given the declaration by the Chief Executive Officer and Chief Financial Officer required by Section 295A 
of the Corporations Act 2001.
This declaration is made in accordance with a resolution of the Directors.
ARI MERVIS
Chair
29 August 2024
Annual Report 2024  |  47

Independent Auditor’s Report
 
PricewaterhouseCoopers, ABN 52 780 433 757 
One International Towers Sydney, Watermans Quay, Barangaroo, GPO BOX 2650, SYDNEY  NSW  2001 
T: +61 2 8266 0000, F: +61 2 8266 9999 
Level 11, 1PSQ, 169 Macquarie Street, Parramatta NSW 2150, PO Box 1155 Parramatta NSW 2124 
T: +61 2 9659 2476, F: +61 2 8266 9999 
Liability limited by a scheme approved under Professional Standards Legislation. 
Independent auditor’s report 
To the members of McPherson's Limited 
Report on the audit of the financial report 
Our opinion 
In our opinion: 
The accompanying financial report of McPherson's Limited (the Company) and its controlled entities 
(together the Group) is in accordance with the Corporations Act 2001, including: 
(a) giving a true and fair view of the Group's financial position as at 30 June 2024 and of its financial 
performance for the year then ended  
(b) complying with Australian Accounting Standards and the Corporations Regulations 2001. 
What we have audited 
The financial report comprises: 
● 
the Consolidated Balance Sheet as at 30 June 2024 
● 
the Consolidated Statement of Comprehensive Income for the year then ended 
● 
the Consolidated Statement of Changes in Equity for the year then ended 
● 
the Consolidated Statement of Cash Flows for the year then ended 
● 
the Notes to and forming part of the Consolidated Financial Statements, including material 
accounting policy information and other explanatory information  
● 
the Consolidated Entity Disclosure Statement as at 30 June 2024 
● 
the Directors’ Declaration. 
Basis for opinion 
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under 
those standards are further described in the Auditor’s responsibilities for the audit of the financial 
report section of our report. 
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis 
for our opinion. 
Independence 
We are independent of the Group in accordance with the auditor independence requirements of the 
Corporations Act 2001 and the ethical requirements of the Accounting Professional & Ethical 
Standards Board’s APES 110 Code of Ethics for Professional Accountants (including Independence 
Standards) (the Code) that are relevant to our audit of the financial report in Australia. We have also 
fulfilled our other ethical responsibilities in accordance with the Code. 
48  |  McPherson’s Limited

Independent Auditor’s Report
 
 
Our audit approach 
An audit is designed to provide reasonable assurance about whether the financial report is free from 
material misstatement. Misstatements may arise due to fraud or error. They are considered material if 
individually or in aggregate, they could reasonably be expected to influence the economic decisions of 
users taken on the basis of the financial report. 
We tailored the scope of our audit to ensure that we performed enough work to be able to give an 
opinion on the financial report as a whole, taking into account the geographic and management 
structure of the Group, its accounting processes and controls and the industry in which it operates. 
Audit Scope 
Our audit focused on where the Group made subjective judgements; for example, significant 
accounting estimates involving assumptions and inherently uncertain future events. 
Key audit matters 
Key audit matters are those matters that, in our professional judgement, were of most significance in 
our audit of the financial report for the current period. The key audit matters were addressed in the 
context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do 
not provide a separate opinion on these matters. Further, any commentary on the outcomes of a 
particular audit procedure is made in that context. We communicated the key audit matters to the Audit 
Committee. 
Key audit matter 
How our audit addressed the key audit matter 
Valuation of goodwill ($23.7 million) and brand 
names ($27.7 million) 
Refer to note 16 Intangible Assets 
Goodwill is allocated to the Australia and New 
Zealand (ANZ) cash generating unit (CGU). The 
recoverable amount of the ANZ CGU is determined 
based on a fair value less costs of disposal 
calculation. Goodwill is tested for impairment 
annually, or more frequently if events or changes in 
circumstances indicate that it might be impaired. 
Brand names are tested for impairment on an 
individual basis annually, and more frequently if 
events or changes in circumstances indicate that they 
might be impaired. The recoverable amount of a 
brand name is determined based on the higher of 
value-in-use (VIU) or fair value less costs of disposal 
(FVLCD) calculations. 
This carrying value and impairment assessment of 
goodwill and brand names was considered to be a 
key audit matter due the following reasons:  
We performed the following procedures, amongst 
others:  
● 
Developed an understanding of the control 
activities relevant to the impairment 
assessment and assessed whether they 
were appropriately designed and 
implemented. 
● 
Assessed whether the Group’s 
determination of CGUs was consistent with 
our understanding of the nature of the 
Group’s operations.  
● 
Assessed whether the ANZ CGU 
appropriately included all assets, liabilities 
and cash flows.  
● 
Compared the Group’s forecast cash flows 
in the impairment models to the Board 
approved budget and other supporting 
evidence.  
Annual Report 2024  |  49

Independent Auditor’s Report
 
 
Key audit matter 
How our audit addressed the key audit matter 
● 
significant judgement is applied by the 
Group in relation to estimating the cash flow 
forecasts used in determining the 
recoverable amount for each Cash 
Generating Unit (CGU); and  
● 
given the magnitude of the amounts 
involved, a possible misstatement of a 
significant assumption could result in a 
material impairment or reversal of 
impairment. 
● 
Assessed the Group’s historical ability to 
forecast cash flows by comparing budgets to 
reported actual results.  
● 
Together with PwC valuation experts, 
assessed the valuation methodology and 
mathematical accuracy of relevant 
calculations in the impairment models and 
compared the discount rates, growth rates 
and royalty rates to historical company data 
and market observable inputs.  
● 
Assessed the reasonableness of the 
disclosures made in the financial report, in 
light of the requirements of Australian 
Accounting Standards. 
Inventory valuation ($25.7 million)  
Refer to note 10 Inventories  
The Group has gross inventories of $32.7 million and 
an inventory provision of $7.0 million.  
The Group values inventory at the lower of cost and 
net realisable value and estimates are required to 
determine the recoverable amount. These estimates 
are based on the Group’s projections of future sales 
volumes and prices.  
This was a key audit matter given the level of 
judgement involved in calculating the inventory 
provision and the magnitude of inventory recognised 
on the Group’s consolidated balance sheet. 
We performed the following procedures, amongst 
others:  
● 
Developed an understanding of the control 
activities relevant to our audit of inventory 
and assessed whether they were 
appropriately designed and implemented.  
● 
Tested the mathematical accuracy of the 
inventory provision calculation.  
● 
Assessed the inventory provision estimate, 
in particular the identification and valuation 
of inventory considered to be at risk of 
requiring a provision. For a selection of 
inventory we: 
o 
compared inventory on hand to 
forecast sales;  
o 
compared forecast sales to 
historical sales; and  
o 
compared the sales price, adjusted 
for costs to sell, to the carrying 
value.  
● 
Assessed the reasonableness of the 
disclosures made in the financial report, in 
light of the requirements of Australian 
Accounting Standards. 
50  |  McPherson’s Limited

Independent Auditor’s Report
 
 
Key audit matter 
How our audit addressed the key audit matter 
Multix divestment  
Refer to note 13 Discontinued Operations  
On 28 June 2024, following a strategic review, 
McPherson’s Limited completed the sale of its Multix 
brand and inventory for $19.0 million.  
We considered the Multix divestment to be a key 
audit matter due to:  
● 
the significance of the transaction to the 
consolidated financial statements and 
performance during the year; and  
● 
the judgement involved in determining the 
allocation of assets and costs to the 
discontinued operation. 
 
We performed the following procedures, amongst 
others:  
● 
Obtained and inspected the relevant 
contracts between McPherson’s Limited and 
International Consolidated Business Group 
Pty Ltd. 
● 
Together with PwC accounting specialists, 
assessed the classification of the disposal as 
a discontinued operation in accordance with 
Australian Accounting Standards. 
● 
Together with PwC valuation experts, 
assessed the methodology and 
mathematical accuracy of the allocation of 
revenue, costs and goodwill to the 
discontinued operation.  
● 
Tested the mathematical accuracy of the 
loss on disposal. 
● 
Assessed the disclosures made in the 
financial report in light of the requirements of 
Australian Accounting Standards.  
Carrying value of other assets ($2.9 million)  
Refer to note 12 Other Assets 
During the year, the amortisation period of the 
Exclusive Distribution Agreement (EDA) was reduced 
from 20 years to 5 years (resulting in amortisation of 
$1.2 million for the year to 30 June 2024).  At 30 June 
2024, the remaining carrying amount of the EDA was 
fully impaired ($3.67 million) in light of current 
performance.  
The key assumptions used in assessing the 
recoverability of the Preferred Brand Agreement 
(PBA) and EDA assets are the sales growth rates, the 
discount rate and the term of the agreement. 
The carrying value of other assets was a key audit 
matter due to the:  
● 
magnitude of the PBA balance; 
● 
magnitude of the EDA impairment and 
amortisation; and 
We performed the following procedures, amongst 
others:  
● 
Assessed the Group’s impairment 
assessment by comparing the recoverable 
amount for the PBA and EDA to the carrying 
value at 30 June 2024.  
● 
Assessed the amortisation methodology 
used by the Group by comparing the useful 
life applied to the terms of the agreements 
and tested the resulting calculations for 
mathematical accuracy.  
● 
Compared the Group’s forecast cash flows 
to Board approved budgets and actual 
results.  
● 
Assessed the expected term and exercise of 
extension options of individual brands under 
the EDA, based on forecast sales.  
● 
Assessed the EDA and PBA valuation 
methodology and mathematical accuracy of 
Annual Report 2024  |  51

Independent Auditor’s Report
 
 
Key audit matter 
How our audit addressed the key audit matter 
● 
significant judgement applied by the Group 
in estimating the cash flow forecasts used in 
determining the recoverable amount of the 
EDA and PBA. 
 
the impairment model and assessed the 
reasonableness of the discount rate in 
comparison to the discount rate for brand 
impairment.  
● 
Assessed the reasonableness of the 
disclosures made in the financial report, in 
light of the requirements of Australian 
Accounting Standards. 
Other information 
The directors are responsible for the other information. The other information comprises the 
information included in the annual report for the year ended 30 June 2024, but does not include the 
financial report and our auditor’s report thereon. Prior to the date of this auditor's report, the other 
information we obtained included the Directors' Report. We expect the remaining other information to 
be made available to us after the date of this auditor's report.  
Our opinion on the financial report does not cover the other information and we do not and will not 
express an opinion or any form of assurance conclusion thereon through our opinion on the financial 
report. We have issued a separate opinion on the remuneration report. 
In connection with our audit of the financial report, our responsibility is to read the other information 
and, in doing so, consider whether the other information is materially inconsistent with the financial 
report or our knowledge obtained in the audit, or otherwise appears to be materially misstated. 
If, based on the work we have performed on the other information that we obtained prior to the date of 
this auditor’s report, we conclude that there is a material misstatement of this other information, we are 
required to report that fact. We have nothing to report in this regard. 
When we read the other information not yet received, if we conclude that there is a material 
misstatement therein, we are required to communicate the matter to the directors and use our 
professional judgement to determine the appropriate action to take. 
Responsibilities of the directors for the financial report 
The directors of the Company are responsible for the preparation of the financial report in accordance 
with Australian Accounting Standards and the Corporations Act 2001, including giving a true and fair 
view, and for such internal control as the directors determine is necessary to enable the preparation of 
the financial report that is free from material misstatement, whether due to fraud or error. 
In preparing the financial report, the directors are responsible for assessing the ability of the Group to 
continue as a going concern, disclosing, as applicable, matters related to going concern and using the 
going concern basis of accounting unless the directors either intend to liquidate the Group or to cease 
operations, or have no realistic alternative but to do so. 
52  |  McPherson’s Limited

Independent Auditor’s Report
 
 
Auditor’s responsibilities for the audit of the financial report 
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is 
free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that 
includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that 
an audit conducted in accordance with the Australian Auditing Standards will always detect a material 
misstatement when it exists. Misstatements can arise from fraud or error and are considered material 
if, individually or in the aggregate, they could reasonably be expected to influence the economic 
decisions of users taken on the basis of the financial report. 
A further description of our responsibilities for the audit of the financial report is located at the Auditing 
and Assurance Standards Board website at: 
https://www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf. This description forms part of our 
auditor's report. 
Report on the remuneration report 
Our opinion on the remuneration report 
We have audited the remuneration report included in the directors’ report for the year ended 30 June 
2024. 
In our opinion, the remuneration report of McPherson's Limited for the year ended 30 June 2024 
complies with section 300A of the Corporations Act 2001. 
Responsibilities 
The directors of the Company are responsible for the preparation and presentation of the 
remuneration report in accordance with section 300A of the Corporations Act 2001. Our responsibility 
is to express an opinion on the remuneration report, based on our audit conducted in accordance with 
Australian Auditing Standards.  
 
 
 PricewaterhouseCoopers 
 
 
Paddy Carney 
Sydney 
Partner 
29 August 2024 
 
Annual Report 2024  |  53

Consolidated Statement of Comprehensive Income 
FOR THE YEAR ENDED 30 JUNE 2024
Note
2024 
$’000
	
2023	1 
$’000
CONTINUING OPERATIONS
Revenue
Sales revenue
144,625
155,174
Other income
28
60
Total revenue and other income
144,653
155,234
Expenses
Materials and consumables
(68,078)
(65,962)
Employee costs
(35,551)
(35,460)
Advertising and promotions
(22,170)
(21,544)
Cartage and freight
(4,787)
(4,981)
Third party warehousing
(838)
(939)
Rental expenses 
(311)
(408)
Depreciation
(5,359)
(5,510)
Amortisation 
(551)
(475)
Other expenses
(15,156)
(14,292)
Impairment of intangible assets
16
(2,761)
(3,162)
Operating (loss) / profit before finance costs and income tax
(10,909)
2,502
Interest income
18
78
24
Borrowing costs
18
(1,905)
(1,786)
Net finance costs
(1,827)
(1,762)
(Loss) / profit before income tax from continuing operations
(12,736)
740
Income tax benefit / (expense)
6
1,350
(2,013)
(Loss) / profit for the year after tax from continuing operations
(11,386)
(1,273)
DISCONTINUED OPERATIONS
(Loss) / profit from discontinued operations, net of income tax
13
(4,605)
(3,788)
(Loss) / profit for the year after tax 
(15,991)
(5,061)
Other Comprehensive Income
Items that may be reclassified to profit or loss
Changes in fair value of cash flow hedges
(80)
(1,621)
Exchange differences on translation of foreign operations
2
(490)
Income tax benefit relating to these items
34
469
Other comprehensive (expense) / income for the year 
(44)
(662)
Total comprehensive (expense) / income for the year
(16,035)
(5,723)
Total comprehensive income for the year to owners of McPherson’s Limited arises from:
Continuing operations
(11,430)
(1,935)
Discontinued operations 
(4,605)
(3,788)
(16,035)
(5,723)
Earnings per share
Cents
Cents
Basic (loss) / earnings per share
26
(11.1)
(3.5)
Diluted (loss) / earnings per share
26
(11.1)
(3.5)
Basic (loss) / earnings per share from continuing operations
26
(7.9)
(0.9)
Diluted (loss) / earnings per share from continuing operations
26
(7.9)
(0.9)
1.	 The 2023 comparative numbers of the Group have been restated to show the discontinued operations separately from the continuing operations.
The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.
54  |  McPherson’s Limited

Consolidated Balance Sheet 
AS AT 30 JUNE 2024
Note
2024 
$’000
2023 
$’000
CURRENT ASSETS
Cash and cash equivalents
8
24,769
7,031
Trade and other receivables
9
24,002
28,893
Inventories
10
25,663
45,159
Derivative financial instruments
11
100
607
Current tax receivable
524
—
Other assets
12
721
992
Total current assets
75,779
82,682
NON-CURRENT ASSETS
Property, plant and equipment
14
5,966
6,675
Right-of-use assets
15
8,510
11,438
Intangible assets
16
54,498
78,814
Other assets
12
2,148
7,588
Total non-current assets
71,122
104,515
Total assets
146,901
187,197
CURRENT LIABILITIES
Trade and other payables
17
26,475
33,247
Borrowings
18
10,673
927
Lease liabilities
3,400
3,736
Provisions
19
5,795
7,081
Derivative financial instruments
11
387
866
Current tax liabilities
—
1,369
Total current liabilities
46,730
47,226
NON-CURRENT LIABILITIES
Other payables
17
—
706
Borrowings
18
—
12,592
Lease liabilities
5,564
8,194
Provisions
19
1,435
1,549
Deferred tax liabilities
6
3,535
7,478
Total non-current liabilities
10,534
30,519
Total liabilities
57,264
77,745
Net assets
89,637
109,452
EQUITY
Contributed equity
20
217,218
217,218
Reserves
21(a)
(1,472)
(1,966)
Accumulated losses
21(b)
(126,109)
(105,800)
Total equity
89,637
109,452
The above consolidated balance sheet should be read in conjunction with the accompanying notes.
Annual Report 2024  |  55

Note
Contributed 
equity
$’000
Reserves 
$’000
Accumulated 
losses 
$’000
Total
equity 
$’000
Balance at 30 June 2023
217,218
(1,966)
(105,800)
109,452
Loss for the year
—
—
(15,991)
(15,991)
Other comprehensive income
—
(44)
—
(44)
Total comprehensive income 
—
(44)
(15,991)
(16,035)
Transactions with shareholders
Dividends provided for or paid
4
—
—
(4,318)
(4,318)
Share-based payment transactions with employees
21(a)
—
538
—
538
Total transactions with shareholders
—
538
(4,318)
(3,780)
Balance at 30 June 2024
217,218
(1,472)
(126,109)
89,637
Note
Contributed
equity 
$’000
Reserves
$’000
Accumulated
losses
$’000
Total
equity
$’000
Balance at 30 June 2022
207,244
8,543
(94,981)
120,806
Loss for the year
—
—
(5,061)
(5,061)
Other comprehensive income
—
(662)
—
(662)
Total comprehensive income 
—
(662)
(5,061)
(5,723)
Transactions with shareholders
Dividends provided for or paid
4
—
—
(5,758)
(5,758)
Shares vested and transferred to employees 
21(a)
231
(231)
—
—
Share-based payment transactions with employees
21(a)
—
127
—
127
Shares issued for Contract Assets and prepayment for inventory
21(a)
9,743
(9,743)
—
—
Total transactions with shareholders
9,974
(9,847)
(5,758)
(5,631)
Balance at 30 June 2023
217,218
(1,966)
(105,800)
109,452
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.
Consolidated Statement of Changes in Equity 
FOR THE YEAR ENDED 30 JUNE 2024
56  |  McPherson’s Limited

Consolidated Statement of Cash Flows 
FOR THE YEAR ENDED 30 JUNE 2024
Note
2024 
$’000
2023 
$’000
CASH FLOWS FROM OPERATING ACTIVITIES
Receipts from customers, inclusive of GST
220,306
233,421 
Payments to suppliers and employees, inclusive of GST
(203,985)
(226,583)
Interest received
78
24 
Interest and borrowing costs paid
(1,474)
(1,600)
Income taxes (paid)/received 
(2,582)
1,286 
Net cash inflows from operating activities
30
12,343
6,548
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for purchase of property, plant and equipment
(1,139)
(1,788)
Payments for purchase of other intangible assets
(1,567)
(61)
Proceeds from sale of business assets
19,000
—
Net cash inflows / (outflows) from investing activities
16,294
(1,849)
CASH FLOWS FROM FINANCING ACTIVITIES
Share issue transaction costs
—
(2)
Proceeds from borrowings
27,185
47,633
Repayment of borrowings
(30,224)
(49,000)
Repayment of lease liabilities
(3,544)
(3,783)
Dividends paid
(4,318)
(5,758)
Net cash (outflows) from financing activities
(10,901)
(10,910)
Net increase / (decrease) in cash held
17,736
(6,211)
Cash at beginning of financial year
7,031
13,139
Effects of exchange rate changes
2
103
Cash held at end of financial year
8
24,769
7,031
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.
Annual Report 2024  |  57

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
1.	 Summary of material accounting policies
The accounting policies adopted in the preparation of these 
consolidated financial statements are set out below. These 
policies have been consistently applied to all the periods 
presented, unless otherwise stated. The financial statements are 
for the consolidated entity consisting of McPherson’s Limited 
and its controlled entities.
A)	 BASIS OF PREPARATION
These general purpose financial statements have been 
prepared in accordance with Australian Accounting Standards 
and Interpretations issued by the Australian Accounting 
Standards Board and the Corporations Act 2001. McPherson’s 
Limited is a for-profit entity for the purpose of preparing the 
financial statements.
Compliance with IFRS
The consolidated financial statements also comply with 
International Financial Reporting Standards (IFRS) as issued 
by the International Accounting Standards Board (IASB).
Historical cost convention
These financial statements have been prepared under the 
historical cost convention, except for certain financial assets and 
liabilities, including derivative instruments, which are carried at 
fair value.
New and amended standards adopted by the Group
The Australian Accounting Standards Board (AASB) has issued 
a number of standards and amendments to standards that are 
mandatory for the first time in the reporting period commenced 
1 July 2023. The Group has assessed and determined that there 
are no new or amended standards applicable for the first time 
for the financial report for the year ended 30 June 2024, that 
materially affect the Group’s accounting policies or any of the 
amounts recognised in the financial statements.
New standards and interpretations not yet adopted 
by the Group
AASB 18 Presentation and Disclosure in Financial Statements 
The AASB issued AASB 18 in June 2024, which sets out 
requirements for the presentation and disclosure of information 
in general purpose financial statements. AASB 18 is effective for 
annual reporting periods beginning on or after 1 January 2027. 
The Group is continuing to assess the full impact of adopting 
AASB 18. 
Other new or amended accounting standards 
The AASB has issued a number of new or amended accounting 
standards and interpretations that are not mandatory for the 
first time in the reporting period commenced 1 July 2023. 
The Group has assessed these standards and interpretations 
and determined that there are no standards or amendments 
to standards that are not yet effective that are expected to 
have a material impact on the Group in the current or future 
reporting periods.
B)	 PRINCIPLES OF CONSOLIDATION
Subsidiaries
Subsidiaries are all entities over which the Group has control. 
The Group controls an entity when the Group is exposed to, 
or has rights to, variable returns from its involvement with the 
entity and has the ability to affect those returns through its 
power to direct the activities of the entity. Subsidiaries are fully 
consolidated from the date on which control is transferred 
to the Group. They are deconsolidated from the date that 
control ceases.
The acquisition method of accounting is used to account for 
business combinations by the Group (refer to Note 1(h)).
Intercompany transactions, balances and unrealised gains on 
transactions between Group entities are eliminated. Unrealised 
losses are also eliminated unless the transaction provides 
evidence of an impairment of the transferred asset. Accounting 
policies of subsidiaries have been changed where necessary to 
ensure consistency with the policies adopted by the Group.
Investments in controlled entities are accounted for at cost in 
the individual financial statements of the parent entity.
Changes in ownership interests
When the Group ceases to have control, any retained interest 
in the entity is remeasured to its fair value with the change 
in carrying amount recognised in profit or loss. This fair 
value becomes the initial carrying amount for the purposes 
of subsequently accounting for the retained interest as an 
associate, joint venture or financial asset. In addition, any 
amounts previously recognised in other comprehensive 
income in respect of that entity are accounted for as if the 
Group had directly disposed of the related assets or liabilities. 
This may mean that amounts previously recognised in other 
comprehensive income are reclassified to profit or loss.
Joint arrangements
Under AASB 11, investments in joint arrangements are classified 
as either joint operations or joint ventures. The classification 
depends on the contractual rights and obligations of each 
investor, rather than the legal structure of the joint arrangement.
Equity method
Under the equity method, investments are initially recognised 
at cost and adjusted thereafter to recognise the Group’s share 
of the post-investment profits or losses of the investee, and the 
Group’s share of movements in other comprehensive income of 
the investee in other comprehensive income. Dividends received 
or receivable from the investee are recognised as a reduction in 
the carrying amount of the investment.
When the Group’s share of losses in an equity-accounted 
investment equals or exceeds its interest in the entity, including 
any other unsecured long-term receivables, the Group does not 
recognise further losses, unless it has incurred obligations or 
made payments on behalf of the other entity.
Unrealised gains on transactions between the Group and its 
associates are eliminated to the extent of the Group’s interest 
in these entities. Unrealised losses are also eliminated unless 
the transaction provides evidence of an impairment of the asset 
transferred. Accounting policies of equity-accounted investees 
have been changed where necessary to ensure consistency with 
the policies adopted by the Group.
58  |  McPherson’s Limited

1.	 Summary of material accounting policies
continued
C)	 SEGMENT REPORTING
Operating segments are reported in a manner consistent with 
the internal reporting provided to the chief operating decision 
maker. The chief operating decision maker has been identified 
as the Chief Executive Officer and Managing Director of 
McPherson’s Limited.
D)	 FOREIGN CURRENCY TRANSLATION 
Functional and presentation currency
Items included in the financial statements of each of the 
Group’s entities are measured using the currency of the primary 
economic environment in which it operates (‘the functional 
currency’). The consolidated financial statements are presented 
in Australian dollars, which is McPherson’s Limited’s functional 
and presentation currency.
Transactions and balances
Foreign currency transactions are translated into the functional 
currency using the exchange rates at the dates of the 
transactions. Foreign exchange gains and losses resulting 
from the settlement of such transactions and from the 
translation of monetary assets and liabilities denominated in 
foreign currencies at year end exchange rates are generally 
recognised in profit or loss. They are deferred in equity if 
they relate to qualifying cash flow hedges and qualifying 
net investment hedges or are attributable to part of the 
net investment in a foreign operation.
Group companies
The results and financial position of foreign operations that have 
a functional currency different from the presentation currency 
are translated into the presentation currency as follows:
	
– Assets and liabilities for each balance sheet presented are 
translated at the closing rate at the date of the balance sheet;
	
– Income and expenses for the statement of comprehensive 
income are translated at average exchange rates, unless this 
is not a reasonable approximation of the cumulative effect 
of the rates prevailing on the transaction dates, in which 
case income and expenses are translated at the dates of 
the transactions; and 
	
– All resulting exchange differences are recognised in other 
comprehensive income.
On consolidation, exchange differences arising from the 
translation of any net investment in foreign entities, and 
of borrowings and other financial instruments designated 
as hedges of such investments, are recognised in other 
comprehensive income. When a foreign operation is sold or 
any borrowings forming part of the net investment are repaid, 
the associated exchange differences are reclassified to profit 
or loss, as part of the gain or loss on sale.
Goodwill and fair value adjustments arising on the acquisition 
of a foreign operation are treated as assets and liabilities of 
the foreign operation and translated at the closing rate.
E)	 REVENUE RECOGNITION
Sales revenue
The Group markets and distributes Health, Wellness and Beauty 
products. Sales are recognised at a point in time when the control 
of the products has transferred, being when the products are 
delivered to the customer, or when the customer has directed 
the Group to warehouse finished goods on its behalf, with the 
risks of control and ownership transferring to the customer. 
The customer has full discretion over the price to sell the 
products, and there is no unfulfilled obligation that could affect 
the customer’s acceptance of the products. Delivery occurs 
when the products have been delivered to the specific location, 
the risks of obsolescence and loss have been transferred to the 
customer, and the Group has objective evidence that all criteria 
for acceptance have been satisfied.
The Group’s products are often sold on terms that include 
settlement discounts and volume rebates. Revenue from these 
sales is recognised based on the price specified in the contract, 
net of estimated discounts and rebates, using the expected value 
method. A contract liability is recognised for expected discounts 
and rebates payable to customers in relation to sales made 
until the end of the reporting period. No element of financing is 
deemed present as sales are made with credit terms normally 
between 30 and 60 days, which is consistent with market practice.
A receivable is recognised when the goods are delivered to the 
customer, or when the customer directs the Group to warehouse 
finished goods on its behalf, with the risks of control and 
ownership transferring to the customer, as this is the point in time 
that the consideration is unconditional because only the passage 
of time is required before the payment is due.
Accounting for refunds 
When the customer has a right to return the product within a 
given period, the entity has a potential obligation to refund the 
purchase price. A refund liability for the expected refunds to 
customers is recognised as an adjustment to revenue in trade 
and other payables. At the same time, the Group has a right to 
recover the product from the customer where the customer 
exercises its right of return and recognises an asset in trade and 
other receivables and a corresponding adjustment to cost of 
sales. The asset is measured by reference to the former carrying 
amount of the product. The costs to recover the products are 
not material because the customer usually returns the product 
in a saleable condition to the Group. 
The Group does not have any contracts where the period 
between the supply of goods or services to the customer and 
payment by the customer exceeds one year. Consequently, 
the Group does not adjust any of the transaction prices for the 
time value of money.
Other income
Other income is recognised when the income is received or 
becomes receivable.
Government grants
Grants from the government are recognised at their fair value 
where there is a reasonable assurance that the grant will be 
received, and the Group will comply with all attached conditions. 
Government grants relating to costs are deferred and recognised 
in profit or loss over the period necessary to match them with the 
costs that they are intended to compensate.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  59

1.	 Summary of material accounting policies
continued
F)	 INCOME TAX
The income tax expense or income for the period is the tax 
payable or receivable on the current period’s taxable income 
based on the applicable income tax rate for each jurisdiction 
adjusted by changes in deferred tax assets and liabilities 
attributable to temporary differences and any unused tax losses. 
The current income tax charge is calculated on the basis of 
the tax laws enacted or substantively enacted at the end of 
the reporting period in the countries where the Company’s 
subsidiaries and associates operate and generate taxable 
income. Management periodically evaluates positions taken in 
tax returns with respect to situations in which applicable tax 
regulation is subject to interpretation. It establishes provisions 
where appropriate on the basis of amounts expected to be 
paid to the tax authorities.
Deferred income tax is provided in full, using the liability method, 
on temporary differences arising between the tax bases of assets 
and liabilities and their carrying amounts in the consolidated 
financial statements. However, deferred tax liabilities are not 
recognised if they arise from the initial recognition of goodwill. 
Deferred income tax is also not accounted for if it arises from 
initial recognition of an asset or liability in a transaction other than 
a business combination that at the time of the transaction affects 
neither accounting nor taxable profit or loss. Deferred income tax 
is determined using tax rates and laws, that have been enacted 
or substantially enacted by the end of the reporting period and 
are expected to apply when the related deferred income tax 
asset is realised, or the deferred income tax liability is settled.
Deferred tax assets are recognised for deductible temporary 
differences and unused tax losses only if it is probable that 
future taxable amounts will be available to utilise those 
temporary differences and losses.
Deferred tax liabilities and assets are not recognised for 
temporary differences between the carrying amount and tax 
bases of investments in foreign operations where the parent 
entity is able to control the timing of the reversal of the 
temporary differences and it is probable that the differences 
will not reverse in the foreseeable future.
Current and deferred tax is recognised in profit or loss except 
to the extent that it relates to items recognised in other 
comprehensive income or directly in equity. In this case, the tax 
is also recognised in other comprehensive income or directly in 
equity, respectively.
Tax consolidation legislation
McPherson’s Limited and its wholly-owned Australian controlled 
entities have implemented the tax consolidation legislation. 
As a consequence, these entities are taxed as a single entity. 
McPherson’s Limited, as the head entity in the tax consolidated 
Group, recognises current tax amounts relating to transactions, 
events and balances of the wholly-owned Australian controlled 
entities in this Group as if those transactions, events and 
balances were its own, in addition to the current and deferred 
tax amounts arising in relation to its own transactions, events 
and balances. Amounts receivable or payable under a Tax 
Funding Agreement with the tax consolidated entities are 
recognised separately as tax-related amounts receivable or 
payable. Expenses and revenues arising under the Tax Funding 
Agreement are presented as income tax expenses or credits.
G)	 LEASES
Lease contracts
The Group leases various offices, warehouses, equipment and 
vehicles. Rental contracts are typically made for fixed periods 
of 12 months to 5 years, but may have extension options. 
Extension and termination options that are reasonably certain 
are included in a number of property and equipment leases 
across the Group. 
Contracts may contain both lease and non-lease components. 
The Group allocates the consideration in the contract to the 
lease and non-lease components based on their relative stand-
alone prices. However, for leases of real estate for which the 
Group is a lessee, it has elected not to separate lease and non-
lease components and instead accounts for these as a single 
lease component.
Lease terms are negotiated on an individual basis and contain 
a wide range of different terms and conditions. The lease 
agreements do not impose any covenants other than the security 
interests in the leased assets that are held by the lessor. Leased 
assets may not be used as security for borrowing purposes.
Lease liabilities 
Lease liabilities are initially measured on a present value basis 
of the following lease payments: 
	
– Fixed payments less any lease incentives receivable; and
	
– Variable lease payments based on a rate initially measured 
at the commencement date, such as CPI.
Lease payments to be made under reasonably certain 
extension options are also included in the measurement of 
the liability. The lease payments are discounted using the 
interest rate implicit in the lease. If that rate cannot be readily 
determined, which is generally the case for leases in the Group, 
the Group’s incremental borrowing rate is used, being the rate 
that an individual lessee would have to pay to borrow the funds 
necessary to obtain an asset of similar value to the right-of-
use asset in a similar economic environment with similar terms, 
security and conditions.
Right-of-use assets
Right-of-use assets are measured at present value comprising 
the following:
	
– The amount of the initial measurement of lease liability;
	
– Any lease payments made at or before the commencement 
date less any lease incentives received;
	
– Any initial direct costs; and
	
– Restoration costs.
Right-of-use assets are generally depreciated over the shorter 
of the asset’s useful life and the lease term on a straight-line 
basis. If the Group is reasonably certain to exercise a purchase 
option, the right-of-use asset is depreciated over the underlying 
asset’s useful life. 
Short term leases
Payments associated with short-term leases of equipment 
and vehicles and all leases of low-value assets are 
recognised on a straight-line basis as an expense in profit 
or loss. Short-term leases are leases with a lease term of 
12 months or less. Low-value assets comprise IT equipment 
and small items of office furniture.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
60  |  McPherson’s Limited

1.	 Summary of material accounting policies
continued
H)	 BUSINESS COMBINATIONS
The acquisition method is used to account for all business 
combinations regardless of whether equity instruments or 
other assets are acquired. The consideration transferred for the 
acquisition comprises the fair value of the assets transferred, 
shares issued, and liabilities incurred or assumed at the date 
of exchange. The consideration transferred also includes the 
fair value of any asset or liability resulting from a contingent 
consideration arrangement. Acquisition-related costs are 
expensed as incurred. Where equity instruments are issued in an 
acquisition, the value of the instruments is their published market 
price as at the date of exchange unless, in rare circumstances, 
it can be demonstrated that the published price at the date 
of exchange is an unreliable indicator of fair value and that 
other evidence and valuation methods provide a more reliable 
measure of fair value. Transaction costs arising on the issue of 
equity instruments are recognised directly in equity.
Identifiable assets acquired and liabilities and contingent liabilities 
assumed in a business combination are, with limited exceptions, 
measured initially at their fair value at the acquisition date. The 
excess of the consideration transferred over the fair value of 
the Group’s share of the identifiable net assets acquired is 
recorded as goodwill (refer to Note 1(r)). If the consideration 
transferred is less than the fair value of the net assets of the 
business acquired, the difference is recognised directly in profit 
or loss as a bargain purchase, but only after a reassessment of 
the identification and measurement of the net assets acquired. 
Contingent consideration is classified either as equity or a 
financial liability. Amounts classified as a financial liability are 
subsequently remeasured to fair value with changes in fair value 
recognised in profit or loss.
I)	
IMPAIRMENT OF ASSETS
Goodwill and intangible assets that have an indefinite useful 
life are tested annually for impairment, or more frequently if 
events or changes in circumstances indicate that they might 
be impaired.
Other assets are tested for impairment whenever events or 
changes in circumstances indicate that the carrying amount 
may not be recoverable. An impairment loss is recognised for 
the amount by which the asset’s carrying amount exceeds its 
recoverable amount. The recoverable amount is the higher of 
an asset’s fair value less costs to sell and value in use. For the 
purposes of assessing impairment, assets are grouped at the 
lowest levels for which there are separately identifiable cash 
inflows (cash generating units). Non-financial assets other than 
goodwill that suffered an impairment are reviewed for possible 
reversal of the impairment at the end of each reporting period.  
J)	 CASH AND CASH EQUIVALENTS
Cash and cash equivalents include cash on hand and deposits 
at call which are readily convertible to cash on hand and are 
used in the cash management function on a day-to-day basis 
net of outstanding bank overdrafts. Bank overdrafts, if any, are 
shown within borrowings in current liabilities in the balance sheet.
K)	 TRADE RECEIVABLES
Trade receivables are recognised initially at fair value and subsequently 
measured at amortised cost using the effective interest method, less 
provision for impairment. Trade receivables are generally due for 
settlement no more than 60 days from the date of recognition.
Collectability of trade receivables is reviewed on an ongoing basis. 
Debts which are known to be uncollectible are written off. The 
Group applies the simplified approach to providing for expected 
credit losses prescribed by AASB 9, which permits the use of the 
lifetime expected loss provision for all trade receivables. To measure 
the expected credit losses, trade receivables have been grouped 
based on shared credit risk characteristics and the days past due.
L)	 INVENTORIES
Inventories are valued at the lower of cost and net realisable 
value. Costs are assigned to individual items of inventory on a 
weighted average basis. Cost includes the reclassification from 
equity of any gains or losses on qualifying cash flow hedges 
relating to purchases of inventory. Cost of work in progress and 
finished manufactured products includes materials, labour and 
an appropriate proportion of factory overhead expenditure, the 
latter being allocated on the basis of normal operating capacity. 
Costs of purchased inventory are determined after deducting 
rebates and discounts. Unrealised profits on intercompany 
inventory transfers are eliminated on consolidation. Net realisable 
value is the estimated selling price in the ordinary course of 
business less the estimated costs necessary to make the sale.
M)	 NON-CURRENT ASSETS, OR 
DISPOSAL GROUPS, HELD FOR SALE 
AND DISCONTINUED OPERATIONS
Non-current assets, or disposal groups, are classified as held for 
sale if their carrying amount will be recovered principally through 
a sale transaction rather than through continuing use and a sale 
is considered highly probable. They are measured at the lower of 
their carrying amount and fair value less costs to sell, except for 
assets such as deferred tax assets, assets arising from employee 
benefits and financial assets.
An impairment loss is recognised for any initial or subsequent write 
down of the asset, or disposal group, to fair value less costs to sell. 
A gain is recognised for any subsequent increases in fair value less 
costs to sell of an asset, or disposal group, but not in excess of any 
cumulative impairment loss previously recognised. A gain or loss 
not previously recognised by the date of the sale of the non-current 
asset, or disposal group, is recognised at the date of derecognition.
Non-current assets, including those that are part of a disposal 
group, are not depreciated or amortised while they are classified 
as held for sale.
Non-current assets classified as held for sale and the assets 
of a disposal group classified as held for sale are presented 
separately from the other assets in the balance sheet. The 
liabilities of a disposal group classified as held for sale are 
presented separately from other liabilities in the balance sheet.
A discontinued operation is a component of the entity that has been 
disposed of or is classified as held for sale and that represents a 
separate cash-generating unit or a group of cash-generating units and 
is a separate major line of business or geographical area of operations 
and is part of a single co-ordinated plan to dispose of such a line of 
business or area of operations. The results of discontinued operations 
are presented separately in the statement of comprehensive income.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  61

1.	 Summary of material accounting policies 
continued
N)	 INVESTMENTS AND OTHER FINANCIAL ASSETS
i)	
Classification
The Group classifies its financial assets in the following 
measurement categories:
	
– Those to be measured subsequently at fair value (either through 
other comprehensive income, or through profit or loss); and
	
– Those to be measured at amortised cost. 
The classification depends on the entity’s business model for 
managing the financial assets and the contractual terms of the 
cash flows. For assets measured at fair value, gains and losses will 
either be recorded in profit or loss or other comprehensive income.
ii)	 Financial assets at fair value through profit or loss
The Group classifies the following financial assets at fair value 
through profit or loss:
	
– Debt investments that do not qualify for measurement 
at either amortised cost or at fair value through other 
comprehensive income;
	
– Equity investments that are held for trading; and
	
– Equity investments for which the entity has not elected 
to recognise fair value gains and losses through other 
comprehensive income.
iii)	 Financial assets at fair value through other 
comprehensive income 
Financial assets at fair value through other comprehensive income 
are equity investments which are not held for trading, and for 
which the Group’s management has elected to present fair value 
gains and losses in other comprehensive income. There is no 
subsequent reclassification of fair value gains and losses to profit or 
loss following the derecognition of the investment. Dividends from 
such investments continue to be recognised in profit or loss as other 
income when the Group’s right to receive payments is established. 
Impairment losses and reversal of impairment losses on equity 
investments measured at fair value through other comprehensive 
income are not reported separately from other changes in fair value.
iv)	 Other financial assets at amortised cost
The Group classifies its financial assets as at amortised cost only 
if both of the following criteria are met:
	
– The asset is held within a business model with the objective of 
collecting the contractual cash flows; and
	
– The contractual terms give rise on specified dates to cash 
flows that are solely payments of principal and interest on the 
principal outstanding.
They are included in current assets, except for those with 
maturities greater than 12 months after the balance sheet date 
which are classified as non-current assets. Financial assets at 
amortised cost are included in receivables in the balance sheet.
v)	 Impairment
The Group assesses on a forward-looking basis the expected 
credit losses associated with its debt instruments carried at 
amortised cost and fair value through other comprehensive 
income. The impairment methodology applied depends on 
whether there has been a significant increase in credit risk. 
For trade receivables, the Group applies the simplified approach 
permitted by AASB 9, which requires expected lifetime losses 
to be recognised from initial recognition of the receivables. 
O)	 DERIVATIVES AND HEDGING ACTIVITIES
Derivatives are initially recognised at fair value on the date 
a derivative contract is entered into and are subsequently 
re-measured to their fair value at the end of each reporting 
period. The accounting for subsequent changes in fair value 
depends on whether the derivative is designated as a hedging 
instrument, and if so, the nature of the item being hedged and 
the type of hedge relationship designated.
The Group documents at the inception of the hedging 
transaction, the economic relationship between hedging 
instruments and hedged items including whether the hedging 
instrument is expected to offset changes in cash flows of 
hedged items. The Group documents its risk management 
objective and strategy for undertaking various hedge 
transactions at the inception of each hedge relationship.
The full fair value of a hedging derivative is classified as a 
non-current asset or liability when the remaining maturity of the 
hedged item is more than 12 months. It is classified as a current 
asset or liability when the remaining maturity of the hedged item 
is less than 12 months. Trading derivatives are classified as a 
current asset or liability.
Cash flow hedges that qualify for hedge accounting
The effective portion of changes in the fair value of derivatives 
that are designated and qualify as cash flow hedges is 
recognised in the cash flow hedge reserve within equity, limited 
to the cumulative change in fair value of the hedged item on a 
present value basis from the inception of the hedge. The gain or 
loss relating to the ineffective portion is recognised immediately 
in profit or loss, within finance costs.
When option contracts are used to hedge forecast transactions, 
the Group designates only the intrinsic value of the option 
contract as the hedging instrument.
Gains or losses relating to the effective portion of the change in 
intrinsic value of the option contracts are recognised in the cash 
flow hedge reserve within equity. The changes in the time value 
of the options that relate to the hedged item are recognised 
within other comprehensive income in the costs of hedging 
reserve within equity.
When forward contracts are used to hedge forecast 
transactions, the Group generally designates only the change in 
fair value of the forward contract related to the spot component 
as the hedging instrument. Gains or losses relating to the 
effective portion of the change in the spot component of the 
forward contracts are recognised in the cash flow hedge reserve 
within equity. The change in the forward element of the contract 
that relates to the hedged item is recognised within other 
comprehensive income in the costs of hedging reserve within 
equity. In some cases, the entity may designate the full change 
in fair value of the forward contract (including forward points) 
as the hedging instrument. In such cases, the gains or losses 
relating to the effective portion of the change in fair value of the 
entire forward contract are recognised in the cash flow hedge 
reserve within equity.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
62  |  McPherson’s Limited

1.	 Summary of material accounting policies 
continued
O)	 DERIVATIVES AND HEDGING ACTIVITIES 
CONTINUED
Amounts accumulated in equity are reclassified in the periods 
when the hedged item affects profit or loss, as follows:
	
– Gain or loss relating to the effective portion of the 
intrinsic value of option contracts where the hedged item 
subsequently results in the recognition of a non-financial 
asset (such as inventory), both the deferred hedging gains 
and losses and the deferred aligned time value of the option 
contracts are included within the initial cost of the asset. The 
deferred amounts are ultimately recognised in profit or loss as 
the hedged item affects profit or loss.
	
– Gain or loss relating to the effective portion of the spot 
component of forward contracts where the hedged item 
subsequently results in the recognition of a non-financial asset 
(such as inventory), both the deferred hedging gains and 
losses and the deferred aligned forward points are included 
within the initial cost of the asset. The deferred amounts are 
ultimately recognised in profit or loss as the hedged item 
affects profit or loss.
	
– The gain or loss relating to the effective portion of the interest 
rate swaps hedging variable rate borrowings is recognised 
in profit or loss within ‘finance cost’ at the same time as the 
interest expense on the hedged borrowings.
When a hedging instrument expires, or is sold or terminated, 
or when a hedge no longer meets the criteria for hedge 
accounting, any cumulative deferred gain or loss and deferred 
costs of hedging in equity at that time remain in equity until 
the forecast transaction occurs, resulting in the recognition 
of a non-financial asset such as inventory. When the forecast 
transaction is no longer expected to occur, the cumulative 
gain or loss and deferred costs of hedging that were reported 
in equity are immediately reclassified to profit or loss. Hedge 
ineffectiveness is recognised in profit or loss within finance cost. 
P)	 FAIR VALUE ESTIMATION
The fair value of financial assets and financial liabilities must be 
estimated for recognition, measurement and disclosure purposes.
The fair value of interest rate hedge contracts is calculated as 
the present value of the estimated future cash flows. The fair 
value of forward exchange contracts and other foreign currency 
contracts are determined using forward exchange market rates 
and volatility at the balance sheet date.
The net nominal value of trade receivables and payables 
are assumed to approximate their fair values. The fair value 
of financial liabilities for disclosure purposes is estimated by 
discounting the future contractual cash flows at the current 
market interest rate that is available to the Group for similar 
financial instruments.
Q)	 PROPERTY, PLANT AND EQUIPMENT
All property, plant and equipment are stated at historical cost less 
depreciation. Historical cost includes expenditure that is directly 
attributable to the acquisition of the property, plant and equipment. 
Subsequent costs are included in the asset’s carrying amount or 
recognised as a separate asset, as appropriate, only when it is 
probable that future economic benefits associated with the item 
will flow to the Group and the cost of the item can be measured 
reliably. The carrying amount of any component accounted for 
as a separate asset is derecognised when replaced. All other 
repairs and maintenance costs are charged to profit or loss 
during the reporting period in which they are incurred. 
Depreciation on assets is calculated using the straight-line 
method to allocate their net cost over their estimated useful lives.
An asset’s carrying amount is written down immediately to its 
recoverable amount if the asset’s carrying amount is greater 
than its estimated recoverable amount (refer to Note 1(i)).
Gains and losses on disposals are determined by comparing 
proceeds with carrying amounts and are included in profit or loss.
R)	 INTANGIBLE ASSETS
i)	
Goodwill
Goodwill is measured as described in Note 1(h). Goodwill on 
acquisitions of subsidiaries is included in intangible assets. 
Goodwill is not amortised, but it is tested for impairment annually, 
or more frequently if events or changes in circumstances 
indicate that it might be impaired, and is carried at cost less 
accumulated impairment losses. Gains and losses on the disposal 
of an entity include the carrying amount of goodwill relating to 
the entity sold.
Goodwill is allocated to cash-generating units or groups of 
cash-generating units for the purpose of impairment testing. 
The allocation is made to those cash-generating units that are 
expected to benefit from the business combination in which 
the goodwill arose. The units or groups of units are identified 
at the lowest level at which goodwill is monitored for internal 
management purposes, being the operating segments.
ii)	 Brand names
The Group recognises brand names that are acquired as part 
of a business combination or that are specifically acquired 
from a vendor. The Group does not recognise internally 
generated brand names. Brand names are initially recognised 
at fair value, if acquired as part of a business combination, 
or at cost, if specifically acquired from a vendor. For brand 
names specifically acquired from a vendor and held at cost, any 
subsequent adjustments arising from a contingent consideration 
arrangement associated with the brand acquisition are reflected 
in the carrying value of the relevant brand name. Subsequent 
to initial recognition, brand names are recognised at cost less 
accumulated impairment losses.
The carrying amount of brand names are not amortised as the 
Directors are of the view that the brand names have an indefinite 
useful life.
Brand names are tested individually for impairment annually, or 
more frequently if events or changes in circumstances indicate 
that they might be impaired. The recoverable amount of a brand 
name is determined based on the higher of the value-in-use or 
fair value less costs to sell.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  63

1.	 Summary of material accounting policies 
continued
R)	 INTANGIBLE ASSETS CONTINUED
iii)	 Customer relationships
Customer relationships acquired in a business combination are 
recognised at fair value at the acquisition date. They have a finite 
useful life and are subsequently carried at cost less accumulated 
amortisation and impairment losses.
The Group amortises customer relationships with a finite useful 
life using the straight-line method over 8 years, based on the 
historical customer attrition rate, which is subject to annual review.
iv)	 IT development and software
Costs incurred in developing products or systems and costs 
incurred in acquiring software and licences that are identifiable 
and unique software products controlled by the Group and will 
contribute to future period financial benefits through revenue 
generation or cost reduction are capitalised as intangible assets. 
Capitalised costs include external direct costs of materials and 
services, direct payroll and payroll related costs of employees’ 
time spent on the project. Amortisation is calculated on a 
straight-line basis generally over 3 to 5 years.
IT development costs only include those costs directly 
attributable to the development phase and are only recognised 
where the Group has an intention and ability to use the asset.
v)	 Research and development
Research expenditure and development expenditure that do 
not meet the criteria in (iv) above are recognised as an expense 
as incurred. Development costs previously recognised as an 
expense are not recognised as an asset in a subsequent period.
S)	 TRADE AND OTHER PAYABLES
These amounts represent liabilities for goods and services 
provided to the Group prior to the end of the financial year 
which remain unpaid. These amounts are unsecured and are 
normally settled within 30 days of recognition. Trade and other 
payables are presented as current liabilities unless payment is 
not due within 12 months after the reporting period. They are 
initially recognised at fair value and are subsequently measured 
at amortised cost using the effective interest method.
T)	 PROVISIONS
Provisions are recognised when the Group has a present 
legal or constructive obligation as a result of past events, it is 
probable that an outflow of resources will be required to settle 
the obligation, and the amount has been reliably estimated. 
Provisions are not recognised for future operating losses. 
Provisions are measured at the present value of management’s 
best estimate of the expenditure required to settle the present 
obligation at the end of the reporting period.
The cost of products and services provided under warranty is 
expensed as incurred. The Company provides for warranties 
based on history of claims and management’s best estimate of 
expected claims.
U)	 EMPLOYEE BENEFITS
i)	
Short-term obligations
Liabilities for wages and salaries, including annual leave expected 
to be settled within 12 months after the end of the period in 
which the employees render the related service, are recognised 
in respect of employees’ services up to the end of the reporting 
period and are measured at the amounts expected to be paid 
when the liabilities are settled. The liability for annual leave is 
recognised in the provision for employee benefits. All other short-
term employee benefit obligations are presented as payables.
ii)	 Other long-term employee benefit obligations
The liability for long service leave and annual leave, which is 
not expected to be settled within 12 months after the end of 
the period in which the employees render the related service, is 
recognised in the provision for employee benefits and measured 
as the present value of expected future payments to be made 
in respect of services provided by employees up to the end of 
the reporting period. Consideration is given to expected future 
wage and salary levels, experience of employee departures and 
periods of service. Expected future payments are discounted 
using market yields at the end of the reporting period on high 
quality corporate bonds with terms to maturity and currency that 
match, as closely as possible, the estimated future cash outflows. 
Remeasurements as a result of experience adjustments and 
changes in actuarial assumptions are recognised in profit or loss.
The obligations are presented as current liabilities in the balance 
sheet if the entity does not have an unconditional right to defer 
settlement for at least 12 months after the reporting date, 
regardless of when the actual settlement is expected to occur.
iii)	 Bonus plans
A liability for employee benefits in the form of bonuses is 
recognised in provisions when there is no realistic alternative 
but to settle the liability and at least one of the following 
conditions is met:
	
– There are formal terms for determining the amount 
of the benefit;
	
– The amounts to be paid are determined before the time 
of completion of the financial report; and
	
– Past practice gives clear evidence of the amount of 
the obligation.
iv)	 Superannuation
Contributions to employee superannuation funds are made by 
McPherson’s Limited and controlled entities. Contributions are 
recognised as an expense as they become payable.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
64  |  McPherson’s Limited

1.	 Summary of material accounting policies 
continued
U)	 EMPLOYEE BENEFITS CONTINUED
v)	 Termination benefits
Termination benefits are payable when employment is terminated 
by the Group before the normal retirement date, or when an 
employee accepts voluntary redundancy in exchange for these 
benefits. The Group recognises termination benefits at the earlier 
of the following dates: (a) when the Group can no longer withdraw 
the offer of those benefits; and (b) when the entity recognises 
costs for a restructuring that is within the scope of AASB 137 and 
involves the payment of terminations benefits. In the case of an 
offer made to encourage voluntary redundancy, the termination 
benefits are measured based on the number of employees 
expected to accept the offer. The liabilities for termination benefits 
are recognised in other creditors unless timing of the payment 
is uncertain, in which case they are recognised as provisions.
vi)	 Employee benefit on-costs
Employee benefit on-costs are recognised and included in 
employee benefit liabilities when the employee benefits to 
which they relate are recognised as liabilities.
vii)	Share-based payments
Share-based compensation benefits are provided to employees 
via the McPherson’s Limited Employee Share Scheme and the 
McPherson’s Limited Performance Rights Plan.
The fair value of options or rights granted to employees 
is recognised as an employee benefit expense with a 
corresponding increase in equity. The fair value is independently 
determined at grant date and recognised over the period during 
which the employees become unconditionally entitled to the 
options or rights.
Non-market vesting conditions are included in assumptions 
about the number of options or rights that are expected to vest. 
The total expense is recognised over the vesting period, which 
is the period over which all of the specified vesting conditions 
are to be satisfied. At the end of each period, the entity 
revises its estimates of the number of options or rights that are 
expected to vest based on the non-market vesting conditions. 
It recognises the impact of the revision to original estimates, if 
any, in profit or loss, with a corresponding adjustment to equity.
Upon the exercise of options or rights, the balance of the 
share-based payments reserve relating to those options or 
rights is transferred to share capital.
V)	 CONTRIBUTED EQUITY AND DIVIDENDS
i)	
Contributed equity
Ordinary shares are classified as equity. Incremental costs 
directly attributable to the issue of new shares or options are 
shown in equity as a deduction, net of tax, from the proceeds.
ii)	 Dividends
Provision is made for any dividend declared by the Directors, 
being appropriately authorised and no longer at the discretion 
of the entity, on or before the end of the financial year but not 
distributed at balance date.
W)	 EARNINGS PER SHARE 
i)	
Basic earnings per share
Basic earnings per share is determined by dividing the operating 
profit after income tax attributable to members of McPherson’s 
Limited by the weighted average number of ordinary shares 
outstanding during the financial year (refer to Note 26).
ii)	 Diluted earnings per share
Diluted earnings per share adjusts the figures used in the 
determination of basic earnings per share to take into account 
the after income tax effect of interest and other financing 
costs associated with dilutive potential ordinary shares and the 
weighted average number of additional ordinary shares that 
would have been outstanding assuming the conversion of all 
dilutive potential ordinary shares.
X)	 BORROWINGS AND BORROWING COSTS
Borrowings are initially recognised at fair value, net of transaction 
costs incurred. Borrowings are subsequently measured at 
amortised cost. Borrowings are removed from the balance sheet 
when the obligation specified in the contract is discharged, 
cancelled or expired. The difference between the carrying 
amount of a financial liability that has been extinguished or 
transferred to another party and the consideration paid, 
including any non-cash assets transferred or liabilities assumed, 
is recognised in profit or loss as other income or financial costs.
Fees paid on the establishment of loan facilities are recognised 
as transaction costs of the loan and are amortised over the 
period of the facility to which they relate, unless a shorter period 
is considered more appropriate.
Borrowings are classified as current liabilities unless the Group 
has an unconditional right to defer settlement of the liability 
for at least 12 months after the reporting period. 
Borrowing costs are expensed as incurred.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  65

1.	 Summary of material accounting policies 
continued
Y)	 GOODS AND SERVICES TAX (GST)
Revenues, expenses and assets are recognised net of the 
amount of associated GST, unless the GST incurred is not 
recoverable from the taxation authority. In this case it is 
recognised as part of the cost of acquisition of the asset or 
as part of the expense.
Receivables and payables are stated inclusive of the amount of 
GST receivable or payable. The net amount of GST recoverable 
from, or payable to, the taxation authority is included with other 
receivables or payables in the balance sheet.
Cash flows are presented on a gross basis. The GST components 
of cash flows arising from investing or financing activities which 
are recoverable from, or payable to the taxation authority, are 
presented as operating cash flows.
Z)	 ROUNDING OF AMOUNTS
The Group is of a kind referred to in Australian Securities 
and Investments Commission (ASIC) Corporations (Rounding 
in Financial/Directors’ Reports) Instrument 2016/191 and in 
accordance with that instrument, amounts in this Directors’ 
Report and the Financial Report have been rounded to the 
nearest thousand dollars unless otherwise stated. 
AA)	PARENT ENTITY FINANCIAL INFORMATION
The financial information for the parent entity, McPherson’s 
Limited, disclosed in Note 32 has been prepared on the same 
basis as the consolidated financial statements, except as set 
out below.
Investments in subsidiaries
Investments in subsidiaries are accounted for at cost in the 
financial statements of McPherson’s Limited. Dividends received 
from subsidiaries are recognised in the parent entity’s profit or 
loss when its right to receive the dividend is established.
AB)	CRITICAL ACCOUNTING ESTIMATES AND 
ASSUMPTIONS
The preparation of financial statements requires the use of 
certain critical accounting estimates. It also requires management 
to exercise its judgement in the process of applying the Group’s 
accounting policies. The area involving a higher degree of 
judgement or complexity, or area where assumptions and 
estimates are significant is discussed below.
Estimated recoverable amount of goodwill and indefinite 
lived brand names
The Group tests goodwill and indefinite lived brand names 
annually for impairment, or more frequently if events or 
changes in circumstances indicate that they might be impaired. 
In calculating the recoverable amount of these assets, the use 
of key assumptions is required. 
Provision for inventory obsolescence 
Inventories are valued at the lower of cost and net realisable 
value. Estimates are required to be made in relation to the 
recoverable amount of inventory based on projected sales 
volumes and sell prices.
Amortisation method and period for contract asset and 
inventory prepayment
The Preferred Brand Agreement contract asset is amortised to 
the income statement over the five-year term of the agreement 
corresponding to the run rate of sales benefitting from the 
agreement. The Exclusive Distribution Agreement inventory 
prepayment is amortised over five years (2023: 20 years) 
on a straight line basis. Refer to Note 12 for additional details 
regarding the change.
The periods for the contract asset and inventory prepayment 
have been determined by estimating the projected future sales, 
purchases and margins over the life of the agreements. The 
judgements involved include estimates of future cash flows, 
assumptions regarding the exercise of extension options and 
assessing relevant discount rates. 
AC)	RECLASSIFICATION
Certain comparative amounts have been reclassified to conform 
with the current year’s presentation to better reflect the nature 
of the financial position and performance of the Group.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
66  |  McPherson’s Limited

2.	 Financial risk management
The Group’s activities expose it to financial risks such as currency risk, interest rate risk, credit risk and liquidity risk. In order to minimise 
any adverse effects on the financial performance of the Group, derivative financial instruments, such as foreign exchange and interest 
rate hedge contracts are used to hedge certain risk exposures. Derivatives are used exclusively for hedging purposes and not as 
trading or other speculative instruments.
Financial risk management is predominantly controlled by a central treasury function under policies approved by the Board of Directors.
Whilst the Group’s hedging policy only allows for highly effective hedge relationships to be established, at times some hedge 
ineffectiveness can arise. Hedge ineffectiveness can arise from the following hedge risks:
Foreign exchange risk
	
– If the timing of the hedged highly probable forecast transaction changes from what was originally estimated; 
	
– If the amount of the hedged highly probable forecast transaction decreases to an amount below the associated hedging instrument 
amount; or 
	
– If differences arise between the credit risk inherent within the hedged item and the hedging instrument.
Interest rate risk
	
– If the underlying interest rate inherent within the Group’s borrowing arrangements differs from the underlying interest rate included 
within the hedging instrument; 
	
– If the Group’s outstanding borrowings reduce to an amount below that included within the hedging instrument; 
	
– If the time period of the hedging instrument goes beyond the maturity date of the related borrowings and it is unlikely that the Group 
would refinance its borrowings for a further period; or 
	
– If differences arise between the credit risk inherent within the hedged item and the hedging instrument.
Credit risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual 
obligations. Credit risk arises from cash and cash equivalents, derivative financial instruments and receivables due from customers.
Liquidity risk
Liquidity risk is the risk that an entity will not be able to meet its financial obligations as they fall due. The Group manages liquidity risk 
by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.
The Group holds the following financial instruments:
Note
2024 
$’000
2023 
$’000
FINANCIAL ASSETS
Cash and cash equivalents
8
24,769
 7,031 
Trade and other receivables
9
24,002
 28,893 
Derivative financial instruments 
11
100
607 
Total financial assets
48,871
36,531
FINANCIAL LIABILITIES
Trade and other payables 
17
26,475
 33,953 
Borrowings 
18
10,673
 13,519 
Lease liabilities 
8,964
 11,930 
Derivative financial instruments 
11
387
866 
Total financial liabilities
46,499
60,268 
The fair value measurements of the derivative financial instruments are shown in Note 2(e). 
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  67

2.	 Financial risk management continued
a)	 Foreign exchange risk
The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with 
respect to the majority of the Group’s foreign currency purchases made in USD. Foreign exchange risk arises from future commercial 
transactions and recognised assets and liabilities denominated in currencies that are not the entity’s functional currency and net 
investments in foreign operations. 
The Board’s foreign exchange risk management policy is to hedge 100% of anticipated cash flows of inventory purchases in USD, 
for 12 months. At balance date, 100% (2023: 100%) of projected USD purchases qualified as “highly probable” forecast transactions 
for hedge accounting purposes. The Group also hedges material exposures arising in foreign currencies other than USD. The Group 
uses a mixture of foreign currency options and forward exchange contracts to hedge its exposures to foreign currency. The weighted 
average hedged rate for the AUD/USD hedges the Group had in place at 30 June 2024 was 0.6483 (2023: 0.6597).
The Group’s exposure to foreign currency risk (being unhedged payable and receivable amounts, and outstanding hedges associated 
with forecast future transactions) at the reporting date was as follows:
A$’000
USD
NZD
EUR
GBP
HKD
AUD
CNY
30 JUNE 2024
Trade receivables 
115
—
—
—
—
—
—
Trade payables
—
—
1
—
94
—
251
Forward foreign exchange contracts – buy foreign currency
16,157
—
—
—
—
—
—
Foreign currency options – buy foreign currency
13,725
—
—
—
—
—
—
30 JUNE 2023 
Trade receivables 
111
2
40
—
—
—
—
Trade payables
2
6
365
482
170
—
212
Forward foreign exchange contracts – buy foreign currency
29,357
—
—
—
—
—
—
Foreign currency options – buy foreign currency
31,654
—
—
—
—
—
—
Group sensitivity 
Based on the financial instruments held at 30 June 2024, had the Australian dollar weakened/strengthened by 5% against 
other foreign currencies at that date, with all other variables held constant, it is estimated that equity would have been 
$628,134 higher / $(494,406) lower (2023: $1,209,708 higher / $(870,498) lower), arising from forward foreign exchange contracts 
and foreign currency options designated as cash flow hedges. The Group’s exposure to unhedged amounts is not material.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
68  |  McPherson’s Limited

2.	 Financial risk management continued
b)	 Interest rate risk
The Group’s main cash flow interest rate risk arises from long-term borrowings with variable interest rates. The Group manages its 
interest rate exposure by maintaining a policy to combine, if considered necessary and approved by the Board, fixed and floating rate 
liabilities through the use of derivative instruments and entry into fixed rate borrowings.
At 30 June 2024, the Group’s debt at variable rates are: 
Weighted 
average
 interest rate
Balance
$’000
% of 
total loans
2024
Bank loans at variable rate 
6.4%
10,000
92%
Net exposure to cash flow interest rate risk
10,000
2023
Bank loans at variable rate 
6.4%
13,000
93%
Net exposure to cash flow interest rate risk
13,000
c)	 Credit risk
The maximum exposure to credit risk at balance date is the carrying amount of the financial assets as summarised in Note 2. For 
derivative instruments, counterparties are limited to approved institutions with secure long-term credit ratings.
Credit limits are set and monitored by management with respect to individual customers and in some instances, debtor insurance is 
taken out against specific customers in order to minimise the credit risk. Credit limits are based on available credit insurance limits, the 
customers’ financial position and prior payment history.
For derivative financial instruments, the Board determines and reviews on a regular basis the coverage required by the Group. The 
Group uses the major Australian banks as counterparties for most of the Group’s derivative instruments. Derivatives entered into by 
foreign subsidiaries also use the major banks from within that country. Refer to Notes 9 and 11 for additional information regarding 
receivables and credit risk exposure.
Trade receivables 
The loss allowance provision as at 30 June 2024 is determined as follows. The expected credit losses below also incorporate forward 
looking information.
2024
$’000
Neither past 
due nor
impaired
Less than 
30 days
30 to 59 
days
60 to 89 
days
90 to 119
days
120 days
or more
Total
Gross carrying amount 
15,658
4,545
109
—
—
—
20,312
Loss allowance provision 
—
—
2
—
—
—
2
Expected loss rate
0.0%
0.0%
2.0%
0.0%
0.0%
0%
0.0%
Credit risk concentration
Four (2023: four) external customers represent $14,025,129 (2023: $15,424,528), which individually amount to 10% or more of the 
Group’s trade receivables. These trade receivables are in relation to the Australia and New Zealand segment.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  69

2.	 Financial risk management continued
d)	 Liquidity risk 
Financing Arrangements 
The Group has access to the following undrawn borrowing facilities at the end of the reporting period:
2024 
$’000
2023 
$’000
Bank loans expiring within one year 
35,000
—
Bank loans expiring beyond one year 
—
32,000
Total undrawn borrowing facilities
35,000
32,000
Following the Multix divestment on 28 June 2024, the Company was in the process of agreeing an amendment to the terms of the working 
capital facility agreement. As at 30 June 2024, the terms had not been agreed. Therefore, as prescribed by AASB 101 Presentation of 
Financial Statements, the debt was classified as current. The balance outstanding under the facility was $10 million as at 30 June 2024. 
On 19 August 2024, the amendment request was approved and is re-classified as non-current.
Refer to Note 18 for further information regarding the financing facilities available to the Group.
Maturity profile of the Group’s borrowings
The table below analyses the Group’s financial liabilities into relevant maturity groupings based on the remaining period at balance 
date to the contractual maturity date. The amounts disclosed are the contractual undiscounted cash flows.
30 June 2024
Less than
1 Year 
$’000
Between
1 & 2 years
 $’000
Between
2 & 3 years 
$’000
Between
4 & 6 years 
$’000
Total
 Contractual
 Cash Flows 
$’000
Carrying
 Amount 
$’000
NON-DERIVATIVES
Payables
26,475 
—
—
—
26,475
26,475
Borrowings
11,522
—   
—
—
11,522
10,673
Lease liabilities
3,400
2,773
2,678
176
9,028
8,964
Total non-derivative financial liabilities
41,397
2,773 
2,678
176
47,025
46,112
DERIVATIVES
Forward foreign exchange contracts – inflow
(16,157)
—
—
—
(16,157)
(16,157)
Forward foreign exchange contracts – outflow
16,182
—
—
—
16,182
16,182
25
—
—
—
25
25
Foreign currency options 
262
—
—
—
262
262
Total derivative financial liabilities / (assets)
287
—
—
—
287
287
30 June 2023
Less than
1 Year 
$’000
Between
1 & 2 years 
$’000
Between
2 & 3 years 
$’000
Between
4 & 6 years 
$’000
Total
 Contractual
 Cash Flows 
$’000
Carrying
 Amount 
$’000
NON-DERIVATIVES
Payables
33,247 
—
706
—
33,953
33,953
Borrowings
1,755
828   
13,828
—
16,411
13,519
Lease liabilities
3,736
3,212
2,617
2,716
12,281
11,930
Total non-derivative financial liabilities
38,738
 4,040 
17,151
2,716
62,645
59,402
DERIVATIVES
Forward foreign exchange contracts – inflow
(29,323)
—
—
—
(29,323)
(29,323)
Forward foreign exchange contracts – outflow
28,716
—
—
—
28,716
28,716
(607)
—
—
—
(607)
(607)
Foreign currency options 
866
—
—
—
866
866
Total derivative financial liabilities
259
—
—
—
259
259
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
70  |  McPherson’s Limited

2.	 Financial risk management continued
e)	 Fair value measurement of financial instruments 
The following financial instruments held by the Group were measured and recognised at fair value at 30 June 2024 and 30 June 2023 
on a recurring basis:
Recurring fair value measurements
30 June 2024
30 June 2023
Level 1
 $’000
Level 2
 $’000
Level 3
 $’000
Total
 $’000
Level 1
 $’000
Level 2
 $’000
Level 3
 $’000
Total
 $’000
FINANCIAL ASSETS AT FAIR VALUE
Derivative financial instruments
—
100
—
100
—
607
—
607
Total financial assets at fair value
—
100
—
100
—
607
—
607
FINANCIAL LIABILITIES AT FAIR VALUE
Derivative financial instruments
—
(387)
—
(387)
—
(866)
—
(866)
Total financial liabilities at fair value
—
(387)
—
(387)
—
(866)
—
(866)
AASB 13 Fair Value Measurement requires disclosure of fair value measurements by level using the following fair value 
measurement hierarchy:
Level 1:	 The fair value of financial instruments traded in active markets is based on quoted market prices at the end of the reporting period.
Level 2:	 The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which 
maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs 
required to fair value an instrument are observable, the instrument is included in Level 2.
Level 3:	 If one or more of the significant inputs is not based on observable market data, the instrument is included in Level 3.
The Group holds Level 2 instruments as at 30 June 2024.
Level 2 instruments 
The fair value of the derivative financial instruments is determined using valuation techniques. The Group uses a variety of methods 
and makes assumptions that are based on market conditions existing at the end of each reporting period. The fair value of forward 
exchange and option contracts is determined using forward exchange market rates at the end of the reporting period.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  71

3.	 Material Items
The Group’s profit / (loss) after income tax includes the following items that are material because of their nature or size:
Expense /
(income)
$’000
Tax (benefit)
/ expense
$’000
Total
$’000
30 JUNE 2024
Impairment of Exclusive Distribution Agreement (EDA)
3,667
—
3,667
Brand impairment
2,761
(270)
2,491
Product rationalisation & exit brand provisioning
2,292
(673)
1,619
Restructuring expenses
1,657
(450)
1,207
Amortisation of Exclusive Distribution Agreement (EDA) 
1,222
—
1,222
Leadership transition expenses
837
(185)
652
Professional fees in relation to ASIC matters
237
(71)
166
Total material items from continuing operations
12,673
(1,649)
11,024
Restructuring expenses relating to Multix business
643
(193)
450
Loss recognised on divestment of Multix business
13,377
(3,951)
9,426
Total material items from discontinued operations
14,020
(4,144)
9,876
Expense /
(income)
$’000
Tax (benefit)
/ expense
$’000
Total
$’000
30 JUNE 2023
Write-back of Dr. LeWinn’s inventory provision
(1,036)
311
(725)
Other brand impairment and asset write down
3,422
(60)
3,362
Leadership transition expenses
484
(148)
336
Professional fees in relation to ASIC matters
411
(123)
288
Restructuring expenses
380
(83)
297
Total material items from continuing operations
3,661
(103)
3,558
Non-recurring Multix brand impairment
8,300
(2,490)
5,810
Total material items from discontinued operations
8,300
(2,490)
5,810
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
72  |  McPherson’s Limited

4.	 Dividends
Details of dividends declared during the year ended 30 June 2024 are as follows:
2024 
$’000
2023 
$’000
Final 30 June 2023 dividend of 1.0 cents per fully paid share (2022: 2.0 cents per fully paid share) 
fully franked at 30%
1,439
2,879
Interim 2024 ordinary dividend of 2.0 cents per fully paid share (2023: 2.0 cents per fully paid share) 
fully franked at 30%
2,879
2,879
Total dividends 
4,318
5,758
DIVIDENDS NOT RECOGNISED AT YEAR END
Since the 2024 financial year end, the Directors have not declared a dividend 
(2023: 1.0 cents per fully paid share)
—
1,439
FRANKED DIVIDENDS
Franked dividends paid after 30 June 2024 will be franked out of existing franking credits or 
out of franking credits arising from the payment of income tax in the year ended 30 June 2024.
Franking credits available for subsequent financial years based on a tax rate of 30%
18,680
18,212
The above amounts represent the balance of the franking account as at the end of the financial year, adjusted for the future receipt of 
the current tax assets.
Dividend reinvestment plan (DRP)
The Company’s dividend reinvestment plan remains suspended.  
5.	 Segment Information
Operating segments are reported in a manner which is consistent with the internal reporting provided to the chief operating decision 
makers. The Chief Operating Decision Maker (CODM) has been identified as the CEO and Managing Director of McPherson’s Limited.
The internal reports reviewed by the CODM, which are used to make strategic decisions, are presented in two operating segments: 
	
– Australia and New Zealand (ANZ); and 
	
– International.
The Group’s financing (including finance costs, finance income and other income) and income taxes are managed on a Group basis 
and are not allocated to operating segments. Assets and liabilities are reported on a consolidated level to the Group’s Chief Operating 
Decision Maker.
Segment revenues
Segment revenues are allocated based on the location in which the customer is located. Sales between segments are eliminated 
on consolidation.
Revenues from continuing operations of approximately $87,787,126 (2023: $90,571,261) were derived from three (2023: three) external 
customers, which individually amount to 10% or more of the Group’s revenue. These revenues were attributable to the Australia and 
New Zealand segment. 
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  73

5.	 Segment Information continued
Segment results 
Australia and 
New Zealand 
$’000
International 
$’000
Corporate 
$’000
Consolidated 
$’000
Less: 
Discontinued 
Operations 
$’000
Continuing 
Operations 
$’000
30 JUNE 2024
Sales to external customers
192,092
5,551
—
197,643
53,018
144,625
Total sales revenue
192,092
5,551
—
197,643
53,018
144,625
Other income 
—
28
—
28
—
28
Total segment revenue and other income 
(excluding interest) 
192,092
5,579
—
197,671
53,018
144,653
EBITDA / (LBITDA) before material items
20,301
(562)
(4,535)
15,204
7,530
7,674
Depreciation and amortisation expense
(5,442)
(130)
(338)
(5,910)
—
(5,910)
Segment EBIT / (LBIT) before material items
14,859
(692)
(4,873)
9,294
7,530
1,764
Material items before tax and borrowing costs
(24,451)
—
(2,242)
(26,693)
(14,020)
(12,673)
Segment EBIT / (LBIT) including material items 
(9,592)
(692)
(7,115)
(17,399)
(6,490)
(10,909)
Interest income
78
—
78
Borrowing costs
(1,905)
—
(1,905)
Profit / (loss) before income tax
(19,226)
(6,490)
(12,736)
Income tax (expense)/benefit
3,235
1,885
1,350
Profit / (loss) after income tax
(15,991)
(4,605)
(11,386)
Australia and 
New Zealand 
$’000
International 
$’000
Corporate 
$’000
Consolidated 
$’000
Less: 
Discontinued 
Operations 
$’000
Continuing 
Operations 
$’000
30 JUNE 2023
Sales to external customers
200,927
9,334
—
210,261
55,087
155,174
Inter-segment sales
716
—
(716)
—
—
—
Total sales revenue
201,643
9,334
(716)
210,261
55,087
155,174
Other income 
35
21
4
60
—
60
Total segment revenue and other income 
(excluding interest) 
201,678
9,355
(712)
210,321
55,087
155,234
EBITDA / (LBITDA) before material items
20,463
(1,273)
(4,154)
15,036
2,888
12,148
Depreciation and amortisation expense
(5,410)
(237)
(338)
(5,985)
—
(5,985)
Segment EBIT / (LBIT) before material items
15,053
(1,510)
(4,492)
9,051
2,888
6,163
Material items before tax and borrowing costs
(10,894)
(62)
(1,005)
(11,961)
(8,300)
(3,661)
Segment EBIT / (LBIT) including material items 
4,159
(1,572)
(5,497)
(2,910)
(5,412)
2,502
Interest income
24
—
24
Borrowing costs
(1,786)
—
(1,786)
Profit / (loss) before income tax
(4,672)
(5,412)
740
Income tax (expense)/benefit
(389)
1,624
(2,013)
Profit / (loss) after income tax
(5,061)
(3,788)
(1,273)
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
74  |  McPherson’s Limited

6.	 Income tax
a)	 Income tax expense
2024 
$’000
2023 
$’000
Current tax
289
1,796
Deferred tax 
(3,470)
(1,730)
Under / (over) provision in prior years
(54)
323
Total income tax expense / (benefit)
(3,235)
389
Income tax expense is attributable to:
Profit / (loss) from continuing operations
(1,350)
2,013
Profit / (loss) from discontinued operations
(1,885)
(1,624)
Total income tax expense / (benefit)
(3,235)
389
b)	 Numerical reconciliation of income tax expense 
2024 
$’000
2023 
$’000
Profit / (loss) from continuing operations before income tax expense
(12,736)
740
Profit / (loss) from discontinued operations before income tax expense
(6,490)
(5,412)
(19,226)
(4,672)
Prima facie income tax (benefit) / expense at 30%
(5,768)
(1,402)
Tax effect of amounts which are not deductible / (taxable) in calculating taxable income:
Tax rate differences in overseas entities
(80)
(170)
Share-based payments (write back) / expense
161
(40) 
Under / (over) provision in prior periods
(54)
323
Impairment of intangible assets
558
949
Amortisation and impairment of contract asset and inventory prepayment
1,713
335
Loss on divestment
62
—
Other
173
394
Income tax expense
(3,235)
389
c)	 Tax expense relating to items of other comprehensive income
Note
2024
 $’000
2023 
$’000
Cash flow hedges 
21(a)
34
469
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  75

6.	 Income tax continued
d)	  Deferred Tax
Deferred tax recognised comprises temporary differences attributable to:
Consolidated 
balance sheet
Consolidated statement 
of profit or loss
2024 
$’000
2023 
$’000
2024 
$’000
2023 
$’000
Brand names
 (5,904)
 (9,735)
 (3,831)
 (2,549)
Customer relationships
 (447)
 (550)
 (103)
 (100)
Employee benefits
 1,499 
 1,938 
 439 
 112 
Right-of-use assets
 (2,493)
 (3,262)
 (769)
 (401)
Lease liabilities
 2,916 
 3,689 
 773 
 379 
Other
 895 
 442 
 21 
 829 
Net deferred tax liability
(3,535)
(7,478)
(3,470)
(1,730)
Reconciliation of deferred tax liabilities, net: 
2024 
$’000
2023 
$’000
As at 1 July
 (7,478)
 (8,993)
Tax expense during the period recognised in profit or loss
 3,470 
 1,730 
Tax income/(expense) during the period recognised in OCI
 34 
 469 
Under/(over) provision in prior years
 439 
 (663)
Foreign currency exchange differences
—
 (21)
As at 30 June
 (3,535)
 (7,478)
7.	 Key management personnel
2024 
$
2023 
$
KEY MANAGEMENT PERSONNEL COMPENSATION
Short-term employee benefits
1,408,827
1,460,558 
Termination benefits
224,410
323,750
Post-employment benefits
93,935
105,148 
Long-term benefits
28,843
(24,351)
Share based payments 1
289,169
(155,279)
Total key management personnel compensation 
2,045,184
1,709,826
1.	 2023 includes $(183,134) from the fair value revaluation of unvested cash based performance rights (624,000 HLP rights and 312,000 ELP rights) retained upon 
resignation, $(47,046) forfeiture of 200,000 commencement rights upon resignation and expense accelerated in respect to share-based performance rights 
(909,000 HLP rights and 455,000 ELP rights) retained upon resignation of the former Managing Director as disclosed in the “Final Director’s Interest Notice” 
provided to the ASX on 2 June 2023. 2024 includes expense accelerated in respect to share-based performance rights (705,000 performance rights) retained upon 
resignation of the former Chief Financial Officer.
Detailed remuneration disclosures are provided in the Remuneration Report contained within the Directors’ Report, which is in section (j) 
of the Directors’ Report.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
76  |  McPherson’s Limited

8.	 Cash and cash equivalents
2024 
$’000
2023
$’000
Cash on hand
2
4
Cash at bank and on deposit (at call)
24,767
7,027
Total cash and cash equivalents
24,769
7,031
9.	 Trade and other receivables
2024 
$’000
2023 
$’000
Trade receivables
20,312
24,378
Provision for impairment
(2)
(8)
Trade receivables, net of impairment
20,310
24,370
Other receivables and prepayments
3,692
4,523
Total trade and other receivables
24,002
28,893
Movements in the provision for impairment of trade receivables 
2024 
$’000
2023 
$’000
Balance at 1 July
(8)
—
Reversal / (provisions) for impairment 
2
(8)
Net receivables written off as uncollectible
4
—
Total provision for impairment
(2)
(8)
Other receivables do not contain impaired assets and are not past due. It is expected that these amounts will be received in full when 
due. Due to the short-term nature of current receivables, their carrying amounts are assumed to be the same as their fair value.
Credit risk
The credit risk relating to trade and other receivables of the Group has been recognised, net of any provision for impairment. The following 
provides an overview of the credit risk associated with trade receivables.
2024 
$’000
2023 
$’000
Neither past due nor impaired
15,658
20,558
Past due, but not impaired:
	
– Less than 30 days
4,545
3,706
	
– 30 to 59 days
109
58
	
– 60 to 89 days
—
42
	
– 90 to 119 days
—
5
	
– 120 days or more
—
9
Gross carrying amount
20,312
24,378
Provision for impairment
(2)
(8)
Net carrying amount
20,310
24,370
Credit risk concentration
Refer to note 2(c) for information about credit risk concentration.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  77

10.	Inventories
2024 
$’000
2023 
$’000
Raw materials
2,670
4,193
Finished goods
30,029
48,409
Total inventories
32,699
52,602
Provision for inventory obsolescence
(7,036)
(7,443)
Total inventories, net of obsolescence provision
25,663
45,159
Inventories recognised as an expense during the year amounted to $99,890k (2023: $107,326k). These were included in Materials and 
Consumables in the consolidated statement of comprehensive income.
Write-downs of inventories to net realisable value amounted to $3,882k (2023: net write-back of $137k). These were recognised as an 
expense during the year and included in Materials and Consumables in the consolidated statement of comprehensive income.
11.	 Derivative financial instruments
Derivatives are only used for economic hedging purposes and not as trading or speculative instruments. 
2024 
$’000
2023 
$’000
CURRENT DERIVATIVE FINANCIAL INSTRUMENT ASSETS
Forward foreign exchange contracts – cash flow hedges
100
607
Total current derivative financial instrument assets
100
607
CURRENT DERIVATIVE FINANCIAL INSTRUMENT LIABILITIES
Foreign currency options – cash flow hedges
262
866
Forward foreign exchange contracts – cash flow hedges
125
—
Total current derivative financial instrument liabilities
387
866
Derivative financial instruments used by the Group
The Group is party to derivative financial instruments in the normal course of business in order to hedge exposure to fluctuations in 
interest and foreign exchange rates in accordance with the Group’s financial risk management policies (refer to Note 2). For information 
about the methods and assumptions used in determining the fair value of derivatives please refer to Note 2(e).
Forward foreign exchange contracts – cash flow hedges
The Group enters into forward foreign exchange contracts to hedge a portion of highly probable forecast purchases denominated in 
foreign currencies, predominantly in USD. The terms of these commitments are twelve months or less.
Foreign currency options – cash flow hedges
The Group has also entered into foreign currency option contracts to partially hedge a portion of anticipated USD purchases. 
At balance date, the outstanding foreign currency option contracts cover the period from July 2024 to June 2025. The portion 
of the gain or loss on the hedging instrument that is determined to be an effective hedge is recognised directly in equity. When 
the cash flows occur, the Group adjusts the initial measurement of the component recognised in the balance sheet by the related 
amount deferred in equity.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
78  |  McPherson’s Limited

12.	Other assets
2024
$’000
2023
$’000
Preferred Brand Agreement (PBA) – current
721
721
Preferred Brand Agreement (PBA) – non-current
2,148
2,970
Total contract asset 
2,869
3,691
Exclusive Distribution Agreement (EDA) - current
—
271
Exclusive Distribution Agreement (EDA) - non-current
—
4,618
Total inventory prepayment
—
4,889
The EDA contract asset has an initial 5-year term commencing 1 July 2022, with an additional three 5-year options to extend the 
arrangements exercisable by McPherson’s, subject to minimum performance thresholds on a brand-by-brand basis. The key assumptions 
used in assessing the recoverability of the EDA asset are the sales growth rates, the discount rate and the term of the agreement. 
In the half year ended 31 December 2023 a revised amortisation period of 5 years to 30 June 2027 (2023: 20 year amortisation period 
to 30 June 2042) was applied to the EDA on a straight line basis, given the difficulties experienced in accurately forecasting the sales 
volumes under the agreement. 
Revenue from the EDA brands for the full year was below expectations. McPherson’s is reviewing its strategy with respect to EDA 
brand performance, including opportunities to expand deeper into the Pharmacy channel, and different supply chain solutions to 
expand shelf-life. However, in light of current performance, accounting standards require the inventory prepayment be fully written 
down during the current period. (FY23: $260,000 write down). This recognises that the recoverability of the asset, at this stage, is 
sufficiently uncertain to warrant amortisation over the remaining 3 years of the initial 5-year term. 
The PBA contract asset is being amortised to the income statement, as a decrease in revenue corresponding to the run rate of sales 
benefitting from the agreement, over the initial 5-year term of the agreement. While three 5-year options exist to renew the PBA, 
these options are exercisable at Chemist Warehouse’s discretion. Consequently, this asset is being amortised over the initial 5-year 
term. The key assumptions used in assessing the recoverability of the PBA asset are the sales growth rates and the discount rate.
13.	Discontinued Operations
a)	 Description
On 28 June 2024, following a strategic review, McPherson’s Limited completed the sale of its Multix brand and inventory to 
International Consolidated Business Group Pty Ltd, as trustee for the ICBG Unit Trust, for $19.2m (inclusive of post-completion 
adjustments). Financial information relating to the discontinued operation for the period to the date of disposal is set out below.
b)	 Financial performance and cash flow information 
The financial performance and cash flow information presented are for the period ended 28 June 2024 (2024 column) and the year 
ended 30 June 2023.
2024 
$’000
2023 
$’000
Revenue
53,018
55,087
Expenses
(45,488)
(52,199)
Profit from operating activities before income tax and impairment
7,530
2,888
Material items before tax
(643)
(8,300)
Income tax expense
(2,066)
1,624
Profit/(Loss) after income tax of discontinued operations
4,821
(3,788)
Loss on sale after income tax (see (c) below)
(9,426)
—
Loss from discontinued operation
(4,605)
(3,788)
Net cash inflow / (outflow) from operating activities
3,904
(2,775)
Net cash inflow / (outflow) investing activities
19,000
—
Net cash inflow / (outflow) financing activities
—
—
Net increase / (decrease) in cash from discontinued operations
22,904
(2,775)
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  79

13.	Discontinued Operations continued
c)	 Details of the sale of the Multix Business
The details of the disposal are set out below:
2024 
$’000
Cash consideration received
19,000
Cash consideration receivable
162
Transaction costs 
(915)
Net consideration
18,247
Carrying amount of net assets sold
(31,317)
Loss on sale before income tax and extinguishment of foreign exchange options
(13,071)
Extinguishment of foreign exchange contracts before tax
(307)
Income tax benefit
3,951
Loss on sale after income tax
(9,426)
The carrying amounts of assets and liabilities as at the date of sale (28 June 2024) were:
28 June 2024 
$’000
Inventories
9,451
Intangible assets (Brand Name and Goodwill)
21,866
Total assets
31,317
Total liabilities
—
Net assets
31,317
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
80  |  McPherson’s Limited

14.	Property, plant and equipment
Leasehold improvements
2024 
$’000
2023 
$’000
At cost
292
292
Accumulated depreciation
(279)
(278)
Total leasehold improvements
13
14
PLANT AND EQUIPMENT
At cost
43,007
41,943
Accumulated depreciation
(37,054)
(35,282)
Total plant and equipment
5,953
6,661
Total property, plant and equipment
5,966
6,675
a)	 Reconciliations
Leasehold
Improvements
 $’000
Plant and
Equipment
$’000
Total 
$’000
Carrying amount at 30 June 2022
10
6,534
6,544
Additions
8
1,780
1,788
Disposals 
—
(18)
(18)
Depreciation expense
(4)
(1,653)
(1,657)
Foreign currency exchange differences
—
18
18
Carrying amount at 30 June 2023
14
6,661
6,675
Additions
—
1,139
1,139
Depreciation expense
(1)
(1,849)
(1,850)
Foreign currency exchange differences
—
3
3
Carrying amount at 30 June 2024
13
5,953
5,966
b)	 Non-current assets pledged as security
Refer to Note 18 for information on non-current assets pledged as security by the parent entity and certain controlled entities. 
15.	Leases
The Group has lease contracts for various items of buildings and other equipment used in its operations. The Company’s obligations 
are secured by the lessor’s title to the leased assets. There are several lease contracts that include extension and termination options.
a)	 Right-of-use assets
2024 
$’000
2023 
$’000
Buildings
6,864
9,378
Equipment and Vehicles
1,646
2,060
Total right-of-use assets
8,510
11,438
Additions to right-of-use assets in 2024 were $580,240 (2023: $2,169,454).
b)	 Amounts recognised in the statement of comprehensive income 
Depreciation charge of right-of-use assets
2024 
$’000
2023 
$’000
Buildings
(2,766)
(2,672)
Equipment and Vehicles
(743)
(1,181)
Total depreciation charge of right-of-use assets
(3,509)
(3,853)
Expenses relating to short-term and low value leases (included in Rental Expense)
(311)
(408)
Interest expense (included in Borrowing Costs)
(189)
(261)
Cash outflow for leases
(3,723)
(4,044)
The maturity analysis of lease liabilities is disclosed in Note 2(d). 
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  81

16.	Intangible assets
Goodwill
$’000
Brand
Names
$’000
Customer 
Relationships
$’000 
Other
Intangibles
$’000
Total 
$’000
AT 30 JUNE 2024
Cost
23,729
41,977
2,700
10,075
78,481
Accumulated amortisation and impairment
—
(14,266)
(1,211)
(8,506)
(23,983)
Net book amount
23,729
27,711
1,489
1,569
54,498
AT 30 JUNE 2023
Cost
 33,729 
53,843 
 2,700 
 9,213 
99,485
Accumulated amortisation and impairment
 —   
(11,505)  
 (873)
(8,293)
(20,671) 
Net book amount
 33,729 
42,338
1,827 
920
 78,814 
Reconciliations
Reconciliations of the carrying amounts of each class of intangible assets at the beginning and end of the financial year are set out below:
Goodwill
$’000
Brand
Names
$’000
Customer 
Relationships
$’000 
Other
Intangibles
$’000
Total
$’000
Carrying amount at 30 June 2022
33,641
53,843
2,165
815
90,464
Additions
—
—
—
268
268
Amortisation charge
—
—
(338)
(137)
(475)
Impairment charge
—
(11,462)
—
—
(11,462)
Contingent consideration adjustment
—
(43)
—
(38)
(81)
Foreign currency exchange differences
88
—
—
12
100
Carrying amount at 30 June 2023
33,729
42,338
1,827
920
78,814
Additions
—
—
—
1,542
1,542
Disposals
(10,000)
(11,866)
—
—
(21,866)
Amortisation charge
—
—
(338)
(213)
(551)
Impairment charge
—
(2,761)
—
—
(2,761)
Contingent consideration release
—
—
—
(680)
(680)
Foreign currency exchange differences
—
—
—
—
—
Carrying amount at 30 June 2024
23,729
27,711
1,489
1,569
54,498
Acquired brand names are not amortised under AASB 138 Intangible Assets, as the Directors consider these to have an indefinite life. 
The brand names are subject to an annual impairment test.
Acquired customer relationships are recognised at their fair value at the date of acquisition and are subsequently amortised on a 
straight-line basis over their estimated useful lives of 8 years.  
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
82  |  McPherson’s Limited

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
16.	Intangible assets continued
Impairment Testing
Goodwill
Goodwill is allocated to the following cash generating units:
2024 
$’000
2023 
$’000
Australia and New Zealand (ANZ)
23,729
33,729
Key assumptions used 
The Group tests whether goodwill has suffered any impairment on an annual basis and more frequently if events or changes in 
circumstances indicate that they might be impaired. For the 2024 reporting period, the recoverable amount of the cash-generating 
units (CGUs) was determined based on a Fair Value less Costs of Disposal (FVLCD) calculation based on a five-year projection period. 
The valuation is considered to be level 3 in the fair value hierarchy due to unobservable inputs used in the valuation. The FVLCD 
valuation technique is considered to be a more appropriate representation of fair value given the state of transformation in progress 
in line with the Company’s strategic reset (refer to ASX announcement dated 15 November 2023).
For the 2023 reporting period, the recoverable amount of the cash-generating unit (CGU) was determined based on a 
value-in-use calculation.
The following assumptions were used in the 2024 FVLCD calculation (2023: value-in-use calculation) calculation: 
	
– EBIT growth rates as per the 5-year plan approved by the Board (consistent approach with the previous financial year). The 5-year 
plan takes into account past performance, the impact of transformation activities and management’s expectations of market 
development.
	
– 18.4% pre-tax discount rate (FY23: 16.9%) estimated using the Capital Asset Pricing Model (CAPM) and reflecting the risks specific 
to the CGU.
	
– 2.5% terminal growth rate (FY23: 2.5%) based on the Reserve Bank of Australia’s long-term target inflation rate.
	
– 2% costs of disposal (FY23: n/a) estimated based on the company’s experience with disposal of assets.
As at 30 June 2024, the FVLCD calculation for the ANZ CGU exceeded the carrying value of its net assets. The surplus amount for 
the ANZ CGU is $16,564,000 (30 June 2023: ANZ CGU surplus is $13,413,000).
Impairment charge
No goodwill impairment charge was recognised in 2024 (2023: nil). 
Impact of reasonably possible changes in key assumptions
If the year one projected EBIT declined by 20% below current estimates, an impairment charge of $1.7 million would arise for the ANZ 
goodwill. The year one projected EBIT would need to reduce by 18.1% to result in the recoverable amount of goodwill equal to its 
carrying amount. 
Brand names
Brand names are tested for impairment on an individual basis annually, and more frequently if events or changes in circumstances 
indicate that they might be impaired. The recoverable amount of a brand name is determined based on the higher of value-in-use 
(VIU) or fair value less costs of disposal (FVLCD) calculations. The valuation is considered to be level 3 in the fair value hierarchy due to 
unobservable inputs used in the valuation.
The fair value less costs of disposal calculations are prepared using the relief from royalty analysis and the value-in-use calculations are 
prepared using a discounted cash flow analysis. Each analysis calculates the future net contribution expected to be generated by the 
brand, which is based on the latest Board approved 2025 budget. Cash flows from financial year 2025 are extrapolated using estimated 
growth rates from the Company’s Board approved five-year plan. The selected royalty rates consider (a) royalty rate benchmarking 
sourced from third-party databases, as well as (b) recent and forecasted EBIT by brand.
The carrying values of the purchased brand names are: 	
2024 
$’000
2023 
$’000
Multix 
—
11,866
Manicare 
9,366
9,366
Dr. LeWinn’s 
5,719
5,719
Maseur 
1,400
2,161
Fusion Health
4,200
4,200
Swisspers
4,156
4,156
Other brand names
2,870
4,870
Total brand names
27,711
42,338
Annual Report 2024  |  83

16.	Intangible assets continued
Brand names continued
Key assumptions used
The assumptions used in the brand name relief from royalty analysis and the discounted cash flow analysis, are set out below:
30 June 2024
Brands
Valuation
method
Estimated
annual sales
revenue
growth rates
Royalty
relief rates
as % of
revenue
Terminal 
year
growth 
rates
Post-tax
discount 
rates
Pre-tax 
discount 
rates
Manicare
FVLCD
3.0% – 8.0%
7.0%
2.5%
13.5%
18.4%
Dr. LeWinn’s
FVLCD
11.7% – 18.4%
4.0%
2.5%
15.0%
20.3%
Maseur
FVLCD
2.9% – 13.0%
2.5%
2.5%
13.5%
18.3%
Fusion Health
FVLCD
5.0% – 16.4%
4.0%
2.5%
13.5%
18.4%
Swisspers
FVLCD
3.0% – 4.9%
2.5%
2.5%
12.0%
16.3%
Other brand names
FVLCD
(1.7%) – 10.2%
0% – 7.5%
(4.0%) – 2.5%
13.5%
18.3% – 18.4%
30 June 2023
Brands
Valuation
method
Estimated
annual sales
revenue
growth rates
Royalty
relief rates
as % of
revenue
Terminal 
year
growth 
rates
Post-tax
discount 
rates
Pre-tax 
discount 
rates
Multix
FVLCD
(8.0%) – 1.7%
2.8%
2.5%
10.0%
13.4%
Manicare
FVLCD
5.5% – 8.0%
6.4%
2.5%
11.0%
14.7%
Dr. LeWinn’s
FVLCD
17.5% – 22.9%
3.8%
2.5%
20.0%
26.8%
Maseur
FVLCD
(0.8%) – 3.3%
4.3%
2.5%
14.0%
19.7%
Fusion Health
FVLCD
9% – 17%
4.7%
2.5%
14.0%
19.0%
Swisspers
FVLCD
4.1% – 7.9%
2.4%
2.5%
10.0%
13.3%
Other brand names
VIU / FVLCD
(6.8%) – 11.9%
3.8% – 9.5%
2.5%
11.0% – 12.0%
14.6% – 16.3%
Impairment charge
At 30 June 2024, a total impairment charge of $2,761,000 was recognised (2023: $11,462,000), pertaining to the following 
non-core brands:
	
– Maseur ($761,000, FY23: $2,900,000)
	
– Revitanail ($1,100,000, FY23: nil), and
	
– Oriental Botanicals ($900,000, FY23: nil)
The impairments reflect reduced royalty rates assigned to these brands. This is driven by lower EBIT margins in the second half 
of FY24, as a result of a more challenging trading environment and the impact of residual costs from the Multix divestment. The 
valuations for Revitanail and Oriental Botanticals also reflect an increase in discount rates.
Impact of reasonably possible changes in key assumptions
If the year one projected sales by brand were 10.0% below the current estimate, an impairment charge of $300,000 would arise for 
Swisspers. An additional impairment of $200,000 for would arise for Maseur and $100,000 for Revitanail.
If the royalty rates by brand were 100 basis points below the current estimate, an impairment charge of $1,600,000 would arise for 
Swisspers and $500,000 would arise for Fusion Health. An additional impairment of $600,000 would arise for Maseur and $100,000 
would arise for Revitanail.
If the discount rates by brand were 100 basis points above the current estimate, an impairment charge of $200,000 would arise for 
Swisspers. An additional impairment charge of $100,000 would arise for both Revitanail and Maseur.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
84  |  McPherson’s Limited

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
17.	 Trade and other payables
2024 
$’000
2023 
$’000
Trade payables
7,027
13,392
Customer contract liabilities
12,366
14,687
Other payables
7,083
5,168
Total current trade and other payables
26,475
33,247
Other payables
—
706
Total non-current trade and other payables
—
706
Total trade and other payables
26,475
33,953
18.	Borrowings 
2024 
$’000
2023 
$’000
Bank loan – unsecured
10,888
927
Debt issue costs
(215)
—
Total current borrowings
10,673
927
Bank loan – secured
—
13,000
Debt issue costs
—
(408)
Total non-current borrowings
—
12,592
Total borrowings
10,673
13,519
2024 
$’000
2023 
$’000
INTEREST INCOME 
Interest income
78
24
BORROWING COSTS 
Borrowing costs applicable to debt facilities
(1,667)
(1,600)
Amortisation of refinancing costs
(238)
(186)
Total borrowing costs
(1,905)
(1,786)
Net borrowing costs
(1,827)
(1,762)
The Group’s three-year facility, denominated in Australian dollars, has a facility limit of $47.5 million (2023: $47.5 million) and expires in 
March 2026. This facility comprises two tranches: 
	
– $45.0 million revolving working capital facility; and
	
– $2.5 million documentary facility, covering the Group’s bank guarantee and letters of credit requirements.
Drawings under the $45.0 million working capital tranche of the facility are required to be backed by eligible trade debtor and eligible 
inventory assets. 
Under the terms of the borrowing facilities, the Group is required to comply with the following key financial covenants: 
	
– Secured leverage ratio must not exceed 2.50 times;
	
– Interest cover ratio must be at least 3.50 times; and
	
– Total shareholder funds must not be less than $70,000,000.
Following the Multix divestment on 28 June 2024, the Company was in the process of agreeing an amendment to the terms of 
the working capital facility agreement. As at 30 June 2024, the terms had not been agreed. Therefore, as prescribed by AASB 101 
Presentation of Financial Statements, the debt was classified as current. The balance outstanding under the facility was $10 million 
as at 30 June 2024. On 19 August 2024, the amendment request was approved and is re-classified as non-current.
In addition to the three-year $47.5 million facility, the Group holds a $5 million overdraft facility (2023: $5 million).
Annual Report 2024  |  85

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
18.	Borrowings continued
Security for borrowings
The Group provides security to its lenders in order to access all tranches of the new debt facility. The Group facilities are secured by 
the following:
	
– Fixed and floating charges over the assets of the parent entity and certain controlled entities;
	
– Mortgages over shares held in certain controlled entities; and
	
– Cross guarantees and indemnities provided by the parent entity and certain controlled entities.
Assets pledged as security
The following assets are pledged as security:
2024 
$’000
2023 
$’000
Property, plant and equipment   
5,943
6,649
Intangible assets
52,930
77,246
Total non-current assets pledged as security
58,873
83,895
Cash
23,843
5,758
Receivables
26,062
27,030
Inventories
23,547
45,086
Total current assets pledged as security
73,452
77,874
Total assets pledged as security
132,325
161,769
19.	Provisions 
2024 
$’000
2023 
$’000
PROVISIONS – CURRENT
Employee entitlements
5,602
6,849
Employee incentives
193
232
Total current provisions
5,795
7,081
PROVISIONS – NON-CURRENT
Employee entitlements 
465
589
Make good provisions
970
960
1,435
1,549
A)	 EMPLOYEE ENTITLEMENTS
Current employee entitlements reflect annual leave and long service leave accrued for the next 12 months. Based on past experience, 
the Group expects that approximately 35% of the current balance will be taken or paid within the next 12 months.
The non-current provision for employee entitlements relates to the Group’s liability for long service leave beyond 12 months from 
balance date.
B)	 EMPLOYEE INCENTIVES
Amounts reflect incentive payments to employees on the basis that certain criteria were fulfilled during the financial year.
Movement in provisions
Movements in each class of provision during the financial year, other than employee entitlements, are set out below:
Employee
incentives
$’000
Make good
provisions
$’000
Carrying amount at 1 July 2023
232
960
Additional provisions charged to profit or loss
383
10
Unused amounts reversed to profit or loss
(73)
—
Payments
(350)
—
Carrying amount at 30 June 2024 
192
970
 
86  |  McPherson’s Limited

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
20.	Contributed equity
2024 
$’000
2023 
$’000
ISSUED AND PAID UP CAPITAL
143,949,141 fully paid ordinary shares (June 2023: 143,949,141)
217,218
217,218
Ordinary shares
Ordinary shares entitle the holder to participate in dividends, and to share in the proceeds of winding up the Company in proportion to 
the number of shares held. On a show of hands, every holder of ordinary shares present at a meeting in person or by proxy, is entitled 
to one vote, and upon a poll each share is entitled to one vote.
Ordinary shares have no par value and the Company does not have a limited amount of authorised capital.
Options and Performance Rights
Information relating to the Group’s Employee Performance Rights and options plans, including details of Performance Rights issued 
and outstanding at the end of the year, is set out in the Remuneration Report within the Directors’ Report and within Note 22.
Capital risk management 
One of the Group’s key objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can 
continue to provide returns for shareholders and benefits for other stakeholders, and to maintain an optimal capital structure to 
reduce the cost of capital.
In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital 
to shareholders, issue new shares or sell assets to reduce debt.
One measure the Group uses to assess its capital structure is its gearing ratio. This ratio is calculated as net bank debt, excluding lease 
liabilities divided by total capital. Net bank debt is calculated as total borrowings less cash assets. Total capital is calculated as net 
bank debt plus total equity.
Note
2024 
$’000
2023 
$’000
Total borrowings 
18
10,673
13,519
Less: Cash assets 
8
(24,769)
(7,031)
Net (cash) / bank debt, excluding lease liabilities 
(14,096)
6,488
Total equity
89,637
109,452
Total capital
75,541
115,940
Gearing ratio
(18.7%)
5.6%
The Gearing ratio decreased from 5.6% to (18.7%) as a result of an increase in cash assets on hand at year end, driven by proceeds 
received from the sale of Multix on 28 June 2024. 
Annual Report 2024  |  87

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
21.	Reserves and accumulated losses
A)	 RESERVES
Note
2024 
$’000
2023 
$’000
Hedging reserve – cash flow hedges
(86)
(40) 
Share-based payments reserve
2,163
1,625 
Foreign currency translation reserve
2,451
2,449 
Financial assets at FVOCI reserve
(6,000)
(6,000)
Total reserves
(1,472)
(1,966) 
CASH FLOW HEDGE RESERVE
Balance 1 July
(40)
1,112
Revaluation – gross
(288)
(208) 
Deferred tax 
6
91
57
Transfer to cost of sales – gross
208
(1,413) 
Deferred tax 
6
(57)
412
Total cash flow hedge reserve
(86)
(40)
SHARE-BASED PAYMENTS RESERVE
Balance at 1 July
1,625
11,472 
Share-based payment expenses
22
538
127
Employee share scheme issued during the year
—
(231)
Chemist Warehouse Alliance shares issued
—
(9,743)
Total share-based payments reserve
2,163
 1,625 
FOREIGN CURRENCY TRANSLATION RESERVE
Balance 1 July
2,449
1,959 
Currency translation differences arising during the year
2
490 
Total foreign currency translation reserve
2,451
2,449 
FINANCIAL ASSETS AT FVOCI RESERVE
Balance 1 July
(6,000)
(6,000)
Total financial assets at FVOCI reserve
(6,000)
(6,000)
B)	 ACCUMULATED LOSSES
Note
2024 
$’000
2023 
$’000
Balance 1 July
(105,800)
(94,981)
(Loss)/ profit after tax
(15,991)
(5,061)
Dividends provided for or paid
4
(4,318)
(5,758)
Total accumulated losses
(126,109)
(105,800)
88  |  McPherson’s Limited

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
21.	Reserves and accumulated losses continued
C)	 NATURE AND PURPOSE OF RESERVES
Cash flow hedge reserve
The hedging reserve is used to record gains or losses on hedging instruments in cash flow hedges that are recognised in other 
comprehensive income as described in Note 1(o). Amounts are subsequently either transferred to the initial cost of inventory or 
reclassified to profit or loss as appropriate.
Share-based payments reserve
The share-based payments reserve is used to recognise the fair value of Performance Rights issued at grant date but not exercised 
or cancelled and shares estimated to be issued under the employee share scheme or commercial agreements, such as the Chemist 
Warehouse Strategic Alliance.
Foreign currency translation reserve
Exchange differences arising on translation of foreign controlled entities are taken to the foreign currency translation reserve, as 
described in Note 1(d). The reserve is recognised in profit or loss when the net investment is disposed of.
Financial asset at fair value through other comprehensive income reserve (FVOCI reserve)
The Group has elected to recognise changes in the fair value of certain investments in equity securities in other comprehensive 
income. These changes are accumulated within the FVOCI reserve within equity. The Group transfers amounts from this reserve to 
retained earnings when the relevant equity securities are derecognised. 
Annual Report 2024  |  89

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
22.	Share-based payments 
A)	 EMPLOYEE PERFORMANCE RIGHTS PLAN
Long-term incentives are chosen to align executives with the objective of improving long-term shareholder returns. During the current 
year, the Group continued with its Performance Rights Plan (the McPherson’s Limited Performance Rights Plan) to provide long-term 
incentives to nominated executives. Participants are granted Performance Rights which only vest if certain performance conditions 
(relating to compound annual growth in earnings per share and total shareholder return as described below) are met and the 
executive is still employed by the Group at the end of the vesting period, or where not employed at the end of the vesting period is 
deemed to be a “good leaver” by the Board.
The number of Rights that will vest will be determined proportionately on a straight line basis as follows:
Type of rights
Grant year
Vesting hurdles
Vesting period
HLP
2022
First 50% of Rights
30% of Rights vesting at +15.0% of underlying EPS CAGR, 
then pro rata to 100% of Rights vesting at +20.0% of underlying EPS CAGR
Remaining 50% of Rights
30% of Rights vesting at +15.0% TSR CAGR, 
then pro rata to 100% of Rights vesting at +20.0% TSR CAGR
3 years
2023
30% of Rights vesting at +20.0% of underlying EPS CAGR, 
then pro rata to 100% of Rights vesting at +35.0% of underlying EPS CAGR
3 years
2024
30% of Rights vesting at +40.0% of underlying EPS CAGR, 
then pro rata to 100% of Rights vesting at + 60% EPS CAGR
3 years
ELP
2022
30% of Rights vesting at +20.0% TSR CAGR, 
then pro rata to 100% of Rights vesting at +25.0% TSR CAGR
4 years
2023
30% of Rights vesting at +35.0% TSR CAGR, 
then pro rata to 100% of Rights vesting at +50.0% TSR CAGR
4 years
2024
30% of Rights vesting at +50.0% TSR CAGR, 
then pro rata to 100% of Rights vesting at + 70% TRS CAGR
3 years
Performance 
Rights (PR)
2022
First 50% of Rights
30% of Rights vesting at +15.0% of underlying EPS CAGR, 
then pro rata to 100% of Rights vesting at +20.0% of underlying EPS CAGR
Remaining 50% of Rights
30% of Rights vesting at +15.0% TSR CAGR, 
then pro rata to 100% of Rights vesting at +20.0% TSR CAGR
3 years
2023
First 66.7% of Rights
30% of Rights vesting at +20.0% of underlying EPS CAGR, 
then pro rata to 100% of Rights vesting at +35.0% of underlying EPS CAGR
Remaining 33.3% of Rights
30% of Rights vesting at +30.0% TSR CAGR, 
then pro rata to 100% of Rights vesting at +45.0% TSR CAGR
3 years
2024
First 67% of Rights
30% of Rights vesting at +40.0% of underlying EPS CAGR, 
then pro rata to 100% of Rights vesting at +60.0% of underlying EPS CAGR
Remaining 33% of Rights
30% of Rights vesting at +50.0% TSR CAGR, 
then pro rata to 100% of Rights vesting at +70.0% TSR CAGR
3 years
90  |  McPherson’s Limited

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
22.	Share-based payments continued
A)	 EMPLOYEE PERFORMANCE RIGHTS PLAN CONTINUED
Set out below is a summary of Performance Rights granted under the plan: 
2024
2023
Average
fair value at
grant date
Number
of rights
Average
fair value at
grant date
Number
of rights
As at 1 July
$0.83
3,812,000
$1.26
1,877,000
Granted during the year
$0.28
4,546,220
$0.47
2,289,000
Exercised during the year
—
—
—
—
Lapsed during the year
—
(581,817)
—
(354,000)
As at 30 June
$0.33
7,776,403
$0.83
3,812,000
Vested and exercisable
—
—
Performance Rights outstanding at the end of the year have the following expiry dates:
Type of Rights
Grant date
Vesting date
Number of rights
30 June 2024
30 June 2023
EQUITY-SETTLED PERFORMANCE RIGHTS
HLP
28 November 2023
22 September 2026
1,336,000
—
ELP
28 November 2023
22 September 2026
668,000
—
HLP
22 November 2022
22 September 2025
909,000
909,000
ELP
22 November 2022
23 September 2026
455,000
455,000
Performance Rights
17 June 2024
22 September 2026
690,220
—
Performance Rights
12 October 2023
22 September 2026
1,655,183
—
Performance Rights
23 September 2022
22 September 2025
766,000
925,000
Performance Rights
24 September 2021
24 September 2024
361,000
470,000
Performance Rights
25 September 2020
26 September 2023
—
117,000
CASH-SETTLED PERFORMANCE RIGHTS
HLP
24 September 2021
24 September 2024
624,000
624,000
ELP
24 September 2021
25 September 2025
312,000
312,000
Total
7,776,403
3,812,000
The fair value of the Performance Rights issued were valued as follows: 
Performance Rights
Fair value
Commencement Rights, 
HLP and other EPS CAGR 
performance rights
Independently valued at grant date, applying a discounted cash flow methodology, using the 
market price of the related shares at the commencement date or grant date less the present 
value of expected dividends forgone prior to vesting.
ELP and other TSR CAGR 
performance rights
Independently valued at grant date using the assumptions underlying the Monte Carlo 
methodology to produce a simulation model which allows for the incorporation of the 
Total Shareholder Return (TSR) hurdle that must be met before these rights vest.
Consequently, in addition to being sensitive to the dividend yield, the ELP Rights are 
also sensitive to market volatility and the initial TSR, with the risk-free rate as a further 
valuation input.
Annual Report 2024  |  91

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
22.	Share-based payments continued
B)	 EMPLOYEE PERFORMANCE RIGHTS PLAN
The fair value of the Performance Rights issued during the year were valued using the following parameters:
HLP
ELP
Share-based
(EPS & TSR)
Share-based
(EPS & TSR)
Valuation date
28 November 2023
28 November 2023
12 October 2023
17 June 2024
Hurdle start date
1 July 2023
1 July 2023
1 July 2023
1 July 2023
Hurdle end date
30 June 2026
30 June 2026
30 June 2026
30 June 2026
Share price at grant date
AUD 0.50
AUD 0.50
AUD 0.39
AUD 0.43
Fair value at measurement date  1
AUD 0.44
AUD 0.07
EPS: AUD 0.34
EPS: AUD 0.38
TSR: AUD 0.03
TSR: AUD 0.07
Exercise price
AUD 0.00
AUD 0.00
AUD 0.00
AUD 0.00
Expected volatility 2
53%
53%
51%
46%
Expected dividend yield p.a 3
4.9%
4.9%
4.9%
5.9%
Risk free rate p.a. 4
4.16%
4.16%
3.91%
3.79%
1.	 To calculate fair value, a Monte-Carlo simulation was used to estimate the likelihood of achieving the relative TSR hurdles. For the EPS hurdles, Black-Scholes-Merton 
model was used to estimate the fair value.
2.	Expected volatility is based on historical closing share price over the three-year period to the valuation date.
3.	Expected dividend yield is based on historic and future yield estimates.
4.	Risk free interest rate is based on three-year yield on Australian government bonds. 
C)	 EXPENSES ARISING FROM SHARE-BASED PAYMENT TRANSACTIONS
Total expenses arising from share-based payment transactions recognised during the period as part of employee benefit expense 
were as follows:
2024 
$’000
2023 
$’000
Cash-settled Performance Rights issued under the Employee Performance Rights plan 1
—
(230)
Share based Performance Rights issued under the Employee Performance Rights plan 2, 3
538
97
Shares estimated to be issued under the Employee Share Scheme
—
29
Total expenses
538
(104)
1.	 2023 includes $(183,134) from the fair value revaluation of unvested cash based performance rights (624,000 HLP rights and 312,000 ELP rights) retained upon 
resignation and $(47,046) forfeiture of 200,000 commencement rights upon resignation of the former Managing Director as disclosed in the “Final Director’s Interest 
Notice” provided to the ASX on 2 June 2023.
2.	2023 includes expense accelerated in respect to share-based performance rights (909,000 HLP rights and 455,000 ELP rights) retained upon resignation of the 
former Managing Director as disclosed in the “Final Director’s Interest Notice” provided to the ASX on 2 June 2023. 2024 incudes expense accelerated in respect to 
share-based performance rights (705,000 performance rights) retained upon resignation of the former Chief Financial Officer.
3.	2023 includes the release of 2022 and 2023 share-based accruals not expected to vest.
92  |  McPherson’s Limited

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
23.	Contractual commitments for expenditure
The Group primarily leases offices, warehouses, motor vehicles and equipment under non-cancellable leases expiring within one to five 
years. The leases have varying terms and renewal rights. On renewal, the terms are renegotiated.
A)	 CAPITAL COMMITMENTS
Aggregate capital expenditure contracted for at balance date, but not provided for in the accounts:
2024 
$’000
2023 
$’000
CAPITAL COMMITMENTS
Property, plant and equipment
—
449
Intangible assets
2,050
—
24.	Contingent liabilities
As announced to the ASX on 9 December 2022, ASIC has commenced civil proceedings in the Federal Court of Australia against 
McPherson’s Limited and a former Chief Executive Officer and Managing Director in relation to events during the period 30 October 2020 
to 1 December 2020. The company is defending these proceedings and has not recognised a provision for the matter in the financial 
statements because there is no current liability or present obligation. The proceedings have been listed for a final hearing on liability in 
the Federal Court of Australia to occur commencing on 2 June 2025. Given the current stage of the proceedings, it is not practicable for 
the company to meaningfully determine a possible outcome or range of outcomes in relation to them for the purposes of disclosing an 
estimate of any possible financial effect, or an indication of the uncertainties relating to the amount or timing of any possible outflow. 
The Group is subject to claims and litigation during the normal course of its business. The Board has considered matters, which are or 
may be subject to litigation at year end and, is of the opinion that no material liability exists other than specifically provided for in these 
financial statements.
25.	Remuneration of Auditors
During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices 
and non-related audit firms:
2024 
$
2023 
$
A)	 AUDITORS OF THE GROUP – PRICEWATERHOUSECOOPERS AUSTRALIA
Audit and review of financial statements
750,000
687,500
Total remuneration for PricewaterhouseCoopers Australia
750,000
687,500
B)	 OTHER AUDITORS AND THEIR RELATED NETWORK FIRMS
Audit and review of financial statements of controlled entities
49,903
64,754
Other non-audit services
	
– Tax services
99,880
171,298
	
– Other assurance services
30,000
59,300
	
– Other non-audit services
31,850
106,850
Total remuneration of other auditors (excluding PwC)
211,634
402,202
Total remuneration of auditors
961,934
1,089,702
Annual Report 2024  |  93

26.	Earnings per share
2024 
Cents
2023 
Cents
Basic (loss) / earnings per share
(11.1)
(3.5)
Diluted (loss) / earnings per share
(11.1)
(3.5)
Basic (loss) / earnings per share from continuing operations
(7.9)
(0.9)
Diluted (loss) / earnings per share from continuing operations
(7.9)
(0.9)
Basic earnings per share from continuing operations excluding material items
(0.3)
1.6
Basic (loss) / earnings per share from discontinued operations
(3.2)
(2.6)
Diluted (loss) / earnings per share from discontinued operations
(3.2)
(2.6)
Reconciliation of earnings used in calculating earnings per share
2024 
$’000
2023 
$’000
Basic and diluted earnings per share
(Loss) / Profit after income tax from continuing operations excluding material items
(362)
2,285
Material items from continuing operations after income tax (Note 3)
(11,024)
(3,558)
(Loss) / Profit after income tax from discontinued operations
(4,605)
(3,788)
(Loss) / profit after income tax
(15,991)
(5,061)
Weighted average number of shares used as the denominator
2024 
Number
2023 
Number
Weighted average number of ordinary shares used as the denominator in calculating basic 
and diluted earnings per share
143,949,141
143,868,850
Information concerning the classification of securities
Performance Rights
Performance Rights granted to employees are considered to be potential ordinary shares and are included in the determination of 
diluted earnings per share to the extent to which they are dilutive (vested). The unvested Performance Rights have not been included 
in the determination of basic earnings per share.
27.	Particulars in relation to controlled entities
Name of entity
Country of Incorporation
Ownership Interest
2024 
%
2023 
%
McPherson’s Limited
Australia
100
100
McPherson’s Consumer Products Pty Ltd 1
Australia
100
100
McPherson’s Consumer Products (NZ) Limited
New Zealand
100
100
McPherson’s Consumer Products Pte Ltd
Singapore
100
100
McPherson’s America Inc.
USA
100
100
McPherson’s Consumer Products (HK) Limited
Hong Kong
100
100
McPherson’s (U.K.) Limited
United Kingdom
100
100
McPherson’s (Shanghai) Co. Ltd.
China
100
100
McPherson’s Limited Employee Security Plans Trust 2
Australia
100
100
Dr LeWinn’s China Limited 3
Hong Kong
—
100
1.	 This subsidiary has been granted relief from the necessity to prepare financial reports in accordance with ASIC Corporations (Wholly-owned Companies) Instrument 
2016/785 issued by the Australian Securities and Investments Commission. For further information refer to Note 32.
2.	The Group does not hold any ownership interests in this entity. However, based on terms of agreements under which this entity is established, the Group has the 
current ability to direct the entity’s activities that significantly affects the entity’s returns.
3.	On 23 February 2024, Dr LeWinn’s China Limited was deregistered.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
94  |  McPherson’s Limited

NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
28.	Related parties 
Directors
Details relating to the insurance of Directors are included in the Directors’ Report. 
Refer to the Remuneration Report within the Directors’ Report for information relating to key management personnel disclosures.
Transactions with controlled entities
Transactions between McPherson’s Limited and its controlled entities in the Group during the year consisted of:
	
– Amounts advanced to and by McPherson’s Limited
	
– Amounts repaid to McPherson’s Limited
	
– Amounts borrowed by McPherson’s Limited
	
– Payment and receipt of interest on certain advances at prevailing rates
	
– Payment of dividends to McPherson’s Limited
	
– Receipt and payment of tax, rent, management and license fees
Balances and transactions between McPherson’s Limited and its controlled entities have been eliminated on consolidation and are not 
disclosed in this note. 
29.	Deed of Cross Guarantee
McPherson’s Limited and McPherson’s Consumer Products Pty Ltd are parties to a Deed of Cross Guarantee under which each 
company guarantees the debts of the others.
By entering into the Deed, McPherson’s Consumer Products Pty Ltd has been relieved from the requirement to prepare a Financial 
Report and Directors’ Report under ASIC Corporations (Wholly-owned Companies) Instrument 2016/785.
A)	 CONDENSED CONSOLIDATED INCOME STATEMENT 
OF THE PARTIES TO THE DEED OF CROSS GUARANTEE
Set out below is a consolidated income statement and a summary of movements in consolidated retained profits for the year ended 
30 June 2024 of the parties to the Deed of Cross Guarantee.
2024 
$’000
2023 
$’000
Revenue
184,575
193,493
Other income
1,185
25 
Expenses
(202,063)
(196,961)
Finance costs
(1,890)
 (1,759)
(Loss) / profit before income tax 
(18,193)
(5,202) 
Income tax benefit / (expense)
3,341
(46)
(Loss) / profit after income tax
(14,852)
(5,248) 
B)	 MOVEMENTS IN CONSOLIDATED ACCUMULATED LOSSES 
OF THE PARTIES TO THE DEED OF CROSS GUARANTEE
2024 
$’000
2023 
$’000
SUMMARY OF MOVEMENTS IN CONSOLIDATED ACCUMULATED LOSSES
Accumulated losses at beginning of the financial year
(115,584)
 (104,578)
(Loss) / profit after income tax for the year
(14,852)
(5,248) 
Dividends provided for or paid
(4,318)
(5,758) 
Accumulated losses at the end of the financial year
(134,754)
(115,584)
Annual Report 2024  |  95

29.	Deed of Cross Guarantee continued
C)	 BALANCE SHEET OF THE PARTIES TO THE DEED OF CROSS GUARANTEE
2024 
$’000
2023 
$’000
CURRENT ASSETS
Cash and cash equivalents
22,273
5,081 
Trade and other receivables
22,867
26,615 
Inventories
24,227
41,959 
Derivative financial instruments
84
624 
Current tax receivable
501
—
Total current assets
69,952
74,279
NON-CURRENT ASSETS
Property, plant and equipment
5,807
6,485 
Right-to-use asset
8,310
10,871 
Intangible assets
54,409
78,718 
Contract assets
2,148
7,588 
Investments
8,825
8,825 
Total non-current assets
79,499
112,487
Total assets
149,451
249,434
CURRENT LIABILITIES
Trade and other payables
42,249
47,388 
Borrowings
888
927 
Lease liabilities
3,237
 3,305 
Derivative financial instruments
387
866 
Provisions
4,722
6,093 
Current tax liabilities
—
1,399
Total current liabilities
51,483
59,978
NON-CURRENT LIABILITIES
Other payables
—
706
Borrowings
9,788
12,595
Lease liabilities
5,511
8,029
Provisions
1,434
1,548
Deferred tax liabilities
3,668
7,612
Total non-current liabilities
20,401
30,490
Total liabilities
71,884
90,468
Net assets
77,567
96,298
EQUITY
Contributed equity
217,218
217,218 
Reserves
(4,897)
 (5,336) 
Accumulated losses
(134,754)
(115,584)
Total equity
77,567
96,298
 
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
96  |  McPherson’s Limited

30.	Notes to the statement of cash flows
A)	 RECONCILIATION OF NET CASH INFLOWS FROM OPERATING ACTIVITIES TO (LOSS) / PROFIT AFTER 
INCOME TAX
2024 
$’000
2023 
$’000
(Loss) / profit after income tax
(15,991)
(5,061)
Non-cash items included in Profit / (loss) after income tax:
Depreciation of property, plant and equipment
1,850
1,657
Amortisation of intangibles assets
551
475
Depreciation of right-of-use asset
3,509
3,853
Share-based payments expense
538
(104)
Impairment of intangible assets
2,761
11,462
Amortisation of contract assets
5,710
1,116
Loss on divestment, net of tax and transaction costs 
12,155
—
Finance costs
131
206
Changes in operating assets and liabilities, excluding the effects from purchase 
or disposal of business assets:
(Decrease)/Increase in payables
(6,792)
(9,454)
(Decrease)/Increase in employee entitlements
(1,402)
(490)
(Decrease)/Increase in net tax liabilities
(5,946)
1,685
Decrease/(Increase) in receivables
4,810
773
Decrease/(Increase) in inventories
10,459
430
Net cash inflows from operating activities
12,343
6,548
B)	 NON-CASH INVESTING AND FINANCING ACTIVITIES
There were no non-cash investing and financing activities in the years ended 30 June 2023 and 2024.
C)	 NET DEBT RECONCILIATION
2024 
$’000
2023 
$’000
Cash and cash equivalents
24,769
7,031
Borrowings 
(10,673)
(13,519)
Net cash / (debt) (excluding lease liabilities)
14,097
(6,488)
Current lease liability
(3,400)
(3,736)
Non-current lease liability
(5,564)
(8,194)
Net cash / (debt) (including lease liabilities)
5,133
(18,418)
Liabilities from financing activities
Borrowings 
$’000
Leases 
$’000
Total 
$’000
As at 1 July 2023
(13,519)
(11,930)
(25,449)
Cash flows
3,039
3,544
6,583
Acquisition – leases
—
(581)
(581)
Disposal – leases
—
3
3
Foreign exchange adjustment
—
(1)
1
Other non-cash movements
(193)
—
(193)
As at 30 June 2024
(10,673)
(8,964)
(19,637)
 
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  97

31.	Events occurring after balance date
On 19 August 2024, an amendment to the terms of the $45 million working capital facility was approved. In respect of the calculation 
period ending on 30 June 2024, the Divestment of Multix was removed from the calculation of the Interest Cover Ratio.
In August 2024, the Group announced its intention to streamline Hong-Kong operations, with supply and procurement functions to 
operate from a centrally managed hub in Australia. As a result, several roles in Hong Kong will be impacted. The Group expects the 
restructuring associated with the reduction in positions to cost between $0.7 million and $1.0 million in 2025. 
There are no other items, transactions or events of a material or unusual nature that have arisen in the period between 30 June 2024 
and the date of this report that, in the opinion of the directors, have significantly affected or may significantly affect the operations of 
the Group, the results of those operations, or the state of affairs of the Group in future financial years. 
32.	Parent entity financial information
A)	 SUMMARY FINANCIAL INFORMATION
The individual financial statements for the parent entity show the following aggregate amounts:
2024 
$’000
2023 
$’000
BALANCE SHEET
Current assets
1,247
2,223 
Total assets
85,845
 168,390 
Current liabilities
13,783
56,848 
Total liabilities
23,463
69,721 
SHAREHOLDERS’ EQUITY
Issued capital
217,218
217,218
Cash flow hedge reserve
(101)
(59) 
Share-based payments reserve
2,163
1,625 
Financial assets at FVOCI reserve
(6,000)
(6,000)
Accumulated losses – 2016 reserve
(116,095)
(116,095)
Retained earnings – 2017–2023 reserve
540
 1,979 
Accumulated losses – 2024 reserve
(35,342)
—
Total shareholders’ equity
62,382
98,668
Profit/(loss) for the period
(32,463)
2,802
Total comprehensive income
(32,505)
1,671
B)	 CONTINGENT LIABILITIES AND GUARANTEES
The parent entity has guaranteed the repayment of borrowings of certain controlled entities.
The cross guarantee given by those entities listed in Note 29 may give rise to liabilities in the parent entity if McPherson’s Consumer 
Products Pty Ltd does not meet its obligations under the terms of the overdrafts, loans, leases, or other liabilities subject to the guarantee.
Entity name
Entity type
Ownership 
Interest
Country of 
incorporation
Country of 
residence for 
tax purposes
McPherson’s Limited
Body corporate
n/a
Australia
Australia
McPherson’s Consumer Products Pty Ltd
Body corporate
100%
Australia
Australia
McPherson’s Consumer Products (NZ) Limited
Body corporate
100%
New Zealand
Australia 1
McPherson’s Consumer Products Pte. Ltd
Body corporate
100%
Singapore
Australia 1
McPherson’s America, Inc.
Body corporate
100%
United States
Australia 1
McPherson’s Consumer Products (HK) Limited
Body corporate
100%
Hong Kong
Australia 1
McPherson’s (U.K.) Limited
Body corporate
100%
United Kingdom
Australia 1
McPherson’s (Shanghai) Business Information Consulting Co. Ltd
Body corporate
100%
China
Australia 1
McPherson’s Limited Employee Security Plans Trust
Trust
n/a
Australia
Australia
1.	 These entities are also a tax resident in their respective countries of incorporation. However, they are an Australian resident under the Income Tax Assessment Act 1997. 
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
98  |  McPherson’s Limited

32.	Parent entity financial information continued
B)	 CONTINGENT LIABILITIES AND GUARANTEES CONTINUED
Basis of preparation 
This consolidated entity disclosure statement (CEDS) has been prepared in accordance with the Corporations Act 2001 and 
includes information for each entity that was part of the consolidated entity as at the end of the financial year in accordance with 
AASB 10 Consolidated Financial Statements. 
Determination of tax residency 
Section 295 (3A)(vi) of the Corporation Act 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. 
The determination of tax residency involves judgement as there are different interpretations that could be adopted, and which could 
give rise to a different conclusion on residency. 
In determining tax residency, the consolidated entity has applied the following interpretations: 
	
– Australian tax residency: The consolidated entity has applied current legislation and judicial precedent, including having regard to 
the Tax Commissioner’s public guidance in Tax Ruling TR 2018/5, however does not take into consideration the relevant income tax 
treaty and guidance from the Commissioner of Taxation where the entity is resident in two jurisdictions. 
	
– Foreign tax residency: Where necessary, the consolidated entity has used independent tax advisers in foreign jurisdictions to assist 
in its determination of tax residency to ensure applicable foreign tax legislation has been complied with. 
Partnerships and trusts 
Australian tax law generally does not contain corresponding residency tests for partnerships and trusts and these entities are typically 
taxed on a flow-through basis. Additional disclosures on the tax status of partnerships and trusts have been provided where relevant.
NOTES TO AND FORMING PART OF THE 
Consolidated Financial Statements
Annual Report 2024  |  99

Additional information required by ASX and not shown elsewhere in this report is as follows. This information is current as at 
24 September 2024.
DISTRIBUTION OF EQUITY SECURITIES
There were 5,010 holders of 143,949,141 fully paid ordinary shares quoted on the ASX. These shares carry one vote per share and carry 
the rights to dividends.
Range
Number of
holders
Ordinary 
shares
% of issued 
capital
1 – 1,000 
1,634
738,950
0.51
1,001 – 5,000 
1,586
4,249,862
2.95
5,001 – 10,000 
616
4,715,766
3.28
10,001 – 100,000 
1,075
32,031,519
22.25
100,001 and over 
99
102,213,044
71.01
Total 
143,949,141
100.00
Holding less than a marketable parcel 
1,769
890,159
0.62
SUBSTANTIAL HOLDERS
The names and shareholdings of substantial shareholders who have notified the Company in accordance with section 671B of the 
Corporations Act 2001 (Cth) as at 24 September 2024 are as follows:
Name
Ordinary
Shares
% of issued
capital
National Nominees Ltd ACF Australian Ethical Investment Limited
18,834,446
13.08%
CW Retail Holdings Pty Ltd
14,223,817
9.88%
Investors Mutual Limited
12,495,860
8.68%
Spheria Asset Management Pty Ltd
10,745,756
7.46%
Pinnacle Investment Management Group Limited
10,726,014
7.45%
Microequities Asset Management Pty Ltd
8,866,354
6.16%
TWENTY LARGEST HOLDERS OF QUOTED EQUITY SECURITIES
Rank
Name
Number
 of Shares
% 
Shares
1
Citicorp Nominees Group
28,269,518
19.64
2
National Nominees Group
20,052,923
13.93
3
CW Retail Holdings Pty Ltd - CW Retail Holdings A/C
14,223,817
9.88
4
J P Morgan Nominees Australia Pty Limited
9,601,843
6.67
5
Gallin Pty Ltd
6,350,000
4.41
6
BNP Paribas Nominees Pty Ltd - IB AU Noms Retail Client
1,641,664
1.14
7
Mr Hansjoerg Zinsli
1,285,000
0.89
8
P C Cotton Pty Ltd - Goldcraft Pty Ltd Super A/C
1,197,483
0.83
9
Mr John Gassner + Mr Nathan Rothchild
1,075,001
0.75
10
Exldata Pty Ltd
863,405
0.60
11
Strategic Value Pty Ltd -Tal Super A/C
575,975
0.40
12
R I Finances Pty Ltd
500,588
0.35
13
HSBC Custody Nominees Group (Australia) Limited
482,341
0.34
14
Ganzi Family Super Pty Ltd - Hansjoerg Zinsli S/F No. 2 A/C
409,000
0.28
15
Ms Kylie Lynette Nuske + Mr Matthew James Cook - Vision Splendid Super A/C
374,258
0.26
16
Exldata Pty Ltd
364,612
0.25
17
Mr Geoffrey William Goode
339,000
0.24
18
Ganzi Family Super Pty Ltd - Hansjoerg Zinsli Super F A/C 
337,500
0.23
19
Mrs Maysa Saboune
329,000
0.23
20
Dr Andrew Richard Conway + Dr Vanessa Joy Teague
313,953
0.22
Top 20 Holders of ordinary fully paid shares
88,586,881
61.54
Total remaining shareholders
55,362,260
38.46
Total ordinary fully paid shares
143,949,141
100.0
Shareholder Information
100  |  McPherson’s Limited

VOTING RIGHTS
Each ordinary share on issue entitles the holder to one vote. Performance Rights have no voting rights.
UNQUOTED EQUITY SECURITIES
The number of unquoted equity securities on issue at 24 September 2024 is 6,479,403 performance rights. The number of holders of 
unquoted securities (performance rights) is 13.
MCPHERSON’S LISTING
McPherson’s Limited is listed on the Australian Securities Exchange.
Shareholder Information
Annual Report 2024  |  101

Corporate Governance Statement
The ASX Corporate Governance Principles and Recommendations 
(Fourth Edition) and the ASX Listing Rules (ASX LR 4.10.3) 
permits entities to elect to publish their Corporate Governance 
Statement and ASX Appendix 4G on its website.
Accordingly, McPherson’s Limited’s (Company) 2024 Corporate 
Governance Statement does not appear in this Annual Report 
and can be located on the Company’s website 
(www.mcphersons.com.au).
To navigate to the Company’s 2024 Corporate Governance 
Statement and ASX Appendix 4G, please click on the “Investor 
Centre/Corporate Governance” tab of the Company’s website.
The Company’s 2024 Corporate Governance Statement 
and Appendix 4G can be found at 
https://www.mcphersons.com.au/corporate-governance
102  |  McPherson’s Limited

Corporate Directory and Financial Calendar
MCPHERSON’S LIMITED
ACN: 004 068 419
ASX CODE: MCP
McPherson’s Limited is a company limited by shares, 
incorporated and based in Australia. Its registered office 
and principal place of business is located at:
105 Vanessa Street
Kingsgrove NSW 2208
Telephone: (02) 9370 8000
Facsimile: (02) 9370 8091
Email: enquiries@mcpher.com.au
Website: www.mcphersons.com.au
COMPANY SECRETARY 
Craig Durham
AUDITOR
PricewaterhouseCoopers
One International Towers Sydney 
Watermans Quay
Barrangaroo NSW 2000
SOLICITORS
Thomson Geer Lawyers
Sixty Martin Place
Level 14, 60 Marton Place
Sydney NSW 2000
Telephone (02) 8248 5800
Facsimile (02) 8248 5899
SHARE REGISTRY
Computershare Investor Services Pty Limited
Yarra Falls, 452 Johnston Street
Abbotsford Victoria 3067
Telephone within Australia: 1300 85 05 05
Telephone outside of Australia: +61 3 9415 5000
Facsimile: (03) 9473 2500
www.computershare.com
www.investorcentre.com/contactus
SHAREHOLDER ENQUIRIES
Shareholders who wish to contact the Company on any 
matter related to their shareholding are invited to telephone 
or write to the Share Registry. It is important that shareholders 
notify the Share Registry in writing if there is a change to their 
registered address, bank account, email address or other 
personal details. For added protection, shareholders should 
always quote their Securityholder Reference Number (SRN).
designdavey
FINANCIAL CALENDAR 1
November 2024
McPherson’s Limited will be holding a hybrid Annual 
General Meeting (AGM) at 11:00am (AEDT) on Wednesday 
27 November 2024. Shareholders can attend the AGM in person 
at the offices of Thomson Geer, Level 14, 60 Martin Place, 
Sydney, 2000 or access the meeting online via the following link:
https://meetings.lumiconnect.com/300-621-354-840
Shareholders will be able to participate in the AGM online using 
a smartphone, tablet or computer.
February 2025
Appendix 4D for the half year ended 31 December 2024
August 2025
Appendix 4E for the financial year ended 30 June 2025
October 2025
Annual Report for the financial year ended 30 June 2025
1.	 Dates and location may be subject to change
Annual Report 2024  |  103


MCPHERSON’S LIMITED ANNUAL REPORT 2024